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2Summary
A variety of aetiological factors serve as targets for both treatment and 
prevention in ischaemic stroke. Research has shifted towards acute therapy 
and improving the risk / benefit ratio in secondary prevention.
Current evidence based practice in ischaemic stroke is discussed in chapter 
one, and the background to subsequent chapters is introduced. The thesis is 
then divided into two broad areas that examine mechanisms by which 
vascular disease may cause ischaemic stroke, and the manner in which 
vascular risk may be modulated. Chapters two to four highlight controversies 
in investigation and management. Chapter two addresses a clinical dilemma 
- essentially whether a carotid lesion ipsilateral to a lacunar stroke should be 
considered symptomatic. Observational data comparing incidence of lacunar 
disease contralateral (group 1) or ipsilateral (group 2) to carotid artery 
disease, and stroke recurrence in patients in whom co-existent lacunar and 
carotid disease had been identified, were analysed. 32 patients had carotid 
disease contralateral to their lacunar stroke, compared to 61 patients with 
ipsilateral lacunar disease. Chi-squared testing indicated a positive 
association between unilateral lacunar stroke and ipsilateral carotid disease 
(p=0.003), and a just significant trend towards more severe carotid disease in 
group 2 (p=0.049). Recurrent ischaemic stroke occurred more commonly in 
group 2 than group 1, although this difference just failed to reach statistical 
significance (p=0.059). A positive association therefore exists between 
lacunar stroke and ipsilateral carotid disease that confers a poor prognosis.
Cryptogenic stroke accounts for approximately 30% of ischaemic stroke. 
Inter-atrial septal abnormalities (patent foramen ovale (PFO) and atrial septal 
aneurysm) have been proposed as a cause of stroke. Chapter three details a 
meta-analysis of data examining the relationship between inter-atrial septal 
abnormalities and stroke. Comparing ischaemic stroke to controls, the odds
3ratio (OR) associated with PFO for all ages was 1.83 (95% C.I.=1.25-2.66). 
For atrial septal aneurysm it was 2.35 (1.46-3.77), and for both lesions in 
conjunction it was 4.96 (2.37-10.39). Homogeneous results were found within 
the group <55 years (3.10 (2.29-4.21), 6.14 (2.47-15.22) and 15.59 (2.83- 
85.87) respectively), and >55 years (1.27 (0.80-2.01), 3.43 (1.89-6.22) and
5.09 (1.25-20.74) respectively). Comparing cryptogenic stroke patients to 
patients with known stroke cause, heterogeneous results derived from total 
group examination (PFO 3.16 (2.30-4.35), atrial septal aneurysm 3.65 (1.34- 
9.97), PFO and atrial septal aneurysm 23.26 (5.24-103.20)). In those <55, for 
PFO the OR was 6.00 (3.72-9.68) with only one study examining atrial septal 
aneurysm or combined lesions. In those >55, 3 studies produced 
heterogeneous results for PFO (2.26 (0.96-5.31)), while no data were 
available on atrial septal aneurysm prevalence. Meta-analysis therefore 
demonstrates significant association between both PFO and atrial septal 
aneurysm and ischaemic stroke in patients <55 years. Further studies are 
needed to firmly establish whether an association exists between PFO and 
ischaemic stroke in those >55 years.
The climate of uncertainty that surrounds the subject of ‘PFO-associated 
stroke’ has led to a wide spectrum of practice amongst specialists, which is 
examined in chapter four, using a questionnaire. 17% of respondents would 
investigate for PFO in all cryptogenic stroke patients, while 60% investigate 
only in those <55 years. 23% would not investigate for PFO at all. Antiplatelet 
therapy alone was chosen as an initial strategy by 47% of respondents for 
those >55 years, and by 33% of respondents for those <55 years (p<0.01 for 
comparison of proportions). In a patient of any age with recurrent events, less 
than 5% of respondents would continue to use antiplatelet therapy alone. 
45% would use warfarin, and 42% would refer the patient for a corrective 
procedure. For a patient with a large PFO, 57% (<55 years) vs 45% (>55 
years) would refer (p=0.01), and for a patient with concomitant atrial septal 
aneurysm, 62% (<55 years) vs 44% (>55 years) would refer (p<0.01). A large
4PFO was felt to be the most important factor in decisions regarding lesion 
correction. Investigation practice varied considerably amongst specialists. 
Randomised trial design should reflect management practice in this area.
The second part of the thesis reports clinical trials designed to examine the 
manner in which agents aimed at the modification of vascular risk may act in 
the acute and subacute phase of ischaemic stroke. The cholesterol- 
independent effects of statins may explain their efficacy in patients at high 
vascular risk. Chapter five reports a small randomised trial of pravastatin 
versus placebo in ischaemic stroke. No difference in whole cerebral perfusion 
was seen after 2 months between the treatment and control arms (p=0.88). 
Similarly, no difference in common (p=0.41) or internal (p=0.84) carotid artery 
flow was evident. No effect on mean arterial blood pressure was detected in 
the pravastatin treated group (p=0.44). Early total and LDL cholesterol 
reduction in the pravastatin group was accompanied by trends towards 
reduction in factor VII (p=0.067) and haematocrit levels (p=0.101), but no 
effect or trend to effect was seen in fibrinogen, C-reactive protein, plasma 
viscosity, von-Willebrand factor or other haemorrheological markers.
Chlamydia pneumoniae infection and raised levels of fibrinogen are risk 
factors for ischaemic stroke in observational studies. Seropositivity to 
chlamydia pneumoniae is independently associated with raised fibrinogen, 
and chlamydia pneumoniae infection may increase vascular risk by increasing 
fibrinogen. The pilot study reported in chapter six was a randomised, double­
blind comparison of azithromycin versus placebo after ischaemic stroke. 
Thirty patients were randomised irrespective of chlamydia pneumoniae 
status. No difference in fibrinogen reduction after ischaemic stroke was 
detected between azithromycin and placebo treated patients (p=0.91), or 
between chlamydia pneumoniae positive and negative patients (p=0.65). No 
differential effect of treatment was detected in the seropositive group 
(p=0.77). No effect of chlamydia pneumoniae seropositivity, azithromycin
5treatment or their interaction was detected on plasma viscosity, C-reactive 
protein or von-Willebrand factor. This pilot phase excludes effects of 
macrolides on fibrinogen levels in unselected patients after ischaemic stroke 
of more than 0.36g/l. A project to investigate antibiotic effects as small as 
0.2g/l will require over 200 patients, and is planned.
The heterogeneity of stroke militates against the view that 'stroke medicine' is 
merely an extension of cardiovascular medicine. While some therapies are 
suitable for a broad spectrum of patients, a variety of different causes and risk 
factors may be at play in the individual, and secondary prevention should be 
tailored to that individual. Further work should aim to define the importance of 
PFOs in the old, the correct management strategy in 'PFO associated stroke', 
the indications for and actions of statins in stroke, and the possible effects of 
anti-chlamydial therapy.
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1.1 Stroke: a vascular brain disease
The pathogenesis of stroke involves vascular injury to neural tissue. Stroke 
risk factors and causes exert their effects on cerebral vasculature, and form 
the basis for secondary prevention strategies, while acute management of 
stroke may be directed at the primary circulatory insult, or its secondary 
neural effects. Considerable research efforts have been directed at each of 
these putative strategies. Large scale randomised trials of intravenous 
thrombolysis have established acute therapy as both feasible and beneficial 
for selected patients 1, while neuroprotective agents, despite considerable 
research interest2, have failed to show benefit in clinical trials to date.
Secondary prevention of stroke has focused chiefly on the modification of 
established vascular risk factors (for example smoking and hypertension), 
and on the treatment of vascular stroke causes (for example carotid 
endarterectomy in severe carotid artery stenosis). While certain questions 
have been answered, an example being the use of low to medium dose 
aspirin in ischaemic stroke 3, controversies remain with regard to vascular risk 
factors, aetiology and management, a number of which the following chapters 
seek to address. Each chapter addresses aspects of ‘what to do second’, 
once the acute phase of ischaemic stroke has passed. A common theme is 
the detailed consideration of the mechanism of stroke recurrence, and how 
established and novel approaches to secondary prevention may affect such 
mechanisms.
To better explain the setting and nature of each controversy, current evidence 
based practice for an individual stroke patient will be described. The difficult 
decisions regarding his / her investigation and management will be 
highlighted, and the research topics will be introduced in turn. While 
rehabilitation and patient-centred occupational and physiotherapy represent 
vitally important factors in the care of stroke patients, these will not be
20
addressed as they are not within the remit of this thesis. The specifics of each 
research subject will be dealt with in the succeeding chapters.
1.2 Evidence based management of the patient with 
ischaemic stroke
Acute investigation and therapy
After symptom onset, rapid evaluation of the stroke patient is recommended. 
Such a policy allows prompt investigation, safe nursing, and specific therapy if 
appropriate. After clinical evaluation by emergency medicine staff and a 
specialist, urgent imaging (Computed Tomography (CT) and/or Magnetic 
Resonance Imaging (MRI)) should be performed. Such investigations may be 
delayed, particularly if thrombolytic therapy is not considered worthwhile. The 
Scottish Intercollegiate Guidelines Network (SIGN) state that CT scanning 
should occur ‘as soon as possible -  preferably within 48 hours -  and no later 
than 7 days’. The proportion of stroke admissions fulfilling these criteria is one 
measure of the quality of stroke care, and adherence to these guidelines has 
proved difficult to achieve within many Scottish hospital trusts. In contrast, 
delays of up to 7 days would be considered unacceptable in other European 
industrialised nations.
Modern MRI techniques are both sensitive and specific in the detection of 
acute haemorrhage, and allow semi-functional assessment of ischaemic 
damage by diffusion/perfusion weighted imaging (DWI/PWI). Such techniques 
may prove useful in choosing individuals who are suitable for thrombolysis 
outside the conventional 3 hour time window 4. Other investigations will 
depend on the individual presentation, but an electrocardiogram (ECG), to 
detect atrial fibrillation (AF), left ventricular hypertrophy (LVH) or evidence of 
cardiac ischaemia / infarction, chest x ray (CXR) for assessment of heart size 
or concurrent infection, and basic haematology and biochemistry would be 
included in the standard assessment in the casualty department.
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Acute management, as alluded to previously, should consist of thrombolytic 
therapy for selected individuals. The disadvantages of intravenous 
thrombolysis with tissue plasminogen activator (IV tPA), namely increased 
early death and symptomatic haemorrhage, are offset by a reduction in 
disability in survivors, so that overall there is a significant reduction in the 
proportion of patients dead or dependent in activities of daily living at follow 
up 1. Current evidence thus favours the use of thrombolysis within 3 hours. 
Data from recent trials have suggested that in patients who have middle 
cerebral artery (MCA) occlusion, the time window may be extended to 6 hours 
with the use of intra-arterial thrombolysis 5.
One of the difficulties with stroke care in the ‘thrombolytic era’ has been the 
assessment of patients within the time window that thrombolytic therapy has 
been proven to be beneficial -  its use is by no means common, even in those 
countries in which a licence has been granted. Recently an observational 
study in the Cleveland area reported that only 1.8% of acute stroke patients 
received intravenous tissue plasminogen activator (IV tPA), despite numerous 
protocol violations 6. Debate also continues about clinical and radiological 
indications, and the correct setting for the use of IV tPA 7. In the UK and 
Europe, thrombolytic therapy is limited to a few specialist centres, and 
ischaemic stroke remains an unlicensed indication. This situation is likely to 
change in the near future: numerous centres have now reported outcome 
results similar to those in the National Institute of Neurological Diseases 
(NINDS) trial 8, and it has become clear that if used by specialists in the 
correct setting, IV tPA is a useful therapy for a minority of cases 9. It may be 
that selected patients will benefit from intravenous treatment beyond 3 hours, 
a contention which is currently being tested in the third international stroke 
trial (1ST III).
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Trials of neuro-protective agents have until now proved negative, which in 
some instances may reflect poor trial design rather than absence of effect. 
There is little pathophysiological basis for neuroprotection in stroke that is 
confined to white matter. Despite this, patients with white matter stroke have 
been included in clinical trials of neuroprotective agents, in the same way as 
individuals with cortical disease. Clinical trials restricted to patients with large 
MCA stroke accompanied by radiological evidence of an ischaemic penumbra 
(using diffusion/perfusion MRI) may be more likely to detect drug effect10. It is 
hoped that slower recruitment may be offset by extended time windows and 
requirements for fewer patients. Surrogate evidence of biological effect in 
man may therefore be defined prior to embarking on further research into 
clinical endpoints, so that ineffective agents are identified quickly and 
development is discontinued. Natural history data from existing trials may 
enable better definition of endpoints relevant to the individual stroke patient, 
another means by which agent efficacy may be more efficiently assessed.
Placement of the patient presenting with stroke is at least in part dependent 
on the clinical presentation. Patients with haemorrhagic stroke requiring 
surgery should be transferred to a specialist unit for urgent evaluation and 
management. If symptoms have resolved within 24 hours (that is, if the 
diagnosis is of transient ischaemic attack (TIA) rather than stroke), the 
clinician may elect not to manage the patient in hospital. If such a policy is 
employed, it is imperative that investigations and clinic review occur shortly 
after presentation so that secondary measures may be instituted quickly. A 
short admission may be more practicable. In-patient care should be based in 
a specialist un it11, and acceptance of such a policy has led to a considerable 
expansion in stroke units in recent years. The situation remains, however, 
unbalanced across the United Kingdom, with the consistent recommendation 
of working groups that stroke care should take place within a specialist unit 
being adhered to variably by different hospital trusts 12.
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Another argument supporting the development of specialist units is that 
control of physiological parameters in the acute stages of stroke may improve 
prognosis. Certainly pyrexia 13, hypoxia and hyperglycaemia 14 are associated 
with poor outcome, but policy on treating such abnormalities differs widely. 
Abnormal physiological measurements may represent co-existent conditions, 
the effect of stroke, or in some instances the cause of stroke, and the effect of 
corrective treatment is likely to depend on which of these associations is 
relevant in the individual. Admission to a unit with a stated policy on the 
correction of such abnormalities makes both detection and correction more 
likely. Evidence that such measures will result in improved outcome has 
recently been published by workers in Scandinavia. Ronning et al noted that 
more aggressive rehabilitation and use of parenteral fluid, aspirin, antipyretics 
and antibiotics was more common in their stroke unit than in the general 
medical ward 15. Indredavik et al assessed which aspects of stroke unit care 
resulted in improved outcomes 16. Stroke units mobilised patients more 
quickly, and used intravenous fluid, heparin, antipyretics and oxygen more 
readily, resulting in less variable blood pressure, avoidance of low diastolic 
blood pressure, and lower glucose levels and temperature. Each of these 
factors was significantly associated with discharge to home within 6 weeks. In 
a multivariate model, shorter time to mobilisation and stabilised diastolic blood 
pressure were both independent factors significantly associated with 
discharge to home within 6 weeks. Whether specific therapy for 
hyperglycaemia will impove outcome is currently being investigated in a large 
trial, which recently reported pilot data 17.
Adequate nutrition is also important in the acute and subacute phases. 
Current practice in this area varies considerably, and randomised evidence is 
scarce 18. What little evidence is available suggests that percutaneous 
gastroenterostomy (PEG) may reduce fatalities and improve nutritional status 
18. The best use of nasogastric (NG) or PEG tubes, and the timing of feeding
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interventions, is the subject of the ongoing 'Feed or ordinary diet1 (FOOD) 
trial.
Control of blood pressure is a contentious area of ischaemic stroke 
management. Because the autoregulatory mechanisms governing cerebral 
perfusion across a range of blood pressures are disturbed after stroke 19, falls 
in blood pressure may be directly transferred to the infarcted area, resulting in 
worse neurologic outcome 20. Conversely, high blood pressures increase the 
theoretical likelihood of haemorrhagic transformation and persistent or 
worsening cerebral oedema, with the consequent possibility of clinical 
deterioration. Clinical data support an increased risk of haemorrhagic 
transformation at diastolic blood pressures above lOOmmHg 21. Thus a 
therapeutic quandary exists: when to treat, with what and for how long. 
Published small trials on this subject have been summarised in a recent 
Cochrane Review 22, but good randomised controlled data are scarce, and 
larger scale trials must assess the efficacy of pharmacological blood pressure 
control both within and without the context of thrombolysis. The rationale 
behind the numerous ongoing studies in this area is explained in table 1.1 
(uses references 23 and 24).
Aspirin therapy should begin in the acute stroke phase, as soon as 
haemorrhage has been excluded by CT or MR imaging. Large scale 
randomised trials were required to show a beneficial effect of antiplatelet 
therapy in the acute prophylaxis of further vascular events. In a recent 
Cochrane review antiplatelet therapy was associated with a small but definite 
excess of 2 symptomatic intracranial haemorrhages for every 1000 patients 
treated, but this was more than offset by a reduction of 7 recurrent ischaemic 
strokes for every 1000 patients treated 3. Only doses higher than 160mg have 
been tested in this acute setting.
25
Modification of vascular risk and secondary prevention
The cornerstone of secondary prevention for both the primary and secondary 
care physician is the modification of vascular risk factors. Patients are 
advised not to smoke (since cigarette use is strongly associated with 
increased stroke risk25), and considerable evidence now exists for the use of 
pharmacological strategies in achieving this goal 26. While good diabetic 
control has been demonstrated to reduce the incidence of microvascular 
complications 27, secondary prevention of macrovascular disease is assumed 
rather than proven.
Meta-analysis of randomised trials examining the long term effects of 
antiplatelet agents in 1994 by the Antiplatelet Trialists Collaboration 
confirmed modest effects in the secondary prevention of vascular events 28. 
The findings have been recently updated 29, and the relative risk reduction 
(RRR) afforded by antiplatelet therapy in all high risk vascular patients 
remained approximately 25%. In those with previous ischaemic stroke or TIA, 
allocation to a mean duration of 29 months of antiplatelet therapy resulted in 
36 fewer serious vascular events per 1000 patients treated 29. Most of this 
evidence relates to aspirin used as a single agent, and there does not seem 
to be an aspirin dose effect 29 30.
Two major stroke secondary prevention trials have been published since the 
1994 meta-analysis 28, both of which examined ways in which secondary 
prevention afforded by aspirin could be improved. Criticism was aimed at the 
second European Stroke Prevention Study (ESPS-2), which was designed to 
investigate the contention that addition of dipyridamole to aspirin would 
improve rates of recurrent stroke and death in stroke patients. This criticism 
stemmed from the choice of aspirin dose (50mg) (which was deemed too 
low), from the inclusion of a placebo group (which with the benefit of data that 
emerged during recruitment was deemed inappropriate) and from one centre 
falsifying results, which were discounted from the final analysis. In fact, the
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results for the aspirin treated group were entirely in line with those of other 
trials that have used much higher doses of aspirin in the secondary 
prevention of stroke 31. The finding that the combination of aspirin and 
dipyridamole afforded a 37% RRR in recurrent stroke over placebo, twice that 
of either aspirin (18%) or dipyridamole (16%) alone 32, has not resulted in 
routine use of this 'combination' strategy. Current Scottish guidelines (SIGN 
guideline number 36: Antithrombotic therapy) recommend the addition of 
dipyridamole to aspirin for patients with recurrent events on aspirin. This 
suggests that its authors accept that the addition of dipyridamole confers 
improved efficacy in secondary prevention. If this is the case, and one 
accepts the low bleeding rates demonstrated in ESPS-2 32, the only barrier to 
the routine use of combination aspirin and dipyridamole therapy is cost. Even 
using conservative estimates of the cost of stroke, the cost of additional 
dipyridamole therapy is outweighed by the cost of recurrent events33.
The CAPRIE trial 34 compared 325mg aspirin and 75mg clopidogrel, a new 
thienopyridine derivative which inhibits platelet aggregation induced by 
adenosine diphosphate. In the overall trial cohort, which included patients 
with ischaemic heart disease (IHD), cerebrovascular disease (CVD) and 
peripheral vascular disease (PVD), a significant benefit in the reduction of a 
combined endpoint (ischaemic stroke, myocardial infarction (Ml) or vascular 
death) was detected. The benefit of clopidogrel over aspirin was small, and 
was largely evident in the subgroup of patients with PVD. Chi-squared test for 
heterogeneity of effects in the different subgroups was significant. To prevent 
a single vascular event, 200 patients would have to be treated with 
clopidogrel rather than aspirin. Given the cost of the new agent (£370 per 
year), current guidelines recommend its use in those who, for whatever 
reason, cannot take aspirin.
Current research interest in this area centres on alternative 'combination 
therapies', and in the use of oral anticoagulation. The recent publication of the
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Warfarin-Aspirin Recurrent Stroke Study (WARSS) 35 confirmed previous 
meta-analyses 36 that failed to demonstrate superior efficacy of warfarin over 
aspirin for patients in sinus rhythm. The Management of ATherothrombosis 
with Clopidogrel in High-risk patients with recent TIA or ischaemic stroke 
(MATCH) trial is comparing the combination of clopidogrel and aspirin with 
clopidogrel alone for the prevention of new ischaemic events 
(cerebrovascular or cardiovascular). Patients will be randomised within three 
months of an ischaemic stroke or TIA, and followed up for 18 months, with an 
anticipated sample size of 7600 patients. The European and Australian 
Stroke Prevention in Reversible Ischaemia (ESPRIT) trial is randomising 
patients with cerebral ischaemia of arterial origin to oral anticoagulation, 
aspirin and dipyridamole or aspirin alone (anticipated sample size 4500).
In patients with AF and recent cerebral ischaemia, meta-analysis of 
randomised evidence suggests that anticoagulants are beneficial, without 
serious adverse effects, for people with nonrheumatic atrial fibrillation and 
recent cerebral ischaemia 37. Anticoagulants reduced the risk of recurrent 
stroke by two-thirds (odds ratio 0.36, 95% confidence interval 0.22 to 0.58). 
The risk of all vascular events was shown to be almost halved by treatment 
(odds ratio 0.55, 95% confidence interval 0.37 to 0.82).
Hypertension increases ischaemic stroke risk, and its treatment (as primary 
prevention) reduces stroke risk 38. Management of blood pressure as a 
secondary prevention measure after stroke was investigated by the recently 
reported Perindopril Protection Against Recurrent Stroke Study 
(PROGRESS), which randomised 6105 patients 39. It was designed to 
determine the effects of blood pressure lowering in both 'hypertensive' 
(systolic>160 mmHg or diastolic>90 mmHg) and 'non-hypertensive' patients 
with a history of stroke or TIA. Active treatment comprised a flexible regimen 
based on the angiotensin converting enzyme (ACE) inhibitor perindopril, with 
the addition of the thiazide diuretic indapamide at the physician's discretion.
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Active therapy reduced blood pressure by 9/4 mmHg, and the risk of recurrent 
stroke by 28% (95% Cl 17-38), with a similar highly significant reduction in 
total vascular events. The effects were seen in both hypertensive and non­
hypertensive subjects, and after all types of initial event. They reproduce (and 
extend to the normotensive population) the findings of an overview which 
summarised antihypertensive secondary prevention studies prior to the 
publication of PROGRESS 40.
The PROGRESS trial, while supporting an intensified approach to blood 
pressure control in all stroke patients, also generates a number of questions. 
Firstly, should all patients be started on a regime of perindopril and 
indapamide? Single agent perindopril therapy (which reduced blood pressure 
by 5/3 mmHg) had no disernable effect on stroke risk: the effects were only 
seen in the combination therapy (perindopril + indapamide) group, in which 
blood pressure was lowered further (12/5 mmHg). It is unclear whether the 
effects seen can be generalised to the use of all antihypertensive agents - in 
other words the reduction in stroke risk may have merely reflected reduction 
in blood pressure, rather than an effect of the specific agents chosen. If blood 
pressure is the clinical target (rather than the prescription of perindopril and 
indapamide), should we be aiming for a target blood pressure, or a target 
pressure reduction? It also remains unclear whether patients with occlusive or 
stenotic disease of major cerebral arteries can safely be started on the 
PROGRESS regime, although small trial data would support the view that 
such an approach will not result in dangerous falls in cerebral perfusion or 
flow41.
1.3 Carotid endarterectomy and subcortical stroke
Carotid endarterectomy for the secondary prevention of stroke in patients with 
varying degrees of carotid stenosis has been tested in randomised controlled 
trials. Large scale studies have been reported from both America 42 43 and
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Europe 44. These trials included patients with symptomatic carotid disease, 
defined as symptoms referable to the hemisphere supplied by the relevant 
carotid artery, or amaurosis fugax in the ipsilateral eye. They showed clear 
benefit for surgery over best medical treatment for patients with more than 
50% stenosis (measured by the NASCET method) or 70% (measured by the 
ECST method) 45. Given the less impressive results of trials in asymptomatic 
carotid artery stenosis 46, despite extremely low complication rates in the 
surgically treated group, the classification of a lesion as symptomatic is 
central to the choice of correct therapy for patients with carotid artery 
stenosis.
The effect of surgery in symptomatic individuals with carotid artery stenosis is 
not uniform, and subgroups that respond differently to surgical intervention 
can be identified both clinically and angiographically. It appears that as age 
and level of stenosis increase, so does the risk of stroke with medical therapy, 
and the benefit to be gained from surgery 45. Clinical characteristics that are 
associated with an increased risk of stroke or death with surgery include 
contralateral carotid occlusion, left-sided carotid disease, the absence of a 
history of Ml or angina, a history of diabetes mellitus and a diastolic blood 
pressure higher than 90mmHg 43. It seems that the long term benefit of 
surgery (over medical treatment) is higher for men than for women, for 
patients who have had a stroke than for those who have had a TIA, and for 
patients with hemispheric symptoms than for those with retinal symptoms 43. 
Simple classification systems have been developed using ECST data that 
incorparate both clinical and angiographic data 47 to enable surgical therapy 
to be offered only to those patients most likely to benefit. These are likely to 
improve with further analysis of individual patient data from trials already 
conducted and from randomised trials that are ongoing.
Lacunar syndromes comprise four different well defined clinical presentations: 
pure motor stroke, pure sensory stroke, sensorimotor stroke and ataxic
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hemiparesis (including dysarthria clumsy hand syndrome and homolateral 
ataxia and crural paresis). These presentations correlate well with small 
infarctions in the subcortical areas of the brain, and it is likely that most are 
caused by a specific vascular pathology affecting the small perforating 
arteries 48. These comprise the lenticulostriate perforating branches of the 
MCA, the thalamoperforating branches of the proximal posterior cerebral 
artery (PCA) and the perforating branches of the basilar artery (BA). Although 
the reported associated risk factors differ between datasets, at least in part 
because of the population that they have studied, hypertension, diabetes and 
hyperlipidaemia are the most consistent correlates of lacunar stroke.
There are substantial pathological and experimental data to support the view 
that lacunar stroke is caused by small vessel pathology, rather than by 
embolism (from carotid arteries or the heart) or haemodynamic mechanisms 
48. Epidemiological and observational studies have found low rates of embolic 
sources in lacunar stroke populations 49. It seems clear that in the population, 
lacunar stroke is rarely associated with carotid stenosis, or other traditional 
embolic sources 50. Other strokes in the subcortical territories include centrum 
ovale infarction, occurring in the territory of the superficial (pial) branches of 
the MCA, and internal borderzone infarcts, occurring between the deep and 
superficial perforating arterial territories. Both of these types of infarction have 
been associated, in literature which stems from analysis of data from the 
major carotid endarterectomy trials, with large vessel carotid disease 5152.
Thus, data from epidemiological literature provide useful pointers to the 
clinician in deciding which patients should be investigated for the presence of 
a proximal (carotid or cardiac) source. Patients with lacunar stroke, in whom 
such lesions are uncommon, are less likely to have positive carotid Doppler or 
echocardiographic investigations. Such considerations are less helpful in 
managing the individual who has been investigated however. Most stroke 
services employ a routine series of investigations in their patients. While small
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subcortical strokes are not usually caused by embolism or haemodynamic 
mechanisms, the detection of a carotid stenotic lesion or cardiac embolic 
source in a patient with a lacunar stroke leaves the practising physician with 
the uncertainty of whether the lacunar syndrome is incidental, or whether it 
has been caused by the embolic source. Practising physicians and surgeons 
need advice on whether patients with severe stenosis and small subcortical 
strokes should be referred for endarterectomy.
Observational information on both association and prognosis, using the sort 
of clinical data that are likely to be available to the practising clinician, may 
provide useful guidance in this situation. The two published subgroup 
analyses from the major trials of carotid stenosis failed to show a significant 
benefit of surgical over medical therapy in lacunar disease patients 53 54. In 
the NASCET paper, a trend to benefit was observed, but was much less 
marked than in the larger cohort of patients with cortical stroke, with the 
confidence interval of the RRR crossing the line of no effect. More recent 
individual patient data from randomised trials of carotid endarterectomy, 
currently reported only in abstract form, suggested benefit was evident in the 
lacunar stroke subgroup for those patients with high degrees of stenosis (80- 
99%)55
Chapter 2 examines information from the Glasgow Western Infirmary 
database, aiming to provide an observational aid in what is a difficult 
management decision. With simple clinical data, and information from routine 
investigations, the study provides useful data that help guide the clinician. 
The literature pertaining to this subject to date is discussed, as are the 
weaknesses and strengths of the analysis presented.
1.4 Echocardiography: investigation for major and minor 
embolic sources
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Transthoracic echocardiography (TTE), transoesophageal echocardiography 
(TOE), and more specialised transcranial Doppler (TCD) techniques to 
assess the presence of cardiac right-to-left shunt, are investigations that are 
conducted in a smaller proportion of stroke patients than brain imaging and 
carotid Doppler. Generally these are conducted to determine cause of stroke, 
although the information they provide may be useful in stratifying cardiac risk 
or in investigating abnormalities that are felt not to have played a role in 
stroke pathogenesis. Features that may favour a request for cardiac 
ultrasound are patients with lesions considered to be embolic, in the absence 
of more common embolic sources (e.g. AF and carotid stenosis), multiple 
cerebral lesions in different sites, the presence of a cardiac murmur or 
abnormal ECG, and absence of conventional risk factors, including age, in 
the individual stroke patient. Diagnostic yield depends on the stroke 
population being studied, and may not lead to a change in immediate 
management.
It is of note that in up to 40% of strokes, no aetiology is found 56. These are 
known as cryptogenic strokes. Various classification systems in different 
stroke data banks produce different rates of cryptogenic stroke. This depends 
on the population being studied, and on the extent of investigations that have 
been conducted to determine stroke cause. Moreover, it hinges on which 
positive investigation results are regarded as causal and which are felt to be 
incidental.
Certain cardiac characteristics felt to represent high cardioembolic risk (e.g. 
left ventricular thrombus, atrial myxoma) will alter management strategy in the 
short term. Other lesions may be of importance in themselves, while probably 
not implicated in the pathogenesis of stroke (for example mitral regurgitation 
and aortic stenosis 57). There remains, however, a group of lesions that may 
be diagnosed by cardiac echocardiography that have an as yet undefined 
pathogenic role. Such lesions have been found in case control literature to be
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associated with stroke (that is they are more common in a stroke population 
than a control population), but are not regarded as definite causes of stroke. 
Causation is difficult to prove, and in practical terms is overshadowed by a 
more pertinent clinical question: does therapy aimed at treatment of the 
lesion, or of its vascular effects, improve the patient’s prognosis?
Minor cardiac embolic sources
Examples of such abnormalities are mitral valve prolapse (MVP), mitral 
annular calcification (MAC), aortic valve calcification (AVC), spontaneous 
echo contrast (SEC), aortic arch atherosclerosis (AAA), atrial septal 
aneurysm (ASA) and patent foramen ovale (PFO). The extent to which 
different physicians will investigate individual stroke patients for each of these 
abnormalities, and the prescribed therapy on detection, is extremely variable. 
Each lesion may merely be a concomitant abnormality, and so any data 
suggesting causation rather than merely association are of vital importance.
The reported association of stroke with MVP has been drawn into question by 
recent revision of diagnostic criteria: the prevalence of MVP is substantially 
higher, and considerably more operator dependent, when single dimensional 
(M-mode) techniques are used. Specificity (for thickened, myxomatous or 
regurgitant valves) is improved without decreasing sensitivity by the adoption 
of 3-dimensional criteria 58. A recent case control study, using the new 
criteria, failed to find an association between MVP and stroke 59. Since the 
rate of diagnosis with these new criteria is much lower (-2% 59) than 
previously reported, exclusion of an association would necessitate a study 
involving extremely large numbers of young stroke patients. It seems clear, 
however, that true MVP is a rare and usually benign cardiac abnormality60.
Autopsy studies have established a higher prevalence of AAA in stroke 
patients as compared to patients with non-vascular neurological disease. 
Aortic arch atheroma was associated with an odds ratio for ischaemic stroke
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of 4.0 (95%CI= 2.1 to 7.8) in a pathological study by Amarenco et a l61. The 
association became stronger when just individuals with cryptogenic stroke 
were examined (OR 5.7; 95%CI= 2.4 to 13.6). As might be expected, the 
incidence of AAA increased with age. The same group proved the same 
association in life, using TOE in 250 stroke patients 62. While plaque 
thickness >1mm and <3.9 mm could not be established as an independent 
risk factor, due to the frequent co-existence of carotid stenosis, plaque 
thickness >4mm was associated with an odds ratio for ischaemic stroke of 
13.8 (95% Cl= 5.2 to 36.1). The association remained significant after 
accounting for other risk factors. Further case-control work has confirmed 
these findings, and suggested that mobile plaques are particularly strongly 
associated with ischaemic stroke 63 64. Furthermore, recurrent vascular events 
are more common in patients with larger degrees of aortic arch wall thickness 
-  the French Study of Aortic Plaques in Stroke group study found the annual 
risk of stroke, myocardial infarction, systemic embolisation or death was 25% 
in individuals with aortic atheroma >4mm, compared to 5.9% in individuals 
with aortic atheroma <1mm 65. Plaque morphology (lack of calcification and 
presence of ulceration) has also been found to be predictive of recurrence 66.
Whether such clear evidence of association merely identifies co-existent 
vascular disease in high-risk individuals likely to develop recurrent stroke, or 
whether AAA is an embolic source is unclear. Cerebrovascular disease is 
likely to worsen in line with aortic arch disease (both resulting from the same 
vascular risk factors). Thus suggesting that the association between AAA and 
stroke is a causal one on the basis of a dose response relationship is 
problematic. Furthermore, putative treatments (antiplatelet therapy, 
anticoagulants or surgical therapy (atherectomy)) have never been subjected 
to randomised trials. If cardio-embolism is postulated and preventative 
therapy planned, a crucial distinction in therapy must be made between 
prophylaxis against thromboembolism and prophylaxis against cholesterol 
embolism. While the former mechanism favours the use of warfarin as a
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prophylactic therapy, a strategy supported by data from the non-randomised 
series published by Dressier et al 67, anticoagulants can increase the 
likelihood of cholesterol emboli 68 69.
MAC is more likely to be a marker of vascular calcification and embolic risk 
than a true embolic source itself. Again case control literature 70 supports the 
contention that MAC is more common in stroke populations than amongst 
control subjects. A placebo treated cohort of patients with MAC from the 
second Stroke Prevention in Atrial Fibrillation (SPAF II) study 71 failed to 
confirm the suggestion that MAC conferred higher embolic risk in patients 
with AF 72. Prospective data from the Framingham cohort have suggested 
that MAC is associated with a relative risk of 2 for stroke after adjustment for 
conventional risk factors, excluding carotid disease 73. It seems unlikely that 
calcific embolus commonly causes stroke, although the presence of MAC in 
conjunction with other embolic factors may provide a clinical indication that 
prophylactic therapy should be more aggressive.
Although case reports and autopsy series 74 have suggested spontaneous 
embolization of calcific material from AVC as a cause of stroke, the small size 
of the calcific emboli makes asymptomatic infarction a more likely 
manifestation. A prospective case control study comparing patients with AVC 
(either with or without aortic stenosis) to controls found no difference in stroke 
rate 57. Surgical treatment should be restricted to those with valvular stenosis 
of sufficient degree. Whether medical therapy for secondary stroke prevention 
should be altered is unclear.
SEC is also postulated as a marker of increased embolic risk. It is an 
echocardiographic finding, taking the appearance of ‘smoke’ in the left atrium, 
and is felt to represent stasis of blood and microaggregates of blood 
constituents. It is much more common in patients with atrial fibrillation and 
mitral valve disease than the general population (19% vs up to 74%) 75. In a
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prospective follow up study of 272 patients with non-valvular atrial fibrillation 
undergoing TEE, the stroke / embolic event rate was 12% per year in patients 
with SEC compared to 3% per year in those without SEC, despite higher 
levels of anticoagulation in the SEC group 76. In the third Stroke Prevention in 
Atrial Fibrillation (SPAFIII) trial, a cross-sectional analysis found SEC to be 
independently associated with an increased risk of thromboembolic events 
(RR 3.7; p<0.001) 77. Although other published reports challenge such 
findings 78, the weight of evidence appears to be in favour of SEC being a 
marker of higher embolic risk in patients with AF. Such a relationship also 
makes pathophysiological sense, and implies that more aggressive 
management policies should be employed in those patients with AF who have 
SEC on TEE. Similarly, mitral valvular strands are associated with stroke risk 
in some studies 79 80.
It is clear from literature review that such ‘new’ or ‘minor’ cardiac sources of 
embolic stroke may be of great importance in the individual clinical situation, 
while their importance becomes both more questionable and difficult to 
quantify in populations. There is literature supporting and refuting association 
for each. Much of the discrepancy is a function of different types and ages of 
patients being enrolled in studies of different design with varying levels of 
stroke definition. Diagnostic criteria and rates of follow up vary, and 
publication bias is likely to play a role.
Patent Foramen Ovale and Atrial Septal Aneurysm
The foramen ovale -  a natural inter-atrial channel allowing a functional right- 
to-left shunt of oxygenated blood from the maternal placenta to the fetus -  
normally closes after birth as pressure in the left atrium exceeds that in the 
right atrium. Permanent closure of the septum is achieved by fibrous 
adhesions between the septum primum and secundum, normally within the 
first 3 months of life. The foramen ovale remains patent in approximately one 
third of the population; largely a small communication (2 to 5mm) is present,
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but in 6% of autopsies a larger PFO is detected (6 to 10mm) 81. Closure of 
patent foramen ovale (PFO) continues to occur throughout life, since its 
incidence declines with increasing age, while average size of lesions tends to 
increase 81, presumably reflecting increased right atrial pressures in the older 
population (see figure 1.1 81).
Normally, mean right atrial pressure is lower than left atrial pressure. 
However, a number of pathological states (for example tricuspid 
regurgitation), and physiological states (for example during coughing or 
Valsalva manoeuvre) can lead to a higher right atrial pressure, allowing 
shunting through a patent channel. Also, even though mean pressure in the 
right atrium is lower than that in the left atrium, the pressure difference may 
be reversed transiently at end-systole, potentially leading to right-to-left 
shunting in the presence of otherwise normal intra-cardiac pressures 82. Thus, 
in the presence of thrombosis within the venous system, a persistent foramen 
ovale may allow shunting of embolic material to the arterial system and brain. 
Alternatively, turbulence at inter-atrial level may predispose to the formation 
of thrombotic material, or the defect may predispose to atrial arrythmias, with 
subsequent embolic potential 83.
An atrial septal aneurysm (ASA) is an outpouching of the inter-atrial septum 
into either the left or the right atrium (see figure 1.2a). Echocardiographic 
criteria for its diagnosis are based on the size and excursion of the aneurysm 
(see figure 1.2b). ASA is proposed to cause stroke by acting as a thrombotic 
surface and embolic source. It is much less prevalent than PFO (1-5% of 
individuals), but PFO is often found in conjunction with it. Stroke mechanism 
in this instance has been hypothesised to be due to thrombus formation 
within the right side of the ASA, with shunting to the arterial side through the 
PFO.
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The literature on the association of PFO and ASA (‘inter-atrial septal 
abnormalities’) with stroke is similar to that on the other ‘minor’ embolic 
sources detailed above. It is characterised by numerous small studies, which 
published reviews have approached in a manner that is neither systematic 
nor complete. In a climate in which randomised trials of secondary prevention 
in patients that have stroke and an inter-atrial septal abnormality are planned, 
definition of the presence and quantification of the level of any association 
assumes great importance. Chapter 3 describes a systematic review and 
meta-analysis of published case-control literature on inter-atrial septal 
abnormalities and stroke. Firm conclusions are drawn, with recommendations 
for future work. Appendix 1 describes a planned study which will aim to 
determine the presence of association in the elderly stroke population.
1.5 Current status of investigation and management in PFO 
associated cryptogenic stroke
Interpretation of observational data, and the translation of the information it 
provides into decisions that truly influence patient management, is fraught 
with difficulty. Although certain characteristics of ‘association’ suggest that the 
relationship detected is more likely to be a causal one, for example the 
presence of a ‘dose-response’ relationship, it does not necessarily follow that 
treatment of a putative ‘cause’ will influence the incidence of its proposed 
effect. A randomised controlled trial is the only proper way to test such a 
hypothesis and the information provided by such studies forms the basis of 
the practice of ‘evidence based medicine’. Designing randomised studies, 
however, requires great skill and attention, especially in the context of rare or 
uncommon diseases or low rates of outcome events. Moreover, observational 
data tend to become available to practising clinicians a number of years 
before proper randomised trials are designed or completed. Clinicians are left 
to practise in an environment where there is no ‘right answer’.
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‘PFO-associated stroke’ illustrates this situation well. Association has been 
demonstrated in numerous studies between PFO and stroke, and because of 
the ‘biologically plausible’ explanation that venous thrombosis and 
paradoxical embolism result in stroke, attention has shifted to treatment. This 
is despite numerous studies that have failed to demonstrate a relationship, 
especially in the older patients that make up the majority of stroke patients, 
and the consistent finding both in clinical practice and published series that 
venous thrombosis is extremely difficult to detect 84. It would be pragmatic to 
argue that such patients should not currently be treated with potentially 
deleterious anti-thrombotic agents, except in the context of randomised 
controlled trials. However, physicians faced with such patients, in whom the 
consequences of stroke recurrence could be devastating, understandably find 
it difficult to await the results of randomised trials.
How physicians react in such a situation is dependent on both training and 
local service availability. It will also depend on the nature of the individual 
physician, and the individual patient. There will always be those who translate 
the information provided by observational literature more readily, just as there 
will always be physicians who treat patients ‘aggressively’, in the belief that 
such an approach will reap long-term benefits. Since no therapy is proven, 
more conservative doctors will favour the secondary preventative measure 
that is likely to carry the least chance of side effects. Others will approach the 
problem more mechanistically: if the root of ischaemic stroke in this situation 
is embolism, would the best preventative measure not be systemic 
anticoagulation?
The two ‘medical’ approaches available were recently examined in a 
substudy of the Warfarin and Aspirin in Recurrent Stroke Study (WARSS)35. 
In WARSS 2206 stroke patients were prospectively randomised to 
prophylactic therapy with either warfarin (to maintain the International 
Normalized Ratio, or INR, in the range of 1.4 to 2.8) or aspirin (325 mg daily),
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and followed for recurrent events during a 2-year period. For the whole study 
group no difference was detected between aspirin and warfarin in the 
prevention of recurrent ischaemic stroke or death or in the rate of major 
haemorrhage.
The PICSS study (Patent foramen ovale In Cryptogenic Stroke Study), a 
substudy of the larger WARSS cohort, has not yet been published. 
Preliminary data have been presented at a recent meeting (27th International 
Stroke Conference, San Antonio, Texas, February 7-9 2002). PICSS aimed to 
determine the two-year rate of stroke recurrence or systemic embolisation in 
medically treated (warfarin or aspirin) cryptogenic stroke patients with a 
patent foramen ovale (PFO), and to compare it to the two-year rate of stroke 
recurrence or systemic embolisation in medically treated cryptogenic stroke 
patients without a PFO. It was powered on the basis that the presence of 
PFO will double the two-year rate of stroke recurrence or systemic
embolization in cryptogenic stroke patients. The study was not powered to 
detect a difference between aspirin and warfarin. The total number of patients 
randomised was 630 with a mean age at randomisation of 59.7 years. There 
were a number of secondary aims:
• To determine the two-year rate of stroke recurrence or systemic
embolization in warfarin treated cryptogenic stroke patients with a PFO, 
and to compare it to the two-year rate of stroke recurrence or systemic 
embolization in warfarin treated cryptogenic stroke patients without a PFO.
• To determine the two-year rate of stroke recurrence or systemic
embolization in aspirin treated cryptogenic stroke patients with a PFO, and 
to compare it to the two-year rate of stroke recurrence or systemic 
embolization in aspirin treated cryptogenic stroke patients without a PFO.
• To obtain pilot data on the natural history of medically treated cryptogenic 
stroke patients with varying sizes of PFO.
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• To obtain pilot data on the natural history of medically treated cryptogenic 
stroke patients with transoesophageal echocardiographically detected 
potential cardiac embolic sources defined as aortic arch mass, left atrial 
spontaneous contrast, or atrial septal aneurysm.
The probability of an event at 2 years in the PFO positive group was 14.8% 
compared to 15.3% in the PFO negative group. No difference in recurrence 
between PFO positive and PFO negative patients was detected in the 
warfarin or aspirin treated cohort. Full data from PICSS will help to delineate 
those features that are associated with the highest risk of recurrence, but to 
answer central management questions, trials concentrating on a younger and 
more stringently selected group will be required.
It is becoming increasingly common, especially in mainland Europe and 
America, to correct PFO lesions surgically. Numerous surgical series have 
been reported, some with flawless results 85. To avoid the need for an open 
procedure, and a period spent on cardiopulmonary bypass, many 
cardiologists are using percutaneous closure devices to correct inter-atrial 
septal defects. Recently, large series of patients treated with percutaneous 
closure have reported a crucial finding: that persistent patency of the PFO 
after attempted closure is associated with stroke recurrence 86 87. Any clinical 
trial to compare medical versus surgical therapy (percutaneous or open 
closure) for PFO associated stroke will require a large number of patients to 
discern what is likely to be a small difference in overall outcome, since 
reported recurrence rates are low in both retrospective series 88 89 and more 
recently in a large prospective cohort90 (see chapter 4 for detailed discussion 
of these data).
It is in the climate of uncertainty described that the survey reported in chapter 
4 was conducted. A questionnaire was distributed to assess whether United 
Kingdom experts felt that patients should be investigated for PFO, and how
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they would act if such a lesion were found. Randomised studies are 
underway in both America (percutaneous closure vs aspirin vs warfarin) and 
Germany (percutaneous closure vs warfarin), and a proper assessment of 
current management practice is a useful precursor to the design of a UK 
based study.
1.6 Stroke, statins and cholesterol
For stroke, in contrast to coronary heart disease (CHD), the relation between 
an increased risk of stroke and increased plasma total cholesterol or low 
density lipoprotein (LDL) cholesterol is in dispute. The largest observational 
analysis, a review of 45 prospective observational cohorts involving 450,000 
individuals and a mean follow up of 16 years, found no association between 
blood cholesterol and total stroke 91. However, many trials reported merely 
fatal strokes (allowing a possible association with non-fatal stroke to be 
missed), and any association with ischaemic stroke may have been diluted by 
an inverse association of serum cholesterol and haemorrhagic stroke, which 
has been reported in other series 92 93. Both these series also suggested 
positive correlations between serum cholesterol and non-haemorrhagic stroke 
risk.
There are several reasons why the epidemiological relationship between 
cholesterol and stroke risk may be weak or absent. First, stroke is a 
heterogeneous condition, with less than half of all strokes being caused by 
large vessel atheroma. This contrasts with the situation in coronary artery 
disease in which nearly all presentations are due to coronary artery 
atheroma. One would not expect cholesterol levels to influence the incidence 
of cardioembolic stroke, or small vessel arteriosclerosis. Second, since 
coronary deaths generally occur in a younger age group, the population with 
cervical or cerebral large vessel atheroma secondary to raised plasma lipids
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is lower by the time that most strokes occur. Total and LDL cholesterol 
decrease with advancing age, as does their relation to CHD.
In acute stroke, poor outcome has been found to correlate with lower total 
cholesterol concentrations by two major stroke registries 94 95. Both these 
groups reported the association in both ischaemic and haemorrhagic 
subtypes. These findings draw into question the use of cholesterol lowering 
agents in the acute phase of stroke: while the Swiss group reported poor 
functional outcome at one month, higher serum cholesterol levels were 
associated with reduced long term mortality in the Glasgow study 94.
Stroke has been studied as a secondary endpoint in cholesterol lowering 
trials which have examined HMG-CoA reductase inhibitors (statins) both as a 
primary prevention measure and after Ml. These data do suggest a beneficial 
effect on incidence of cerebrovascular events. Four published meta-analyses, 
three of which examined specifically the effect of statins 96 97 98 and one of 
which examined all lipid lowering drugs " ,  have reached broadly similar 
conclusions. They indicate that statins reduce the risk of stroke by 
approximately 30% in patients with CHD. These analyses are dominated by 
data from three large studies: the West Of Scotland COronary Prevention 
Study (WOSCOPS) (primary prevention in high risk hypercholesterolaemic 
individuals), the Scandinavian Simvastatin Survival Study (4S) (secondary 
prevention in hypercholesterolaemic individuals) and the Cholesterol and 
Recurrent Events (CARE) study (secondary prevention in patients with 
‘normal’ (<6.2 mmol/l) cholesterol). The more recently published LIPID trial 
(again a secondary prevention trial in patients with CHD) showed consistent 
results.
Some of the uncertainty in the cerebrovascular population without CHD will 
be addressed by the publication of the recently completed Heart Protection 
Study (HPS) 10°. This enrolled 20,000 high risk patients, and a preliminary
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subgroup analysis has been posted on the internet (www.ctsu.ox.ac.uk). 
Although full publication and adjudication of all events is awaited, significant 
benefit (-24% RRR) in the reduction of all vascular events was seen in 
patients with a history of ischaemic stroke (and no history of CHD). No 
heterogeneity of benefit was seen between groups with different types of 
vascular event or risk at baseline.
Two major multicentre trials are awaited. The Risk Evaluation and Stroke 
Prevention in the Elderly- Cerivastatin Trial (RESPECT) trial is a primary 
prevention study with cerivastatin, ongoing in Northern Europe, which has 
stroke incidence as its primary outcome measure 101. The Stroke Prevention 
by Aggressive Reduction in Cholesterol Levels (SPARCL) study examines the 
role of the statin which has the most potent effect on serum cholesterol 
(atorvastatin) in the secondary prevention of stroke and other major vascular 
events after an initial ischaemic or haemorrhagic cerebral event. Patients with 
CHD will be excluded from these studies.
The mechanism by which statin therapy produces effects on CHD mortality 
may be particularly pertinent to stroke prevention. It is clear that the profound 
reduction in cholesterol levels attributable to statin therapy produces 
regression in both coronary and carotid atheromatous lesions 102 103. This 
improvement occurs over 4 years, and was not evident at 2 years in the 
Multicentre Anti-Atheroma Study (MAAS) 102. However, the reduction in 
vascular events observed in both 4S and WOSCOPS occurred within 2 years: 
much sooner than would be expected as a result of reduced atheroma 
progression or regression. Moreover, no relationship between risk reduction 
of major coronary events by statin and baseline LDL concentration was found 
104 105. In WOSCOPS the effect of therapy was highest in those patients in the 
middle quintile of LDL at baseline: it appeared that treatment effect was 
independent of LDL concentration 105. Similarly, preliminary data from HPS
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show similar benefit in vascular event reduction in all three tertiles of baseline 
LDL and total cholesterol.
Statins do more than ju s t lower cholesterol
For the reasons above alternative mechanisms have been proposed to 
explain the action of statins. Numerous authors have investigated the 
possible effects of statins on vascular endothelial reactivity, 
haemorrheological markers and vasomotor tone in an attempt to explain their 
effects 106 107. Statins appear to stabilise plaque by a number of mechanisms, 
and have antiproliferative effects due to reduced levels of oxidized LDL and 
intermediates in cholesterol metabolism, which have been implicated in the 
control of cell proliferation. Improvements in endothelial function and 
vasomotor tone have been demonstrated in both coronary and forearm 
vasculature. Cardiovascular reactivity (as measured by blood pressure 
response to incremental infusions of angiotensin II and noradrenaline) is 
improved by pravastatin 108. Conclusive evidence from a recent controlled trial 
demonstrated that pravastatin lowered systolic, diastolic and pulse pressures 
in hypercholesterolaemic patients with moderate hypertension 109.
Improved myocardial perfusion (measured by thallium-201 SPECT scanning) 
has been demonstrated after only 12 weeks of fluvastatin therapy 11°. Such 
effects of statins have not been studied in cerebral vasculature in humans. 
However, acute LDL and fibrinogen reduction has been shown to have 
beneficial effects on cerebral blood flow 111. An alternative mechanism by 
which statins may improve cerebral blood flow has been elegantly 
demonstrated in a murine model: improved perfusion, reduced infarct size 
and improved neurological function occurred by selective up-regulation of 
endothelial nitric oxide synthase (eNOS) 112. The blood flow and 
neuroprotective effects of statins were absent in eNOS knockout (deficient) 
mice. Both up-regulation of eNOS and down regulation of inducible nitric 
oxide synthase (iNOS) are potentially neuroprotective 113.
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Effects on intravascular thrombosis
The effects of statins on endothelial function, smooth muscle cell proliferation 
and plaque composition may only partially explain their effects on myocardial 
and cerebral perfusion and early effects on vascular event rate. Numerous 
studies have documented the effects of statins on blood constituents 114, 
including fibrinogen, plasma viscosity, endogenous tissue plasminogen 
activator (tPA), plasminogen activator inhibitor 1 (PAI-1), von-Willebrand 
factor, d-dimers and factor VII. Each of these ‘haemorrheologicar markers 
has been proposed as a marker of vascular risk, and as a potential target for 
pharmacologic therapy in cerebrovascular disease. The evidence linking each 
of these markers of blood ‘thickness’ with stroke is discussed below.
The Edinburgh Artery Study reported the relationship between blood 
viscosity and incident vascular events, and examined the complex inter­
relationships between plasma and whole blood viscosity, haematocrit and 
fibrinogen 115. The results suggested that blood viscosity was as strong a 
predictor of cardiovascular events in older individuals as LDL cholesterol or 
diastolic blood pressure. Furthermore, the component of viscosity due to 
plasma (which is largely determined by fibrinogen level) seemed to be at least 
as important as that due to haematocrit. In addition to thrombogenic effects, 
fibrinogen and viscosity may have a direct effect on cerebral blood flow -  an 
inverse relation has been shown to exist in the elderly between fibrinogen and 
viscosity levels and middle cerebral artery velocity measured by transcranial 
Doppler116.
There is a large amount of epidemiological evidence suggesting that plasma 
fibrinogen levels are significantly associated with cerebrovascular events, 
and that the association may explain to some extent the association between 
smoking and stroke. Data from the Gothenberg and Framingham studies 
have shown that plasma fibrinogen is an independent prognostic risk factor
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for stroke 117118. Similarly, the Oxfordshire Community Stroke Project (OCSP) 
demonstrated that an elevated plasma fibrinogen level (in addition to 
generalised hypercholesterolaemia and elevated low-density lipoproteins) 
was a risk factor for prevalent cerebrovascular events 119.
Fibrinogen is an acute phase protein which commonly rises during the acute 
phase of stroke and is a potent predictor of vascular risk in stroke survivors 
12°. Randomised clinical trials with ancrod, a serine protease derived from the 
venom of the Malayan pit viper and which acts as a defibrinogenating agent, 
have been recently reported. The Stroke Treatment with Ancrod Trial (STAT) 
121 showed efficacy similar to that of tPA, with a 23% increase in patients with 
a favourable functional status (Barthel score >95) in comparison to placebo. 
The study was, however, dogged with the methodological problems of 
administering ancrod as a 74 hour infusion requiring plasma fibrinogen 
monitoring, and sullied by the almost simultaneous termination of the 
concurrently running European Trial 122. Patients receiving ancrod in Europe 
had a higher 90 day mortality than placebo treated patients: it is not yet 
apparent why.
Endogenous tPA is the primary mediator of intravascular fibrinolysis: in a 
paper based on data from the Physicians Health Study the age-adjusted 
relative risk for total stroke among men with baseline tPA concentrations 
above the 95th percentile of the control distribution was 3.51 (95% Cl=1.72- 
7.17)123. This finding was confirmed by the Edinburgh Artery Study 124. PAM, 
which is also produced by endothelial cells, inhibits the activity of tPA and 
thereby the fibrinolytic process (see figure 1.3 125). Levels have been shown 
to be independently associated with prevalent I HD and increased incident 
IHD in persons with established arterial disease 126. In a study of 135 acute 
stroke patients and 77 controls, increased levels of both tPA (reflecting 
fibrinolytic activation) and PAI-1 (reflecting increased fibrinolytic inhibition) 
were seen in the acute phase of stroke 127. In the acute stroke group, the
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concentrations of tPA and PAI-1 antigen appeared to differ little between the 
acute and convalescent phases (they remained raised), arguing against those 
authors who have suggested their presence to reflect an acute phase 
reaction. However, only 23% of stroke subjects were re-examined in the 
convalescent phase. More recently, assays that measure tPA complexed with 
PAI-1, have demonstrated that tPA/PAI-1 complex is independently 
associated with the development of first ever stroke 128. The interplay 
between these factors in the activation and inhibition of the fibrinolytic 
pathway is shown in figure 1.4125.
D-dimer levels reflect fibrin turnover and thrombogenesis, and may be a 
useful marker of thrombogenesis. Their use in the clinical diagnosis of venous 
thromboembolism has received increasing interest in recent years, but they 
have are also associated with prevalent and incident IHD in longitudinal 
studies 129. In the Physicians Health Study, d-dimer levels were significantly 
predictive of incident arterial, but not venous, vascular events in a population 
free of vascular disease at outset 13°.
Von Willebrand factor (vWF) is synthesised by and stored in endothelial 
cells. When released, vWF seems to mediate platelet aggregation and 
adhesion to the vascular endothelium, and has been proposed as an indicator 
of endothelial disturbance or dysfunction 131. Levels have been shown to 
correlate with the presence of left ventricular dysfunction, atrial fibrillation and 
peripheral vascular disease 132. High concentrations of vWF are associated 
with ischaemic cerebrovascular disease, although the association has only 
been detected in small studies. It may reflect either endothelial dysfunction 
associated with cerebral thrombosis or its risk factors, or ischaemia related 
release of vWF from infarcted tissue.
The relationship between factor VII and vascular disease appears less strong 
than those described for fibrinogen, tPA and PAI-1. The Northwick Park Heart
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Study reported a strong relationship between factor VII activity and recurrent 
vascular events 133. This has not, however, been confirmed by subsequent 
data: the PRIME study confirmed relationships reported for other haemostatic 
factors but showed evidence of an acute phase or consumptive fall in factor 
VIIc levels after myocardial infarction, with levels approaching those of 
healthy matched controls at 3 months 134.
Studies that have examined statin effects on such vascular markers are 
small. Different effects have been reported for each of the different naturally 
occurring (lovastatin and pravastatin), semi-synthetic (simvastatin) and 
synthetic compounds (fluvastatin, cerivastatin and atorvastatin). Some of the 
reported effects have been deleterious 135. The most promising in terms of 
atherothrombotic effects appears to be pravastatin 114. In a randomised trial 
pravastatin had significant (and clinically important) effects on plasma and 
whole blood viscosity and fibrinogen over a 10 week course, while simvastatin 
had no such effects 136. The effect of statins on haemostatic markers in the 
acute phase of ischaemic stroke has not been reported.
An acute phase response during and immediately after acute vascular events 
is well documented. Patients with high levels of markers of acute phase 
response (for example CRP) have a poorer prognosis after both acute stroke 
and acute Ml than patients without such findings 137 138. As well as marking 
poor prognosis after acute events, it seems that a chronic low grade 
inflammatory response is associated with incident vascular events over long 
periods of follow-up. A recent study by Danesh et al confimed previous 
findings that a twofold increase in the risk of future cardiovascular events is 
associated with even mildly raised concentrations of CRP 139. The 
accompanying meta-analysis revealed an odds ratio for CHD of 1.9 (95% C I
1.5 to 2.3) when comparing individuals in the highest and lowest CRP tertiles. 
A weaker association was discovered for serum amyloid A protein.
50
It has been proposed that in addition to effects on Theological markers, many 
of which demonstrate an ‘acute phase response’ as alluded to above, statin 
therapy may have a more generalised ‘anti-inflammatory’ action, which may 
benefit patients with vascular disease. Such theories are supported by data 
from the CARE study, which examined those patients with evidence of ‘acute 
inflammation’ (high CRP or serum amyloid A levels) who were randomised to 
pravastatin or placebo. In stratified analyses the association between 
inflammation and risk was significant among those randomised to placebo 
(RR=2.11, p=0.048), but was attenuated and non-significant among those 
randomised to pravastatin (RR=1.29, p=0.5), suggesting an anti-inflammatory 
effect of statin therapy which modulates cardiovascular risk. Again, statin 
effects on such markers after stroke have not been reported in a randomised 
trial.
Chapter 5 reports a clinical trial designed to investigate the acute effect of 
statins in stroke. As endothelial, anti-proliferative, anti-oxidant, anti­
inflammatory and Theological effects of statins are becoming increasingly 
recognised in the field of cardiology, their use in the acute phase of coronary 
syndromes is becoming more widespread. In stroke, statins may have a role 
in maintaining cerebral perfusion, neuroprotection, reduction of final infarct 
size and in the acute prophylaxis of further vascular events. If beneficial 
effects on important surrogate markers can be demonstrated in the acute 
phase, larger studies with hard clinical endpoints may be designed to 
examine the effects of acute statin therapy in the wider stroke population.
1.7 Alternative vascular risk factors: can infections cause 
stroke?
While identified risk factors (for example smoking and blood pressure) play a 
large part in the genesis of ischaemic stroke, numerous other factors have 
become evident over recent years. The association between elevated levels
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of homocysteine and both coronary and cerebral vascular disease is 
becoming increasingly clear 14°, and two large trials (Vitamin Intervention in 
Stroke Project (VISP) and VITAmins TO Prevent Stroke (VITATOPS)) are 
currently following-up randomised cohorts with the aim of establishing 
whether homocysteine lowering with B vitamins can influence vascular risk. 
Another active research area concerns the possibility that chronic infections 
may cause stroke.
Both pyrexia 13 and high levels of systemic inflammatory markers 137 confer a 
poor outcome in stroke, but may reflect the effects of the stroke insult itself 
rather than marking an inflammatory cause. Associations have been reported 
between stroke and recent bacterial infection 141, viral infection 141, and with 
clinical correlates of chronic dental infection (for example severe periodontal 
disease and missing teeth) 142. Other studies have reported histological 
evidence of bacteria or viruses in atheromatous or non-atheromatous blood 
vessels (both cerebral and coronary), in addition to sero-epidemiological 
studies reporting association with antibody measurements. These studies, 
pertaining largely to the CHD population, are well summarised elsewhere 143. 
Many of these studies can be criticised with regard to their selection of control 
patients, and the choice of antibody titre and type chosen empirically to 
indicate ‘seropositivity’ or ‘active infection’.
Numerous mechanisms by which infections may increase stroke risk have 
been proposed. These are outlined in figure 1.5 i43. The infectious agent may 
have effects on the arterial wall, causing endothelial injury or dysfunction, 
smooth muscle proliferation or local inflammation. The most convincing 
experimental evidence supports the effects of chronic or acute infection in the 
circulation, through systemic inflammation, cross reactive antibodies, or 
effects on cardiovascular risk factors, such as LDL, homocysteine or 
fibrinogen 143.
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Chlamydia Pneumoniae and its association with stroke
Chlamydia pneumoniae frequently causes community acquired respiratory 
infections such as sinusitis, pharyngitis, and pneumonia. There are epidemics 
due to C. pneumoniae infection every 5 to 7 years in Northwestern countries, 
with a 50% to 70% prevalence of seropositivity in middle aged adults. Most 
adults are infected 2 to 3 times during their lifetime. It is an obligate 
intracellular gram-negative bacterium, and after ingestion by circulating 
macrophages may trigger or perpetuate inflammatory changes that contribute 
to the development of atherosclerosis, either directly or indirectly (see figure
1.6 144). Both chronic and acute chlamydial infection appear to be associated 
with a pro-coagulant state.
The specific association of chlamydial infection and stroke has been reported 
by numerous workers. Wimmer et al demonstrated (with 
microimmunofluorescence antibody techniques) that chlamydia IgA and 
specific IgG levels in circulating immune complexes were significantly higher 
in stroke patients than controls 145. An even stronger effect was demonstrated 
by Cook et al, with acute chlamydial infection being associated with an odds 
ratio of 4.2 (95% Cl 2.5 to 7.1) for stroke/TIA, and chronic chlamydial infection 
being associated with an odds ratio of 4.4 (95% Cl 3.0 to 6.5) 146. Reported 
associations with prevalent cerebrovascular disease are strengthened by 
recent work on incident stroke: Fagerberg et al reported that high titres to 
chlamydia pneumoniae were associated with a relative risk of 8.58 for future 
stroke in a high risk population, albeit with a wide confidence limit (1.07 to 
68.82) 147. Other workers, however, have failed to confirm these findings 148.
Hyperfibrinogenaemia has been found to be consistently correlated with 
chlamydial infection. The association was originally described in 1994 149, 
when seropositivity to both C. Pneumoniae and Helicobacter Pylori was 
independently associated with raised fibrinogen in a small general practice 
based case-control study. Subjects had no history of vascular disease. A
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larger study by the same authors found both H.pylori and C.pneumoniae to 
be associated with CHD, even after extensive adjustment for confounders, 
and confirmed the association of infection with leucocyte count and with 
fibrinogen 150. The same authors found that C. pneumoniae was associated 
with higher concentrations of factor VII antigen 150. In a study of patients with 
unstable angina, the association between persistent C.pnuemoniae infection 
(assessed by IgA titres) and increased fibrinogen levels was independent of 
other risk factors evaluated in multivariate analysis 151.
Treatment trials that have used antibiotics in CHD have already been 
published, and represent a promising avenue for modern secondary 
prevention. No treatment trials have been conducted in cerebrovascular 
patients. In a randomised, placebo controlled study macrolide antibiotics 
(azithromycin) were given to a series of male survivors of Ml with raised 
serum anti-C.pneumoniae titres 152. The study found a four-fold increase of 
adverse cardiovascular events among the group with elevated C.pneumoniae 
titres who received no antibiotic therapy compared with the group that had 
negative serology (odds ratio 4.2; 95% Cl 1.2 to 15.5). In contrast, 
seropositive treated patients treated with azithromycin had a similar outcome 
to seronegative patients (OR 0.9; 95%CI 0.2 to 4.6). Subjects receiving 
azithromycin had a significant fall in certain levels of serum and monocyte 
activation markers, including fibrinogen (see below). Unfortunately the results 
of this study do not help to distinguish between a chlamydia-specific effect of 
azithromycin and a more generalised anti-inflammatory effect, because only 
seropositive patients received therapy.
The ROXIS (roxithromycin in ischaemic syndromes) study found a significant 
effect of antibiotic therapy on recurrent ischaemic event rate at 30 days after 
non-Q wave coronary syndromes 153. However, 6 months after the study 
treatment termination, there was no longer any significant difference between 
the treatment and placebo groups 154. About half the population studied were
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seropositive (lgG>1:64) at inclusion, and event rates in this subgroup did not 
differ significantly between those receiving placebo and those receiving 
roxithromycin. Other trials in the CHD population are planned, and are well 
summarised elsewhere 155. These are hoped to provide worthwhile 
information on hard endpoints, while also adding to knowledge about how 
chlamydia may lead to vascular events. The proper elucidation of this 
mechanism is vitally important in the delivery of therapy to those most likely to 
benefit.
If chlamydial infection leads to hyperfibrinogenaemia, and therefore a 
hypercoagulable state predisposing to vascular events, then treatment of 
chlamydial infection may reduce fibrinogen. Demonstrating this would 
improve arguments that chlamydia is a cause of vascular disease, rather than 
an incidental association, since its treatment reduces a potent factor in 
determining vascular risk. Recently Torgano et al published a study of 84 
‘chronic’ CHD patients who were seropositive for both C.pneumoniae and 
H.pylori antibodies, and who had normal acute phase reactants 156. They 
assessed the effect of treatment (omeprazole, clarithromycin and tinidazole 
for H.pylori positive patients, and clarithromycin for C.pneumoniae positive 
patients) on fibrinogen levels at 6 months. Treatment significantly reduced 
fibrinogen at 6 months in the overall study population and in the groups of 
patients divided according to H.pylori or C.pneumoniae positivity, the largest 
decrease being observed in patients with both infections. Unfortunately, the 
study was not placebo-controlled, and gave no information about antibiotic 
effect on fibrinogen in patients without H.pylori or C.pneumoniae infections.
Other markers of vascular risk or inflammation have been studied. As 
mentioned previously, Gupta et al demonstrated significant effects on 
monocyte/macrophage tissue factor and the surface adhesion molecule 
CD11b 152. The ACADEMIC (Azithromycin in Coronary Artery Disease: 
Elimination of Myocardial Infection with Chlamydia) study, a placebo
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controlled study of azithromycin vs placebo in 302 C pneumoniae positive 
CHD patients, found antibiotic effects on CRP and interleukin-6 (IL-6) levels 
after 6 months. Fibrinogen was not measured, and no effect on 
cardiovascular endpoints was detected. What characterises all of these 
studies is the lack of distinction betweeen a 'generalised' anti-inflammatory 
effect of macrolide antibiotics, and a chlamydia-specific effect, which should 
play a part only in those individuals who are seropositive for the infection.
Chapter 6 describes the pilot phase of a small randomised placebo controlled 
trial in acute ischaemic stroke patients designed to answer some of the 
mechanistic questions that have stemmed from the work summarised above. 
Both patients with and without serological evidence of chlamydial infection will 
be treated with azithromycin or placebo, and the effect on plasma fibrinogen 
followed. If an effect on plasma fibrinogen is detected, the study will be able 
to establish whether all patients benefit in terms of fibrinogen reduction, or 
just those seropositive for chlamydia. Effects on other markers (CRP, plasma 
viscosity and vWf) will be explored.
1.8 Concluding comments
If ongoing research into ‘novel’ vascular markers proves positive, the 
secondary prevention of stroke will change considerably. Patients of the 
future may be provided not just with antithrombotic and anti-hypertensive 
therapy, but with a statin, an antibiotic, B-vitamins and other supplements. 
The interaction of the different agents in the reduction of future risk, the cost- 
effectiveness of different therapies and drug compliance in a functionally 
impaired population are some of the issues that will require clarification if 
randomised trials prove positive.
Epidemiological data suggest that the causes and risk factors for stroke may 
not necessarily be synonymous with those for CHD. Interest in novel ‘stroke’
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risk factors has largely followed preliminary work in the CHD population, 
which is larger, easier to study and younger. However, vascular ‘brain’ 
disease is a more complex and heterogeneous condition than vascular heart 
disease. The three main mechanisms for stroke, namely small vessel 
arteriosclerosis and thrombosis, embolism from a proximal source, and large 
vessel atherothrombosis, contrast with the one mechanism for Ml: coronary 
atheroma. Additionally, stroke can affect grey or white matter, the 
neuroprotective targets for each being different. It is this complexity which has 
militated against positive trial results in stroke. Such considerations suggest 
that inclusion and classification of stroke in both trials and clinical practice 
should become more detailed, acknowledging the complexity that exists. 
Furthermore, experimental and ‘pre-clinical’ research should concentrate on 
‘stroke-specific’ risk factors and causes, rather than merely transcribing work 
from the CHD population.
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Chapter 2: Association between carotid disease and 
ipsilateral lacunar stroke
65
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2.1 Introductioni
Major surgical intervention trials have established the role of carotid 
endarterectomy in the management of patients with carotid stenosis 44 157 42. 
Increasingly, consideration of the benefit that is likely to be derived by 
patients with specific clinical characteristics 47 and the costs that might be 
incurred by surgical intervention 158, has resulted in calls for a more selective 
policy of referral for vascular surgical attention. Central to evidence-based 
decision making in this area is the assessment of whether a carotid lesion is 
symptomatic: patients with symptomatic stenoses are at much higher stroke 
risk than those with asymptomatic lesions 159, at least in the first 3 years 16°, 
and derive greater benefit from intervention than those with asymptomatic 
lesions 42 46. Moreover, recent data on 'surgical skill' have shown that peri­
operative stroke rates in clinical practice are likely to be considerably higher 
than those achieved in carotid endarterectomy trials 161.
Published guidelines currently recommend consideration of endarterectomy 
in patients with symptomatic severe stenosis 162. While evidence of cortical 
stroke or transient ischaemic attack (TIA) ipsilateral to a severely stenotic 
carotid lesion strongly suggests that the stenosis caused the cerebral lesion, 
lacunar or subcortical stroke in combination with ipsilateral carotid stenosis 
presents a more challenging clinical picture. Because most lacunar strokes 
and subcortical lesions are caused by intrinsic small vessel disease (often 
secondary to hypertension or diabetes) 48, stenosis in these patients may be 
incidental, and surgical correction may expose the patient to the risks of 
surgery with no more benefit than would be derived from a ‘blanket’ policy of 
surgical correction in all detected stenoses. Published literature supports the 
view that large vessel stenosis is rare in lacunar stroke and TIA in comparison 
to cortical disease 163 164 165 166, but more common than in the general 
population 167 168. Studies have not been of sufficient size to detect a clear 
association between 'lacunar' presentation and extracranial vascular disease
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165 169 170 j ^ e fyyQ maj0r trials of ‘symptomatic’ carotid stenosis included 
patients with lacunar syndromes and subcortical lesions on CT scanning, but 
subgroup analysis was unable to detect significant benefit from surgery in 
either the ECST 53 or NASCET 54 study. Sample sizes were small however: in 
ECST only 43 patients with severe stenosis had CT evidence of lacunar 
infarction at randomisation, and only 5 ischaemic strokes occurred in this 
group during the follow-up period 53.
The aim of this analysis was to investigate any association between carotid 
lesions and subcortical syndromes, by comparing the prevalence of clinical 
lacunar syndromes and subcortical strokes ipsilateral and contralateral to 
ultrasonically detected carotid disease. Furthermore the risk of recurrent 
stroke was determined by record-linkage analysis in the two groups.
2.2 Methods
The Western Infirmary Acute Stroke Unit serves a catchment population of 
200,000. All patients who present within 72 hours of onset of acute 
neurological deficit likely to be of vascular origin are admitted irrespective of 
age or severity of presentation. Approximately 800 patients are admitted each 
year. Patients who present less acutely, or who may be better assessed in a 
clinic environment, are seen at a rapid referral clinic that occurs twice a week. 
All patients given a stroke diagnosis are classified using the Oxford 
Community Stroke Project171 method. Patients with a clinical diagnosis of TIA 
are classified in a similar manner 166. Classification is performed by the 
admitting Senior House Officer, and verified by a consultant physician within 
24 hours. Brain imaging using either CT or MRI is performed within 72 hours 
of admission (or within 1 week if seen in clinic) on all patients with a clinical 
diagnosis of stroke, and almost all patients with TIA. A carotid Doppler 
examination is routinely performed in all patients. Clinical and radiological 
data from each patient are reviewed and verified during a weekly meeting
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attended by a neurologist, a radiologist and a team of specialist stroke 
physicians (one of whom will have been involved in the original clinical 
classification) before being recorded prospectively on a database. Carotid 
ultrasound findings are not used in clinical or radiological classification of 
stroke subtypes, and are recorded on a separate database. Clinical and 
radiological data for each patient have been linked to ultrasound data for the 
purposes of this study.
We analysed the database records for those patients admitted between April 
1994 and 1998. The database for this period contained information for 3721 
patients in total, 2445 (66%) of whom had linked data on Doppler results, and 
3213 (86%) of whom had CT or MRI results recorded. We extracted data for 
those patients who had concurrent evidence of unilateral lacunar disease 
(LD) (as defined by a clinical lacunar syndrome with normal imaging or 
imaging evidence of unilateral subcortical infarction) and unilateral carotid 
disease (CD) (as defined by a moderate (50-70%), severe (>70%) or 
occluded single carotid vessel on ultrasound). Of 1093 LD patients on the 
database, 835 had linked Doppler data (since CT or MRI formed part of the 
definition of LD, all LD patients had imaging data). Individuals with bilateral 
LD or bilateral CD were not included in the analysis. These amounted to 4 
patients with bilateral CD and bilateral LD, 16 patients with bilateral CD and 
right LD, 14 patients with bilateral CD and left LD, 7 patients with right CD and 
bilateral LD and 6 patients with left CD and bilateral LD. Patients with striato- 
capsular infarction or large subcortical infarction extending into cortical 
territories on CT or MRI were classified on the database as 
cortical/subcortical and were excluded, while those with a separately 
classified cortical lesion or event were included. The incidence of contralateral 
LD and CD (group 1) was compared to the incidence of ipsilateral LD and CD 
(group 2). Risk factors (smoking, hypertension, atrial fibrillation, 
hyperlipidaemia and diabetes (types I and II)) in the two groups were 
assessed. Proportions with moderate, severe and occluded vessels in the two
!I 68ii
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' groups were calculated. Age and first recorded ward blood pressure were
also analyzed and compared.
Using follow-up data we assessed the recurrence rate of ischaemic stroke in 
the two groups. Follow up was by record-linkage 172 to both hospital 
discharge records (to obtain information on recurrent ischaemic stroke) 173 
and death records from the Registrar General of Scotland. This technique has 
been validated in an epidemiological study of hypertension 174 and has been 
used for monitoring end points in a large clinical trial 175. The method of 
record-linkage is reliable, but admissions to private hospitals or institutions 
outside Scotland are not recorded. Patients in groups 1 and 2 with separate, 
additional cortical lesions or cortical events ipsilateral to the side of their CD, 
who thereby fulfilled conventional descriptions of ‘symptomatic carotid 
disease’ (4 in group 1, 8 in group 2), were excluded from the follow-up 
analysis. Data for those patients whose first recorded stroke diagnosis was 
during their admission to our unit, and for whom follow-up data were available 
(18 in group 1, 37 in group 2), were used to calculate the cumulative 
proportion in each group remaining stroke-free. The comparison of groups 1 
and 2 formed the primary follow-up analysis. In addition, stroke-recurrence 
data for all patients on the database whose first recorded stroke diagnosis 
was during their admission to our unit, and who presented with LD but had no 
CD (n=435), or who had CD but no evidence of LD (n=126), were analyzed 
as supplementary information.
A Chi-squared test of association was performed to determine whether there 
was an association between unilateral CD and unilateral LD. A significance 
level of 5% was used (without Yates’ correction). Treating moderate, severe 
and occluded carotid vessels as ordered and equally spaced points on a 
scale, a chi-squared test for trend was conducted to test for linear trend in 
severity of CD in groups 1 (contralateral) and 2 (ipsilateral). The proportion of 
patients with specific risk factors was assessed in both groups and compared.
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With contralateral / ipsilateral disease as the response variable, a multivariate 
analysis by forward stepwise logistic regression was conducted using BMDP 
software. A significance level of 5% was used for inclusion in the model. 
Mean age and first recorded ward blood pressure in the two groups were 
normally distributed, and were compared by t-testing. Kaplan-Meier analysis, 
using Statistica software (version 5.1 StatSoft, Inc. (1997)) was performed in 
both groups, and the ‘ipsilateral’ and ‘contralateral’ groups were compared 
using a Log-rank test. Data for patients on the database within the same 
period with just LD (no CD) (group 3) and just CD (no LD) (group 4) are also 
presented, and were compared to the initial two groups, by an extended 
(multiple sample) Log-rank test. No specific adjustments were made when 
directly comparing groups 3 and 4 to the original two groups, but data on 
these comparisons were viewed in the context of multiple tests having been 
conducted.
2.3 Results
The incidence of right and left LD in those with right and left CD is shown in 
table 2.1. The chi-squared test of association was strongly positive (p=0.003), 
and it can be seen from the table that lacunar strokes were more common on 
the side of carotid lesions. Mean age in (contralateral) group 1 was 73.4 
years compared to 70.1 years in (ipsilateral) group 2 (p=0.12). Mean (first 
ward reading) systolic blood pressures were 154 (group 1) and 165 (group 2) 
(p=0.06), while diastolic blood pressures were 91 and 89 respectively 
(p=0.31). Table 2.2 shows a chi-squared test for linear trend across the 
carotid disease groups (moderate stenosis, severe stenosis and occluded). 
The chi-squared test proved narrowly positive (p=0.049), with a trend towards 
higher severity of CD in group 2 (ipsilateral). The proportions of patients with 
each stroke risk factor are presented in table 2.3. No significant differences 
were found between the two groups. In the logistic regression model, severity 
of carotid disease was significantly predictive (p=0.048) of the presence of
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ipsilateral LD. No other risk factor was significant after carotid disease was 
added to the model (smoking, p=0.10; hypertension, p=0.97; AF, p=0.72; 
hyperlipidaemia, p=0.43; type II diabetes mellitus, p=0.93; type I diabetes 
mellitus, p=0.45).
The cumulative proportion of patients remaining stroke-free for groups 1 and 
2 is shown in figure 2.1. No stroke / TIA outcome events were recorded in 
group 1. Clear divergence can be seen between the two groups in the figure, 
but this trend did not reach conventional statistical significance (p=0.059). 
Eight patients were treated with carotid endarterectomy during follow up, one 
in group 1, and seven in group 2. Only one of these patients (from group 2) 
sustained a recurrent ischaemic stroke, 570 days after endarterectomy. 
Figure 2.2 presents data for LD (without CD) (group 3, n=435) and CD 
(without LD) (group 4, n=126), as well as groups 1 and 2. Multiple-sample 
testing showed survival to be significantly different in the 4 groups (p=0.003) 
shown in figure 2.2. Comparing the groups individually, there was no 
significant difference between group 1 and group 3 (p=0.320), or between 
group 1 and 4 (p=0.196). Neither groups 3 and 4 (p=0.248) nor groups 2 and 
4 (p=0.073) differed significantly, but comparison of groups 2 and 3 indicated 
that the presence of ipsilateral (but not contralateral) large vessel carotid 
disease confers a markedly poorer prognosis to those patients presenting 
with lacunar stroke or TIA (p=0.002). Stroke-free survival (with both ischaemic 
cerebrovascular events and death from all causes counted as a complete 
response) was also examined. Eight deaths not due to recurrent ischaemic 
stroke occurred in group 1 (3 vascular, 3 oncological and 2 respiratory), while 
6 such deaths occurred in group 2 (4 vascular, 1 oncological and 1 unknown). 
The trend to better outcome in group 2 (compared to group 1) disappeared 
(p=0.688 for comparison).
2.4 Discussion
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The impetus for this analysis stemmed from a genuine uncertainty as to the 
correct management course in what is a challenging clinical situation. We 
have found a strong association between unilateral carotid disease and 
subcortical syndromes. A trend towards increased severity of carotid disease 
in patients with ipsilateral lacunar stroke suggests a ‘dose-response’ 
relationship, which supports an aetiological hypothesis as the explanation for 
that association. In the logistic regression model, a single step increase in 
carotid disease severity (from moderate to severe, or from severe to 
occluded) was associated with an odds ratio for ipsilateral lacunar disease of 
1.93, with a wide and marginally significant 95% confidence interval of 1.01 to 
3.67.
If causation is discounted, it is difficult to explain the association detected. 
The implication is that, either by embolism or haemodynamic (‘low flow’) 
mechanisms, lacunar syndromes have resulted from ipsilateral large vessel 
disease. One might feel more able to accept that an ipsilateral carotid 
stenosis has caused a lacunar stroke if, in the individual patient, risk factors 
for small vessel disease are absent. However, when data for just those 
patients who have risk factors for small vessel disease (defined as a history of 
hypertension (treated or untreated) or a history of diabetes (type I or II)) are 
examined, chi-squared analysis continues to reveal a positive association 
between unilateral LD and ipsilateral carotid lesions (p=0.042). Thus, even in 
those patients with subcortical presentation or pathology in whom one might 
reasonably assume an ipsilateral carotid lesion to be incidental, there remains 
evidence of association between the two.
Calculation of the cumulative proportion of patients remaining ‘stroke-free’ 
adds some weight to the assertion that carotid disease is instrumental in the 
pathogenesis of ipsilateral subcortical infarction. A trend towards higher rates 
of cerebrovascular events in group 2 (with ipsilateral LD and CD) compared to 
group 1 failed to reach conventional significance (p=0.059), probably due to
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the low patient numbers for whom data were available and the absence of 
outcome events in (contralateral) group 1. The divergent findings shown in 
figure 2 reflect natural history rather than surgical morbidity. Patients in both 
groups received best medical therapy, including antiplatelet treatment and 
modification of risk factors. While those with lacunar and carotid disease on 
opposite sides had a similar prognosis to those with just lacunar stroke / TIA 
(and no carotid lesion), the prognosis of patients with carotid and lacunar 
disease on the same side was substantially (and significantly) worse.
Doppler data were not available for 24% of the LD patients on the database. 
While Dopplers were conducted in these patients, the information is not linked 
to the main database containing clinical and radiological data. This is an 
important source of bias within our sample, because the LD patients lacking 
ultrasound data may have had a different incidence of CD. Carotid Doppler, 
however, has been routinely conducted on all patients in our stroke unit since 
1994 and is not requested on the basis of clinical syndrome or scan 
appearance. While every effort is made in the weekly clinical meetings to 
ensure validity of the data entered into the database, it remains possible that 
incorrect clinical classification of lacunar strokes may also have biased our 
results.
The follow-up analysis was performed on 56% of group 1 (18 of 32) and 61% 
of group 2 (37 of 61). Patients were excluded from follow-up if the stroke that 
necessitated admission to our unit was not their first. Exclusion was 
necessary since their first stroke may have been a cortical event ipsilateral to 
their CD , thus denoting a ‘conventional’ symptomatic stenosis. Twelve 
patients (4 in group 1 and 8 in group 2) had a separately classified cortical 
stroke ipsilateral to their CD (on our database), and so were removed from 
follow-up analysis. However, record-linkage data were unavailable at the time 
of the study for 10 patients in group 1, and 20 patients in group 2. These
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missing data, representing a third of the total dataset, represent another 
important potential source of bias.
It is unfortunate that the record-linkage data used in this study are not side- 
specific, and also do not enable us to distinguish between recurrent cortical 
and subcortical ischaemic events. It has been previously reported that 
recurrent large vessel strokes are more common in patients who present with 
small vessel disease than are small vessel recurrent events in patients with 
large vessel presentations 50 176. The most likely explanation for such a 
finding was felt to be the co-existence of large and small vessel disease in the 
patients that presented with a small vessel syndrome (routine screening of 
the carotid arteries was not performed in these studies). A possible 
explanation in the light of the data presented here is that some of the 
presenting small vessel syndromes represented symptomatic manifestations 
of large vessel disease in the same way as the recurrent cortical strokes.
There is both pathological 177 and clinical tria l52 evidence that infarcts of the 
centrum ovale (in the territory of the superficial rather than deep perforating 
arteries) are associated with large vessel disease, though observational data 
are less conclusive 178 179. Internal watershed (internal borderzone) infarction, 
between the superficial and deep territories, is also regarded to result from 
haemodynamic effects distal to diseased large vessels 180 51. These infarct 
types, along with large (>15mm) subcortical infarctions, may have been 
included in the ‘lacunar disease' group, since the level of vascular localisation 
required to confidently diagnose such lesions is not documented on the 
database. Such infarct types represent a problem with the analysis 
presented, because there is literature to suggest that they are associated with 
large vessel disease, and so their presence may denote a ‘symptomatic’ 
carotid lesion. Our patients had no clinical cortical features, however, and our 
assessment is a pragmatic one: many clinicians dealing with stroke have 
seen patients present with clinical features suggesting a subcortical locality
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and either a normal scan or a scan demonstrating a subcortical stroke. Our 
results indicate that in such patients ipsilateral carotid disease is more 
common and more severe than contralateral carotid disease, and that its 
presence is associated with a poor prognosis. Such findings support 
investigation for carotid disease and also consideration of surgical referral in 
this group.
A related problem in the assignment of whether a carotid lesion is 
‘symptomatic’ is those patients who present with AF and are found to have 
carotid stenosis. Should one blame the ischaemic stroke on the cardiac or the 
carotid abnormality? Such individuals were not included in either major 
endarterectomy trial45. Recently, work examining stroke recurrence published 
from the NASCET trial has advised caution in referral: it was estimated that 
approximately 20% of strokes in the territory of symptomatic carotid arteries 
with 70-99% stenosis were ‘unrelated to the carotid lesion’ (that is, they were 
classified as lacunar or cardioembolic) 181. In patients with less than 70% 
stenosis, 'approximately 35% of strokes were due to causes other than the 
large artery lesion'181.
Another recently published analysis from NASCET detailed those patients 
included in the trial with ‘probable’ and ‘possible’ lacunar stroke 54. Patients 
with high grade carotid stenosis had a greater risk of lacunar infarction than 
patients with lesser degrees of stenosis. A trend towards benefit of surgery for 
patients with 50-99% stenosis was observed in those with ‘probable’ (relative 
risk reduction (RRR) 35%, 95% Cl= -100% to 81%) and ‘possible’ (RRR 53%, 
95% Cl= -62% to 88%) lacunar stroke. Benefit was most marked in the group 
presenting with non-lacunar stroke, who gained highly significant benefits 
from surgery (RRR 61%, 95% Cl= 34% to 82%). There were, however, three 
times as many patients in this group (665 vs 210 in the probable lacunar 
group).
The trend to benefit observed in the lacunar subset of the NASCET trial 54 
does not necessarily imply that a large vessel lesion caused the ‘possible’ or 
‘probable’ lacunar lesion -  benefits are evident in asymptomatic individuals -  
but it is reassuring that trend is to benefit rather than to harm. The results 
suggest that a larger sample size would confirm benefit in individuals with 
lacunar stroke and carotid stenosis. Such an analysis has now been 
undertaken with individual patient data from the NASCET, ECST and 
Veterans Affairs trials 55, after completion and presentation of the analysis 
presented here, and is currently published in abstract form. It showed that in 
patients with high degrees of stenosis (70-99%), endarterectomy was 
beneficial in patients presenting with lacunar events. Such patients benefit 
less than those with cortical stroke and the same degree of stenosis. Patients 
presenting with cortical stroke also benefit from endarterectomy for lesser 
degrees (50-69%) of stenosis 55. Incorporation of stroke type into a simple 
clinical scoring system, like that already proposed by Rothwell et a l47, could 
greatly improve the efficiency by which referrals are made.
To discount the possibility that lacunar and subcortical syndromes may relate 
to either embolism or low flow from a proximal carotid source could therefore 
deny worthwhile preventative therapy to an important subset of patients. 
Published literature increasingly suggests that lacunar stroke is a complex 
and heterogeneous entity. Higher rates of embolic sources have been 
observed in lacunar stroke than comparative control groups 182 183, and 
diffusion weighted imaging has called into question the theory that all lacunar 
lesions are due to disease of a single perforator184.
Other related analyses are reported in the literature. In a paper based on data 
from the NASCET trial, no association was reported between leukoaraiosis 
(white matter change) and angiographically detected carotid stenosis 185. 
While leukoaraiosis may confer a poor prognosis 186, it is unlikely to arise from 
artery-to-artery embolism, and represents a different form of white matter
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pathology to that studied here. Increasing severity of carotid stenosis has 
been linked to higher incidence of radiographic central infarction 187. Another 
study 170 reported no significant difference in severity between ipsilateral and 
contralateral internal carotid artery disease in lacunar infarction. Our study 
differed in that we examined the incidence of unilateral LD and unilateral CD, 
and compared patients with contralateral and ipsilateral findings. This is likely 
to increase the possibility of detecting an association (should one exist), since 
patients with generalized vascular disease manifesting as concurrent (and 
often bilateral) carotid and small vessel disease are less likely to be included. 
The methodology presented here concentrates on the possibility of an 
embolic or haemodynamic mechanism (‘low flow’) linking the two, and 
requires far higher patient numbers than have been previously reported. The 
finding of bilateral carotid disease in the individual patient with a lacunar 
syndrome should not deter the clinician from considering the possibility that 
the ipsilateral lesion may be responsible for the clinical presentation.
Endarterectomy, performed by centres with very low peri-operative stroke and 
death rates, has been proven to be effective in carefully selected 
asymptomatic patients with severe carotid stenosis 46 188. Debate continues 
about the wisdom of adopting such policies in clinical practice 189 19°, and 
whether the impressive surgical results achieved in clinical trials are possible 
in general hospital settings 191 161. Even if a policy of endarterectomy in 
asymptomatic severe stenosis is favoured, priority must be given to those 
lesions considered symptomatic, since yearly risk of stroke on medical 
treatment is so much higher for symptomatic lesions, and absolute risk 
reduction achieved by surgical intervention is so much greater. After two 
years the number needed to treat to prevent one stroke in ‘symptomatic’ 
severe stenosis is 6 42, compared to 67 in asymptomatic lesions 46. Many 
other factors will play a part in the decision to recommend endarterectomy in 
the individual clinical setting 47, but data supporting the view that patients with 
lacunar stroke and high degrees of stenosis will benefit from intervention are
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emerging 54 55. The simple acknowledgement that an ipsilateral lacunar 
syndrome can denote a symptomatic stenosis is important in both risk 
stratification and in the planning of investigation and management.
CO COo>in
CD CO
CNo>
CD in
oot~-
Ta
bl
e 
2.
1:
 C
hi
 s
qu
ar
ed
 
Ta
bl
e 
sh
ow
in
g 
the
 
nu
m
be
rs
 
of 
pa
tie
nt
s 
wi
th 
un
ila
te
ra
l 
rig
ht
 a
nd
 
lef
t 
la
cu
na
r 
di
se
as
e 
(L
D)
 w
ho
 
als
o 
ha
d 
un
ila
te
ra
l 
rig
ht
 o
r 
lef
t 
ca
ro
tid
 
di
se
as
e 
(C
D)
. 
Ch
i-s
qu
ar
ed
 
te
st
 o
f 
as
so
ci
at
io
n 
giv
es
 
X2
= 
8.
82
, 
d.
f. 
= 
1, 
p=
0.
00
3.
TJ
00 00
CN
CD
00 CN CD
O
ID
O
ID
o\t--
Ta
bl
e 
2.
2:
 C
hi
-s
qu
ar
ed
 
te
st
 f
or
 t
re
nd
 
sh
ow
in
g 
the
 
nu
m
be
rs
 
of 
pa
tie
nt
s 
in 
gr
ou
ps
 
1 
an
d 
2 
m
od
er
at
e 
st
en
os
is
, 
se
ve
re
 
st
en
os
is 
or
 
oc
cl
ud
ed
 
ca
ro
tid
 
ve
ss
el
s 
on 
ca
ro
tid
 
ul
tra
so
un
d 
ex
am
in
at
io
n.
 P
er
ce
nt
ag
e 
of 
the
 
to
ta
l 
in 
ea
ch
 
ca
ro
tid
 
di
se
as
e 
ca
te
go
ry
 
are
 
sh
ow
n 
in
 
br
ac
ke
ts
. 
Ch
i-s
qu
ar
ed
 
te
st
 f
or 
lin
ea
r 
tre
nd
 
giv
es
 
X
2= 
3.
88
, 
d.
f. 
=1
, 
p=
0.
04
9.
ooo
< / )  JZ
Q.
05
CO
o
CD
ID
d
CD
CN
O
CD
o o
Q.
Q.
CNI
a
ID
ID 05 CD
cl a>
Q.
a.
O) £
00
CD
ID05
ID 00 CD O
Q.
LL
Ta
bl
e 
2.
3:
 T
he
 
pr
op
or
tio
n 
of 
pa
tie
nt
s 
in 
gr
ou
p 
1 
(c
on
tra
la
te
ra
l) 
an
d 
gr
ou
p 
2 
(ip
si
la
te
ra
l) 
wi
th 
ea
ch
 
str
ok
e 
ris
k 
fa
ct
or
 
In 
the
 
th
ird
 
co
lu
m
n,
 a 
(tw
o-
si
de
d)
 p
-v
alu
e 
for
 t
he 
co
m
pa
ris
on
 
of 
the
 
2 
pr
op
or
tio
ns
 
is 
gi
ve
n,
 n
on
e 
of 
wh
ich
 
re
ac
he
d 
the
 
co
nv
en
tio
na
l 
le
ve
l 
of
 
si
gn
ifi
ca
nc
e 
(5
%
).
Isc
ha
em
ic 
str
ok
e 
IT
IA 
+ 
En
d 
of 
fol
low
 
up
00
<N
§ ■  § ■  O O
CD CD
- - - O
1010 inat oat inoo oooo
ooo
oooo
o  U)
s  &■O
oo
ooCN|
eajj-a^ojjs Bumjeuiej uoj^iodojd dAj;e|nuino
i
Fi
gu
re
 
2.
1:
 K
ap
la
n-
M
ei
er
 a
na
lys
is 
for
 p
at
ien
ts
 
in 
gr
ou
ps
 
1(
n=
18
) 
an
d 
2 
(n
=3
7)
. 
Th
e 
pa
tie
nt
s 
are
 
cla
ss
ifi
ed
 
as 
ha
vin
g 
a 
co
m
pl
et
e 
re
sp
on
se
 
(O
) 
if 
the
y 
ha
ve
 
a 
re
cu
rre
nt
 i
sc
ha
em
ic
 
str
ok
e 
(fa
ta
l 
or 
no
n-
fa
ta
l) 
or 
TIA
 
an
d 
are
 
ce
ns
or
ed
 
(+
) 
at 
the
 
en
d 
of 
the
 
pe
rio
d 
fo
r 
wh
ich
 
fo
llo
w-
up
 
da
ta 
we
re
 
av
ai
la
bl
e.
 D
ea
th
 
fro
m 
ca
us
es
 
ot
he
r 
tha
n 
str
ok
e 
is 
ce
ns
or
ed
 
(+
). 
Th
e 
cu
m
ul
at
iv
e 
pr
op
or
tio
ns
 
re
m
ai
ni
ng
 
st
ro
ke
-fr
ee
 
are
 
sh
ow
n 
ov
er
 t
im
e 
in 
the
 
2 
gr
ou
ps
. 
Fo
llo
w-
up
 
da
ta 
are
 
re
st
ric
te
d 
to 
12
00
 
da
ys
.
Isc
ha
em
ic 
str
ok
e 
I T
IA 
+ 
En
d 
of 
fol
low
 
up
c m  c o  r t -
§*§■ & & 
e s s e
(D O  (3  O
004-0>)Oj;s Bmuieuiej uopjodojd OApeinuino
u>
+— " °
10u> o mo> oo> inoo o00
CO>»
CO73
o
E
Q
O B
a. 0
2 2 
0)-&)
E-Sto E 
> - »  0  LO 0 
CO -C t* O II .<2 C ^ 
- c Q 0) 
O t
£
Q
po ^  q. x:
= 5  ~
2 ~  
O J q
Is- 0 
CO CO
II c
C O 
Q .  
CM CO
q.2
o -2 0
°> Q.
ir- O
7  °
-S ro IlT o)^ c 
Q - >3 ro 2 ■*= o> w 
c <°— -Q
■2 JC  f t :  
0 0 
CO
0 JO Q. O
O 2  
CO CO 
C/> JO
■S' c 0 0
0 0 
i _  Q .U 0 
0 sz
c
0
B  0
1— J; 
0 0
B  joO 0
V ) ~o
0  Q .
1 *  
S |
i sM—
1  &8 §
Q &> 
0 Tf 
X i 0
0 x:— 4_i
>  • -  
CO 0
2 E
0
 ^ 0
€  §co
■° i  
§■61 x: 
£ w
.o 0
"O CO
P 0
o 2 
>
CN
OO
s  »•g c
8 1  
0
J  E±s 0
O c/>
E .1<d -e
0
SZ
oQ.
^  2 0 Q.
S j
"O co
2 g o E
C/> Z2c o
8
0 <0 CM Cl- t— 0 || 
*  c
CM q “ 
CM —I
2 "3
□>£ 
i l  >
0
a > f .
■0+0
c0 o _ > ( D °^  i_ o  r  o cn
I—  C/) T-
0  0  o
^ o :5
CO .c£ 0  •ti "►* CO 0  o
1 ^  c
g 2 To o +3 a) c </) £:
83
Chapter 3: Inter-atrial septal abnormalities and stroke: 
a meta-analysis of case control studies
3.1 Introduction
Individual case studies and series in the 1980s postulated a causal role for 
inter-atrial septal abnormalities (patent foramen ovale (PFO) and atrial septal 
aneurysm (ASA)) in the etiology of embolic stroke 192 193. Numerous case 
control studies have been published since examining the frequency of inter- 
atrial septal abnormalities in patients with stroke or transient ischaemic attack 
(TIA) in comparison to controls. Similarly designed studies aiming to establish 
whether such abnormalities were more likely to be found in individuals with 
‘cryptogenic’ stroke (stroke without other clear cause) followed. Ambiguous 
findings have left clinicians uncertain as to whether they should investigate for 
such abnormalities, and whether positive results should be regarded as 
causal or incidental. Published reviews have provided an interpretation of the 
literature without systematically evaluating available evidence 194. Studies 
differ in the age groups examined and in the control groups chosen, but 
similarities can be found in design and methodology, such that they may be 
grouped together using simple, clinically intuitive criteria. Whilst the results of 
such an exercise cannot address the appropriate management of such 
patients, a systematic review and meta-analysis has implications for current 
investigational and therapeutic strategies, and for further research.
3.2 Methods
A systematic search was made using both Medline and BIDS (Bath 
Information and Data Services) bibliographic databases for the keywords 
‘patent foramen ovale’, ‘atrial septal aneurysm’ and ‘right-to-left shunt’. This 
resulted in a total of 2738 references, which were individually assessed. All 
studies that examined the prevalence of PFO, ASA or a combination of both 
in a stroke population were examined in full. All those that met the criteria 
defined below were included in the meta-analysis. The bibliographies of all 
included studies, many excluded studies, and any review articles were
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searched for additional suitable studies. Both English and foreign language 
journals were examined. Unpublished data were not sought. Inclusion criteria 
were:
1. Case control studies that compared prevalence of PFO or ASA in 
ischaemic stroke or TIA patients to non-stroke control patients using a 
validated diagnostic technique.
2. Case control studies that compared prevalence of PFO or ASA in patients 
with cryptogenic stroke to patients with known stroke cause using a 
validated diagnostic technique.
3. Case control studies that compared prevalence of PFO or ASA in patients 
with cryptogenic stroke to non-stroke control patients using a validated 
diagnostic technique.
Clear definitions of the terms in italic are given in the definitions section 
(see below). The three broad comparisons above were each divided into 
‘total’ (patients of all ages), ‘young’ (< 55 years) and ‘old’ (> 55 years). 
Differing inclusion criteria dictate that patients aged 55 may be included in 
either category. If planned analysis of a different age group above or below 
55 years was stated in the objectives / methods section of the paper, results 
are included within the relevant comparison. If such an age subgroup was 
studied as a ‘post-hoc’ analysis within a larger study (i.e. it may have been 
defined and analyzed after knowledge of results) these data are excluded. 
Two studies divided patients into groups older or younger than 50 195 196, and 
one used an age cut-off of 60 years 197. These are included in the separate 
age analyses as if ’55 years’ was the division used.
Both fixed effects (Mantel-Haenstzel) and random effects (Der-Simonian 
Laird) methods of meta-analysis were used 198, and the combined odds ratio 
(OR) from each method was tabulated. Using a significance level of 10%, 
homogeneity of trials was assessed for each comparison. If significant
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heterogeneity was not detected, results were presented graphically (forest 
plot) using the fixed effects method. If significant heterogeneity was present, 
reasons for this were investigated, and the comparison was presented 
graphically using the random effects method. Sensitivity analysis was 
performed for each group of trials, and possible sources of bias were 
examined. Funnel plots were constructed to investigate publication and 
related bias 1" .  Explanations of the terms in italics are given in appendix 2.
Definitions
ATRIAL SEPTAL ABNORMALITIES 
Patent foramen ovale (PFO)
Presence of right-to-left shunt (R-to-L shunt) at inter-atrial level. One study 
included patients with atrial septal defect (ASD) in the published data 195. This 
was defined as a defect in the septum primum or secundum, or a defect 
>0.5cm wide in the region of the fossa ovalis, with left-to-right flow. The 
investigators reported that the relative frequencies in the case and control 
groups were not substantially altered if analysis was restricted to patients with 
PFO (i.e. just those with R-to-L shunt). All other trials excluded patients with 
ASD.
Atrial Septal Aneurysm (ASA)
Base width 1.5cm or greater and with at least 1.1cm excursion into either the 
left or the right atrium or a sum of the total excursion into the left or right 
atrium of 1.1cm or greater 20°. Some studies used stricter criteria 201. All 
studies used transesophageal echocardiography. Base width not mentioned 
in one paper 202.
DIAGNOSTIC TECHNIQUE (When more than one technique was used in a 
study, the most sensitive has been chosen for analysis)
Trans crania I Doppler (TCD)
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(PFO)-Gelatin or saline contrast. Timing of microbubble spike(s) ranged 
between 4 and 20 seconds after injection. Studies performed at rest, 
coughing and with Valsalva maneuver in most studies.
Transthoracic Echocardiography (TTE)
(PFO)-Gelatin or saline contrast. Appearance of at least one microbubble of 
contrast in left atrium (LA) within 4 cardiac cycles of opacification of the right 
atrium (RA).
Transesophageal echocardiography (TEE)
(PFO)-Gelatin or saline contrast. Contrast opacification (at least 1 
microbubble) of LA within 3 seconds or 4 cardiac cycles of opacification of 
RA. All studies examining ASA used TEE, and the echocardiographic 
definition is given above.
STROKE SUBCLASSIFICATION 
Non-stroke control patients
Normal volunteers, hospitalized or echocardiographic (patients receiving an 
echocardiographic examination for another reason) control patients who are 
compared to patients with stroke / TIA.
Ischaemic stroke /  transient ischaemic attack (TIA)
Sudden clinical focal neurological deficit consistent with the diagnosis of 
stroke (confirmed as ischaemic by computed tomography (CT) or magnetic 
resonance imaging (MRI)), or TIA (lasting less than 24 hours). One study did 
not mention cranial imaging 203. One study included patients with peripheral 
(arterial) embolus 204; three others examined such patients, but they were 
removed from the analysis where possible 205 206 197.
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Known stroke /  TIA cause (non-cryptogenic stroke)
Levels of clarification of cause differ considerably between studies. Minimum 
requirements are assessment of cardiac rhythm (electrocardiogram (ECG)), 
assessment of presence of carotid stenosis (by Doppler, with one exception 
that used a clinical bruit 203) and assessment of alternative cardioembolic 
source (by TTE). Many earlier papers used angiography in their assessment 
207 208 84 Assessment of pro-coagulant markers differs, and if conducted 
these have been used for classification 209 202 84 210 211. Many studies used 
accepted stroke data bank criteria in their definition of cryptogenic stroke, 
namely those of the NINDS (National Institute of Neurological Diseases) 
stroke data bank 212 213 214 211, and the BADISEN (Banco de datos de Ictus de 
la Sociedad Espanola de Neurologia) system 215. These classify strokes into 
those of determined cause (cardioembolic, lacunar (small vessel), large artery 
atherosclerotic or of unusual but determined cause) or cryptogenic. All other 
studies used a similar system, and for this analysis non-cryptogenic stroke 
includes patients with the following causes of stroke: arterial dissection, 
carotid stenosis > 50% (one study used stenosis > 31% 196), intra-cranial 
atherosclerosis with stenosis > 50% of the corresponding vessel, angiitis, 
migrainous infarction, coagulopathies, systemic disorders (e.g. lupus / 
Hughes syndrome), atrial fibrillation (AF) (chronic or paroxysmal on ECG), 
recent (within 6 weeks) myocardial infarction, dilated cardiomyopathy, 
rheumatic mitral stenosis, mitral / aortic vegetation or prosthesis, left atrial or 
left ventricular tumor / thrombus, spontaneous left atrial echo contrast and 
complex atheroma between the aortic valve and the left subclavian artery 
origin. Mitral valve prolapse (MVP) is regarded as a cause of stroke in some 
trials 212 213 214 211 216 204 215 217, but generally as a risk factor (see below). Two 
studies 183 218 assessed as ‘undetermined’ those individuals with more than 
one cause of stroke. These patients are defined as having non-cryptogenic 
strokes for this analysis.
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Cryptogenic stroke /  TIA
Those patients without predetermined cause for stroke, as described above. 
One study included those with AF and spontaneous echo contrast in its 
cryptogenic stroke group219. Another classified those with AF on TEE / Holter 
monitoring as cryptogenic 22°. One study excluded (i.e. defined as non- 
cryptogenic) patients with hypertension (> / = 170/95) 203. In all other studies 
hypertension is regarded as a risk factor.
RISK FACTORS
Increasing the risk of stroke, but not necessarily the cause of stroke (e.g. 
hypertension, diabetes, hypercholesterolaemia, smoking, alcohol use, oral 
contraceptive pill, migraine, and generally MVP (see above)). ASA is 
regarded as a risk factor in those studies examining PFO, and PFO is 
regarded as a risk factor in those studies examining ASA.
3.3 Results
Details of the comparisons performed in the total category (all ages) (table 
3.1), in the young (<55 years) (table 3.2) and in the old (>55 years) (table
3.3) will be considered in turn:
Patent Foramen Ovale: stroke vs non-stroke controls
The ‘total’ comparison, comparing ischaemic stroke patients to non-stroke 
controls yielded 15 studies for PFO 202 221 222 223 205 216 195 208 224 206 225 215 207 
197 204 (see figure 3.1). Significant heterogeneity was detected, which 
appeared largely to result from the different ages of participants. If the trials 
are divided into two separate groups, of positive studies 202 221 222 208 206 207 197 
204 and neutral/negative studies 223 205 216 195 224 225 215, and the ages of 
included patients are compared, a difference exists between the mean age of 
patients in the positive (44.8 years) and neutral/negative (61.1 years) trials 
(p=0.022). No significant trends were observed in the diagnostic technique
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employed, attempts to blind observers to the clinical diagnosis, choice of 
controls, or retrospective vs prospective design. A funnel plot did not suggest 
publication bias.
Homogeneous results were obtained in the younger age group (figure 3.2). 
This comparison included nine trials 202 221 222 216 195 208 207 197 204, which 
produced a common effect measure of 3.10 (2.29-4.21). A funnel plot was 
asymmetric, suggesting possible bias towards the publication of positive 
results. In the older age group (figure 3.3), more heterogeneous results were 
evident 195 197 204. The odds ratio from both fixed and random effects analysis 
crossed the line of no effect. The largest study showed the least association, 
but examination of individual trials provided no explanation for the difference 
in effect.
Patent foramen ovale: cryptogenic stroke vs known stroke cause
This comparison was characterized by numerous small studies estimating a 
reasonably consistent positive effect. Twenty-two studies were included 183 202
211 212 205 213 217 216 195 226 210 208 214 84 225 209 215 227 207 196 197 204 S^QQ f j g u r e
3.4). Chi-squared test for heterogeneity was significant, but the studies that 
were the source of the heterogeneity detected within the group 183 211 205 were 
well conducted, with clear definitions of cryptogenic stroke. Funnel plot was 
symmetrical.
When considering purely the younger age group, more consistent results 
were obtained (figure 3.5). Effects were homogeneous (p=0.29), and the nine 
eligible studies 202 211 217 216 195 208 84 207 196 gave a symmetric funnel plot. Data 
were scarce in the older age group with each study employing a different 
diagnostic technique (TTE 21\  TEE 195 and TCD 196), and the two most recent 
studies estimating a consistent non-significant effect (figure 3.6).
Patent foramen ovale: cryptogenic stroke vs non-stroke controls
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The heterogeneity evident in this group (see figure 3.7) enabled trials to be
divided into those with a point OR of 1-2 205 195 225, those with a point OR 2-4 
216 219 215 220 203 197 anc| wjt|1 a p0jnt q r  >4 202 208 207 204. Analysis of
these three groups showed a trend towards greater patient age in trials with a 
lower OR (p=0.08, by ANOVA). The groups did not differ in diagnostic 
technique, the presence of blinding, in their choice of controls or in design. 
The group with OR 2-4 tended to have less detailed criteria for the diagnosis 
of cryptogenic stroke, and one trial in each group included lacunar stroke 
within their ‘cryptogenic’ classification. A funnel plot did not suggest bias. 
Again, subdivision into age bands revealed much more homogeneous results, 
both in the young 202 216 195 208 207 (figure 3.8), and in the old 195 203 (figure 
3.9).
Atrial septal aneurysm: stroke vs non-stroke controls
For the total comparison (figure 3.10), negative studies 223 224 225 recruited 
older patients than the positive studies 228 206 200 197 229 202 (p=0.014). Once 
more, funnel plot appearance did not suggest publication bias. Comparisons 
in the young 228 202 206 229 (figure 3.11) and old 228 206 (figure 3.12) were 
homogeneous, and estimated a clear increased prevalence of ASA in stroke 
patients compared to controls.
Atrial septal aneurysm: cryptogenic stroke vs known stroke cause
The heterogeneity evident in the total comparison (figure 3.13) was due to 
the presence of one negative/neutral study 183. This study was well conducted 
(although blinding of echocardiographers was not mentioned) with clear 
definitions of cryptogenic stroke. It found an increased prevalence of ASA in 
lacunar stroke. The four remaining studies 202 226 218 225 estimate a combined 
odds ratio of 5.30 (2.70-10.42). Only one study defined and studied a younger 
age group 202. No studies were available for analysis in those over 55 years.
Atrial septal aneurysm: cryptogenic stroke vs non-stroke controls
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Data are scarce for this comparison, but homogeneous results were obtained 
in the ‘total’ group 202 219 225 (figure 3.14), estimating a significant effect. Only 
one study has been conducted in the young 202, and none in the old.
Combination of patent foramen ovale and atrial septal aneurysm: stroke 
vs non stroke controls
Homogeneous results are obtained for total patients 202 223 206 200 (figure 
3.15) and in the younger group 202 206 (figure 3.16), albeit with extremely wide 
confidence limits. Only one study was found in the old 206.
Combination of patent foramen ovale and atrial septal aneurysm: 
cryptogenic stroke vs known stroke cause
Assessment yields a significant odds ratio, with a very wide confidence 
interval, in the total group 202 226 (figure 3.17), and only one study in the 
younger group 202.
Data on the final comparison for the combination of both lesions (cryptogenic 
stroke vs non-stroke controls) comes from a single study 202.
3.4 Discussion
The literature on prevalence of inter-atrial septal abnormalities in stroke is 
both extensive and confusing. Erroneous conclusions can be drawn from 
observational data on a small number of subjects viewed in isolation. A 
number of studies have failed to show a significant association of inter-atrial 
septal abnormalities with stroke in the young 216 195 204 228 229. Consideration 
of the greater body of literature supporting an association is biased, and fails 
to provide proper assessment of the level of association. The data presented 
in this analysis allow a number of firm conclusions to be reached, in addition 
to suggesting areas requiring further research.
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Meta-analysis of observational studies has been criticized since it can 
generate ‘spurious precision’ from disparate data sets. It may, however, 
clarify an extensive and confusing literature by organization and collation of 
the available information. Pre-defined inclusion criteria, systematic 
examination of trials to detect sources of heterogeneity and bias, and the 
consistent results found in separate age bands support the methods 
presented here. We did not seek unpublished data when conducting this 
analysis. Publication and related bias was examined by visual inspection of 
funnel plots, and asymmetry was not often evident. Funnel plots, however, 
remain an insensitive measure, open to different interpretation between 
observers 198. Referral bias presents a major source of difficulty, particularly in 
those studies employing retrospective design or TEE. Some studies included 
only those referred for TEE, introducing bias 227 212 213 223 214 200 206. Such 
populations are likely to be similar to those with ‘embolic’ stroke 228. 
Numerous studies only investigated for, or reported, either ASA or PFO, so 
the associations demonstrated may partly be with both lesions in conjunction 
rather than with either alone. Blinding of observers was often ignored or 
poorly defined, which is concerning given the amount of inter-observer 
disagreement in diagnosis 23°. Such disagreement may result from different 
diagnostic criteria, or from methodological inconsistencies 231, and may partly 
explain the widely different detection rates in the studies included. These 
ranged (for PFO) from 10%-44% for stroke, 31 %-77% for cryptogenic stroke, 
4%-25% for known stroke cause and 3%-22% for controls, and (for ASA) from 
2-17% for stroke, 4-25% for cryptogenic stroke, 0.2-22% for known stroke 
cause and 0-15% for controls. Prevalence of PFO declines with advancing 
age, whilst average lesion size increases 81. Variation in prevalence also 
stems from the different diagnostic techniques employed. Although the 
specificity and sensitivity of TCD in comparison to TEE are well defined 232, 
TTE underestimates the presence of PFO and ASA 233. The different extents 
to which cryptogenic stroke was investigated for and defined, and the details 
of that definition, did not exert any clear effect on study conclusion.
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Recruitment rates were lower in TEE studies (65%-76%), with investigators 
experiencing difficulties with patients’ consent, tolerance of the procedure, 
and in obtaining satisfactory images.
When classified on the basis of age and abnormality detected, published 
studies have been shown to demonstrate a fairly homogeneous effect, 
despite the differences in their design. The unequivocal finding that both PFO 
and ASA are associated with ischaemic stroke in the young is important. The 
implication for planned investigation is that PFO should be sought in the 
young (<55 years), and if found should not be regarded as incidental. 
Although less frequently detected, ASA is more strongly associated with 
ischaemic and cryptogenic stroke than PFO. Since reliance on TCD and TTE 
will not provide the clinician with accurate information on this and other 
potentially important cardiac embolic sources 194, this meta-analysis supports 
wider use of TEE in young stroke patients.
Less work has been conducted in the older age group (>55 years), and the 
results presented highlight the areas in which data are lacking. The finding 
that heterogeneity within ‘total’ comparisons is eliminated by grouping into 
age bands, and that negative trials are more likely to stem from the inclusion 
of older patients, suggests that age exerts an effect on the relationship 
between inter-atrial septal abnormalities and stroke which is clinically 
relevant. Other stroke causes and risk factors are more likely to play their part 
in the old, and the association of PFO with both total and cryptogenic 
ischaemic stroke in those >55 years remains unconfirmed. The odds ratio for 
cryptogenic stroke compared to known stroke cause in those >55 years 
nearly reached significance, while results in the stroke vs control comparison 
were much more equivocal. These findings are consistent with the hypothesis 
that a true effect exists which is easier to detect once patients with more 
common causative factors have been excluded.
Does the association demonstrated in the young imply causation? Both 
abnormalities in conjunction are consistently more strongly associated with 
ischaemic stroke than either alone, and are associated with higher rates of 
recurrent stroke 88 90. This, coupled with the reported finding that larger PFOs 
213 227 216 a n c | ^SAs 202 a r e  m Q re  st ro n g |y  associated with cryptogenic stroke
than smaller abnormalities, and are more likely to lead to recurrence 234, 
suggests a ‘dose-response’ relationship supporting causality. In addition the 
relationship is biologically plausible, cerebral ischaemia or infarction resulting 
either by paradoxical embolism from a venous source or by in situ thrombosis 
at an atrial level. Despite such arguments, documentation of venous 
thrombosis in patients whose stroke mechanism is felt to be paradoxical 
embolism has proved unrewarding 84.
Secondary prevention for stroke patients with PFO is a subject of 
considerable debate, and is addressed further in chapter 4. Neither open 
heart surgery 235, nor transcatheter closure 87 guarantee freedom from 
recurrent events. A surgical series (with flawless clinical outcome) has 
outlined proposed criteria for surgical correction which have been reached 
after many years of both clinical practice and research in this area 85. A large 
prospective series recently reported the risk of recurrent cerebrovascular 
events in 581 patients < 55 years with unknown stroke cause who were 
treated with aspirin 90. After 4 years, the risk of recurrent stroke was 2.3% 
(95% Cl 0.3 to 4.3%) among patients with PFO alone, 15.2% (95% Cl 1.8 to 
28.6%) among patients with PFO and ASA, and 4.2% (95% Cl 1.8 to 6.6%) 
among patients with neither abnormality. There were no recurrences in the 
small (n=10) group with ASA alone. The currently unpublished Patent 
Foramen Ovale in Cryptogenic Stroke (PICSS) substudy of the Warfarin 
Aspirin Recurrent Stroke Study (WARSS) (see chapter 1) provides no 
information regarding the role of corrective techniques and does not have the 
statistical power to determine best medical therapy. In addition to ongoing 
randomised trials of closure versus antithrombotic therapy, active
investigation for atrial septal abnormalities, and large scale prospective data 
collection, as proposed by Kasner et al 236, may improve estimation of the 
risks and benefits of the different therapeutic strategies available, and provide 
useful evidence on which to base therapeutic decisions.
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Chapter 4: Investigation and management of stroke 
associated with patent foramen ovaie
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4.1 Introduction
The association of patent foramen ovale (PFO) with ischaemic stroke is 
confirmed in patients <55 years, but remains uncertain in the older age group 
237. Atrial septal aneurysm (ASA), a less common abnormality characterised 
by 'bulging' of the inter-atrial septum, has been shown to be even more 
strongly associated with ischaemic stroke. Such associations are evident 
when stroke patients are compared with normal controls, and are more clearly 
apparent when patients with cryptogenic stroke (stroke that has no known 
cause) are compared to patients with a ‘known’ cause of stroke 237. 
Association does not necessarily imply causation, but such a relationship is 
both biologically plausible (either by paradoxical embolism from a venous 
source or by in situ thrombosis at atrial level) and supported by observational 
data. Larger PFOs are more strongly associated with cryptogenic stroke than 
smaller lesions 213 227 216. ASA size also determines the strength of its 
association with cryptogenic stroke 202. Additionally, the combination of PFO 
and ASA is more strongly associated with stroke than either alone 237, and 
more likely to lead to recurrence than either alone 88 90.
At present it is unclear whether patients should be investigated for PFO -  
only association is proven. With no randomised data to inform a therapeutic 
approach, management decisions similarly lack a firm basis. Stroke is often 
attributed to the presence of a PFO after other causes of stroke (for example 
atrial fibrillation (AF)) are discounted, but whether suspicion of a pathogenic 
role should dictate changes in therapy is extremely difficult to answer at 
present. The natural history of patients with ‘PFO-associated stroke’ seems 
benign: published retrospective literature suggests a yearly recurrence rate of 
stroke or TIA of approximately 3% per year 88 89. A recent large prospective 
series found a stroke recurrence rate of 2.3% (95% Cl 0.3 to 4.3%) in aspirin 
treated patients < 55 years with isolated PFO after a follow-up period of 4 
years (5.6% for stroke or TIA)90. In contrast to single lesions (which seemed
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to have no impact on outcome), the presence of both ASA and PFO was 
predictive of stroke recurrence in this study; patients with both lesions had a 
recurrence rate of 15.2% (95% Cl 1.8 to 28.6%) after 4 years. These data 
concur with the same authors' retrospective series 88. Clinical context, 
recurrent events and large echocardiographic lesions may also characterise 
those patients with a poor prognosis.
Series of patients treated with medical therapy (aspirin or anticoagulants) 88 89 
90, surgery 85 and percutaneous closure 86 87 have provided useful 
information, without defining the correct approach in those patients who are 
investigated. The Patent foramen ovale In Cryptogenic Stroke Study (PICSS) 
(see chapter 1), will improve data on the natural history of medically treated 
patients with PFO when published in full. PICSS was not, however, powered 
to address the central management question of whether antiplatelet or 
anticoagulant therapy is more appropriate in the individual, nor did it assess 
the role of corrective techniques. The mean age of the randomised population 
in PICSS (59.7 years) was higher than that of the group for whom association 
has been firmly established 237, and this is a significant factor in the 
interpretation of its findings. Mechanisms of index stroke and recurrence other 
than embolism from PFO occur more commonly in such older cohorts, 
because other stroke causes and risk factors are more prevalent. This is 
borne out by the discrepancy between recurrence rates in PICSS (-15% over 
2 years) and the large prospective series of younger patients treated with 
asprin discussed above (-4% over 2 years)90.
In the absence of randomised evidence, decision making in 'PFO associated 
cryptogenic stroke' is likely to depend highly on individual experience and 
local expertise. We wished to assess the clinical practice of physicians with 
specialist experience in stroke and neurology. Such an analysis may provide 
useful information that will aid the design of pragmatic clinical trials.
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4.2 Methods
A clinical questionnaire was distributed to members of the British Association 
of Stroke Physicians (BASP), and to members of the Association of British 
Neurologists (ABN). A total of 860 questionnaires were posted, 136 to the 
111 full and 25 associate members of the BASP and 724 to the 474 ordinary 
(consultants) and 250 associate (trainees in neurology) members of the ABN. 
Questionnaires were posted between December 1999 and February 2000, 
before the publication of the prospective stroke recurrence data detailed 
above 90, and the presentation of the PICSS results summarised in chapter 
1. The questionnaire is provided in the information box below.
Investigation for inter-atrial septal abnormalities may be a standard part of a 
policy of programmed investigation for some physicians. We wished to 
assess whether specialists felt that information about the presence of PFO 
was useful when other causes of stroke had been ruled out, both in patients 
older and younger than 55 years.
The management decision ‘tree’ is based on the criteria proposed by Devuyst 
and Bogousslavsky 85. They postulate that surgical therapy should be 
reserved for patients < 60 years of age with PFO and stroke who satisfy two 
of the following criteria: 1) recurrent events on initial therapy or multiple 
ischaemic lesions on magnetic resonance imaging, 2) Valsalva manoeuvre or 
cough preceding stroke, 3) large (>50 microbubbles in the left atrium on 
transoesophageal echocardiography (TOE)) PFO and 4) associated inter- 
atrial septal aneurysm (ASA) 85. Initially, a patient displaying none of these 
characteristics was considered. Subsequently, a patient displaying each of 
these features in isolation was presented, and alterations in management 
were assessed. We used 'recurrent events' rather than 'recurrent events or 
multiple ischaemic lesions' as a clinical scenario, and a 'large PFO' was 
defined as > 25 microbubbles of right-to-left shunting on TOE or transcranial
Doppler (TCD) 213 234, or > 4mm diameter on TEE 227. A further finding 
(documented venous thrombosis at the time of stroke) was felt clinically 
relevant in the context of ‘presumed’ paradoxical embolus 238 84I and was 
included as a fifth clinical feature.
Finally, the clinician was then asked whether they would refer the patient to a 
cardiologist for consideration of a corrective procedure (percutaneous or 
surgical closure) if two or three of these factors were present. If more than 
one combination of clinical findings would lead to referral, the respondent was 
asked to state the combination they felt would confer the highest risk of stroke 
recurrence. The entire series of management questions was presented in the 
context of a patient both younger and older than 55 years.
Investigational data were tabulated, allowing division of respondents into four 
groups: those who would investigate all patients (YY), those who would 
investigate only the young (YN), those who would investigate only the old 
(NY), and those who would not investigate a patient in either age group (NN). 
Management data were tabulated for the entire group of respondents, and for 
each of these ‘investigator’ subgroups. Relevant proportions were compared 
using chi-squared tests (significance level 5%), and were predefined.
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Questionnaire Patent Foramen Ovale
Investigation: In a young patient (<55 years), when standard investigations (ECG, 
transthoracic echo (TTE) and carotid Dopplers) fail to reveal a cause of ischaemic embolic 
stroke, do you investigate for patent foramen ovale (PFO) with contrast transcranial 
Doppler (TCD) or contrast transoesophageal echocardiography (TOE)?
Yes No (please circle your response)
In an older patient (>55 years), when standard investigations (ECG, transthoracic echo 
(TTE) and carotid Dopplers) fail to reveal a cause of ischaemic embolic stroke, do you 
investigate for patent foramen ovale (PFO) with contrast transcranial Doppler (TCD) or 
contrast transoesophageal echocardiography (TOE)?
Yes No
Management: In a young patient (< 55 years) with a small PFO (< 25 micro-bubbles of 
right-to-left shunt; < 4mm on TOE), no contra-indication to anticoagulation or surgery, and 
negative investigations for embolic stroke cause (cryptogenic stroke), do you:
A prescribe an antiplatelet agent (e.g. aspirin) I combination (e.g. aspirin I
dipyridamole)
B prescribe warfarin
C insert vena cava filter
D refer for cardiological opinion regarding a corrective surgical procedure
Which course of action would you take in the following situations?
1 recurrent events on initial therapy A B C D
2 Valsalva manoeuvre or cough preceding stroke A B C D
3 large (>25 microbubbles; >4 mm on TOE) PFO A B C D
4 associated atrial septal aneurysm (ASA) A B C D
5 documented venous thrombosis at the time of stroke A B C D
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Would you consider referral for corrective procedure (option D) if the patient had
6 a combination of two of factors 1 to 5? Y (factors .... and ....) N
7 a combination of three of factors 1 to 5? Y (factors and ....) N
(if more than one is appropriate, answer with the combination which you feel confers the 
greatest risk of recurrent events)
Management: In a older patient (> 55 years) with a small PFO (< 25 micro-bubbles of 
right-to-left shunt; < 4mm on TOE), no contra-indication to anticoagulation or surgery, and 
negative investigations for embolic stroke cause (cryptogenic stroke), do you:
A prescribe an antiplateiet agent (e.g. aspirin) I combination (e.g. aspirin I
dipyridamole)
B prescribe warfarin
C insert vena cava filter
D refer for cardiological opinion regarding a corrective surgical procedure
Which course of action would you take in the following situations?
1 recurrent events on initial therapy A B C D
2 Valsalva manoeuvre or cough preceding stroke A B C D
3 large (>25 microbubbles; >4 mm on TOE) PFO A B C D
4 associated atrial septal aneurysm (ASA) A B C D
5 documented venous thrombosis at the time of stroke A B C D
Would you consider referral for corrective procedure (option D) if the patient had
6 a combination of two of factors 1 to 5? Y (factors .... and ....) N
7 a combination of three of factors 1 to 5? Y (factors ......... and ....) N
(if more than one is appropriate, answer with the combination which you feel confers the 
greatest risk of recurrent events)
128
4.3 Results
A total of 261 questionnaires were returned, representing a 30% response 
rate. Investigation policy is summarised in table 4.1. The majority of 
respondents (60%) reported that their normal practice was to investigate 
‘young’ patients with cryptogenic stroke, but not to investigate the old (YN 
investigators). Importantly, nearly a quarter of the physicians who replied 
(23%) do not investigate for PFO (NN investigators) at all, even in a young 
patient whose stroke cause is undefined.
The second portion of the analysis concerned patient management. 
Considering the young (<55 years) initially, the response to the first question 
(examining practice outwith the context of putative markers that might 
persuade the clinician to adopt a more aggressive management plan) is 
tabulated in table 4.2a. Responses for each of the five situations that are 
thought to support a paradoxical embolic mechanism or to mark a worse 
prognosis are given in tables 4.2b (recurrent events on initial therapy), 4.2c 
(Valsalva manoeuvre or cough preceding stroke), 4.2d (large PFO), 4.2e 
(associated ASA) and 4.2f (documented concurrent DVT). Questions 6 and 7 
assess whether combinations of these five situations may persuade the 
clinician to opt for a corrective procedure, and indicate which factors are felt 
to confer the highest risk: they are presented in the form of a pie chart (figure 
4.1 a-d).
Patient management in the old (> 55 years) is presented in tables 4.3a 
(uncomplicated patient), 4.3b (recurrent events on initial therapy), 4.3c 
(Valsalva manoeuvre or cough preceding stroke), 4.3d (large PFO), 4.3e 
(associated ASA) and 4.3f (documented concurrent DVT). Figures 4.2 a-d 
illustrate the effect of multiple factors on referral decisions in the old. About 
40% of respondents did not answer questions 6 and 7 in either age group.
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General considerations
The occurrence of recurrent events (‘clinical worsening’) tended to lead to 
more aggressive medical management, rather than referral for lesion 
correction. This effect was evident across investigator groups, including those 
who would not investigate for PFO. ‘Structural worsening’ (co-existence of 
ASA or a large PFO) prompted referral for correction, a policy used on its own 
by ‘non-investigators’ (NN) and in combination with warfarin therapy by 
‘investigators’ (YY). Rates of non-response were higher for questions 
regarding management in the old and for the question regarding a history of 
Valsalva manoeuvre or cough preceeding stroke. A history of Valsalva 
manoeuvre or cough at stroke onset did not significantly alter rates of warfarin 
use or rates of referral for correction in any investigator group in the young. 
Consistent with this are the responses to questions 6 and 7, which indicate 
that the presence of Valsalva manoeuvre or cough at stroke onset is the least 
important variable when clinicians determine suitability for a corrective 
procedure. Use of inferior vena cava filter was low in all groups and for all 
clinical scenarios.
Total group: uncomplicated scenario
Antiplatelet therapy alone was chosen as an initial strategy by 47% of 
respondents in the older age group (>55 years), and by 33% of respondents 
in the younger age group (<55 years) (p<0.01 for comparison of proportions). 
However, antiplatelet therapy remained more popular than warfarin for initial 
medical management in young uncomplicated patients (51% vs 17%, 
p<0.01). A higher proportion of all respondents refer for an opinion regarding 
correction first-line in the young than the old (42% vs 18%, p<0.01). Warfarin 
usage did not differ significantly between young and old (18% vs 13%,
p=0.12).
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Total group: recurrent events
If cerebrovascular events recur, less than 5% of respondents would leave a 
patient of any age on antiplatelet therapy alone. There is a trend to higher use 
of a combination of both warfarin and correction in the young compared to the 
old (p=0.05). Referral for correction, alone or in combination with antiplatelet 
therapy, is more common in younger patients (p<0.01), while there was a 
trend to higher use of warfarin alone in older patients (p=0.06, comparing 
young and old).
Total group: large PFO or concomitant ASA
In both age groups, warfarin was used by -17% of respondents for individuals 
with large PFOs or with co-existent ASAs. It was used alone in only -10%, 
representing no change from use in the uncomplicated patient, and in 
combination with referral for correction by -7%. In general, such ‘structural 
findings’ prompted referral for correction: for a patient with a large PFO, 57% 
(young) vs 45% (old) would refer (p=0.01 for comparison), and for a patient 
with concomitant ASA, 62% (young) vs 44% (old) would refer (p<0.01 for 
comparison).
Total group: concurrent DVT
Concurrent DVT commonly led to treatment with warfarin both for patients 
<55 years (62%) and >55 years (53%). Inferior vena cava filter insertion, 
while remaining rare, was most common for this scenario (7% in both age 
groups). In those <55 years referral for correction was less common than in 
uncomplicated patients (24% vs 43%, p<0.01), rates in the old remaining 
unchanged (19% vs 18%, p=0.77).
YY investigators: uncomplicated scenario
Aspirin was chosen as the most appropriate medical management in both 
young and old age groups, although YY investigators were the group least 
likely to use aspirin monotherapy as first line. Referral for correction was
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chosen by 54% of respondents for patients <55 years and by 37% of 
respondents for patients >55 years (a significant increase when compared to 
the total group, p<0.01). Warfarin was used as an initial therapy in -20% of 
patients (young or old).
YY investigators: recurrent events
More than half of the YY group would now prescribe warfarin for a patient of 
any age. 51% of YY investigators would refer for correction in the young, 
though are a little more reluctant to do so in the old (39%).
YY investigators: iarge PFO or concomitant ASA
In the young, 63% would refer for a corrective procedure with a large PFO, 
and 63% would refer for correction with a concomitant ASA. These rates are 
not significantly altered by patient age. Warfarin is more likely to be used in 
combination with surgery than on its own in both age groups.
YY investigators: concurrent DVT
73% would use warfarin in the young, and 63% in the old. This is used in 
combination with surgery by only a minority (15% and 10% respectively).
YN investigators: uncompiicated scenario
Aspirin monotherapy was significantly more common in the older age group 
(54% vs 35%, p<0.01), and referral for correction more common in the young 
(43% vs 16%, p<0.01).
YN investigators: recurrent events
Policy in the old now switches to warfarin in the majority (54%), and 
cardiological referral in a quarter. This represents a lower referral rate than 
YY investigators (YN=25%; YY=41%; p<0.05), but a shift towards active 
management strategies by doctors who would not routinely investigate this
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| age group. In the young, referral rates did not differ from those seen in the YY
I group (YN=44%; YY=51 %; p=0.43).
YN investigators: Large PFO or concomitant ASA
Rates of surgical referral were higher for the young than the old (for large 
PFO, 58% young, 40% old; for ASA 65% young, 51% old). However, referral 
was significantly more common in the older age group than for the 
uncomplicated patient aged over 55 years (p< 0.01 for either abnormality).
YN investigators: associated DVT
Warfarin monotherapy was again the most popular choice, with referral for
correction being recommended by 27% in the young and 20% in the old.
NN investigators: uncomplicated scenario
NN investigators showed the highest rate of non-response (30%). Nearly a 
quarter of respondents in this group felt referral to be appropriate first-line in 
the young.
NN investigators: recurrent events
High warfarin usage (~40%) was observed in both the young and old. 
Referral for correction was common in the young (41% of respondents). 
Referral for correction was also common in the old, where significantly more 
patients were referred than in the YN group (33% vs 25%, p=0.01).
NN investigators: Large PFO or concomitant ASA
Rates of referral in the NN group were not significantly different from those in 
the YY group. In the young, 63% of YY investigators and 63% of NN 
investigators would refer for a corrective procedure with a large PFO. 63% of 
YY and 65% of NN investigators would refer for correction with a concomitant 
ASA. The age of the patient had no appreciable effect on decision making.
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NN investigators: associated DVT
NN investigators differed from other subgroups in their rate of cardiological 
referral for patients with associated DVT. 34% of YY investigators regard 
referral as part of their management plan in this situation compared to 13% of 
NN investigators (p=0.0164). Warfarin is used by about half of the 
respondents in both age groups, and 7% would recommend insertion of an 
inferior vena cava filter.
Questions 6 and 7
For a patient <55 years 49% of clinicians answered ‘yes' to question 6. The 
majority of these responders had recommended referral on the basis of one 
abnormality in the previous series of questions (121/130, 93%). Moreover, the 
majority of non-responders to question 6 had also recommended referral on 
the basis of a single ‘poor prognostic marker’ (69/105, 66%). Thus, 72% 
would refer with one clinical indicator of likely recurrence, and 76% would 
refer on the basis of two abnormalities or fewer. Using data from question 7, 
78% would recommend referral with three abnormalities or fewer. The older 
age group are thought to merit referral less, although response rates were 
similar: 64% with two abnormalities or fewer, and 67% with three 
abnormalities or fewer. There remains a substantial minority who do not feel 
that multiple clinical or structural characteristics would persuade them to seek 
a cardiological opinion: even with 3 factors present, 17% would not refer a 
patient >55 years.
The factors that are felt by responders to questions 6 and 7 to represent the 
greatest risk of recurrent events are illustrated in figure 4.1b, figure 4.1d, 
figure 4.2 b and figure 4.2d. No weighting is given to the order in which the 
responses were made. A large PFO was consistently felt to be the most 
important factor in decisions regarding lesion correction in the complicated 
patient, followed closely by the presence of recurrent events and then by a 
concurrent ASA. The presence of a large PFO combined with an ASA was felt
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to be the combination of two factors that most merited referral for correction 
(19 respondents for patients < 55 years, 15 respondents for patients > 55 
years), followed by the combination of recurrent events and a large PFO.
4.4 Discussion
Questionnaires examine practice only in those who respond to them and can 
never properly illustrate clinical management situations: each patient is 
different, and in real life we are not restricted to a finite set of responses. 
However, each physician has his or her own concept of a 'reasonable' 
investigation and management plan in clinically defined groups of individuals, 
based on their experience, their teaching, and their assessment of pertinent 
literature. There are many controversial areas of medicine where the 
collective opinion of those involved in making ‘difficult’ decisions can help to 
guide those with less experience. Furthermore, a proper assessment of 
practice in an area in which no consensus has been reached informs the
design and planning of pragmatic clinical trials.
Observational studies and indirect analyses have failed to provide clarity for 
clinicians in PFO associated unexplained stroke, and randomised evidence is 
badly needed. Decision-analysis models have been used to simulate the 
decision-making process 239. As is necessary in such exercises numerous 
assumptions were made, including that paradoxical embolism caused stroke 
in the hypothetical cohort of patients, that the risk of stroke recurrence
remained constant over time, and that the efficacy of anticoagulation
(compared with aspirin) would equal that seen in the major trials of patients 
with AF. The authors concluded that if the estimated risk of paradoxical stroke 
recurrence exceeded 0.8% per year, anticoagulation or surgical closure 
represented the preferred strategies. The annual stroke or TIA recurrence 
rate does not differ between the published series of medical therapy (aspirin 
or warfarin) (3.4% 88 and 3.8% 89) and percutaneous closure (3.4% 86), but is
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clearly above the level at which decision analysis would favour 'therapeutic 
abstention'.
The most common investigation group in this study (YN investigators) reflect 
the balance of observational evidence 237. A trend to association is, however, 
evident in the older age group, particularly (as in this questionnaire) when a 
cryptogenic group is defined 237, and investigation should not be avoided on 
the basis of age alone. Management decisions seem less dependant on age: 
for the complicated patient detailed in questions 6 and 7, responses for those 
patients older and younger than 55 are strikingly similar.
The questionnaire was worded with the aim of reflecting the practical 
decisions presented by clinical practice. Respondents were asked whether 
they would 'refer to a cardiologist for consideration of a corrective procedure', 
rather than whether they would recommend correction. This may explain the 
high level of referral in uncomplicated patients <55 years with a small PFO 
(42%). Antiplatelet therapy was the preferred initial strategy in those over 55 
years. 'Structural worsening' (a large PFO or a concomitant ASA) precipitated 
referral, whereas 'clinical worsening' (recurrent events) led to the prescription 
of warfarin.
Non-responders were more common for questions regarding management in 
the older age group, probably reflecting either uncertainty about management 
in this group, or respondents tiring during completion of the questionnaire. 
Fatigue may also have contributed to the similarity in response to questions 6 
and 7 in the old. Alternatively, age may be discounted (or relatively less 
important) when a patient is regarded at high risk of recurrence. Response to 
the question about Valsalva manoeuvre was also low, perhaps indicating that 
respondents interpret this aspect of the history as less ‘concrete’ than the 
others addressed. It is unfortunate that individuals responding to the 
questionnaire were not classified by their background (ABN or BASP) or their
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level of experience (consultant or trainee), since it would have been 
interesting to assess whether any significant differences were found between 
such groups.
Often before requesting an investigation we are asked ‘will it change your 
management?’ This is a reasonable question: it guards against excessive use 
of investigations, limits costs and saves patients from unnecessary distress. A 
striking finding in this analysis is that those individuals who would not 
investigate a patient for PFO (NN investigators) reported similar rates of 
warfarin use and referral for closure to YY investigators. For these individuals, 
knowledge about PFO clearly would change management plan, and 
avoidance of investigation is not serving the best interests of the patients 
under their care. A change in management is not the only consideration in 
deciding whether to investigate patients for PFO after stroke: advice about 
natural history can be given from observational data and the documented 
presence of PFO may be helpful if a patient returns with further symptoms 
suggestive of stroke disease.
Because management does change even in non-investigators, the results of 
this analysis support more thorough investigation of stroke patients. The 
nature of the stroke lesion and the presence of co-existent risks and causes 
should influence investigation strategy. In cryptogenic (unexplained) stroke, 
PFO should be sought, certainly in the young and possibly in the old, and 
while TOE is the 'gold standard' investigation, a useful screening test for 
clinicians with limited access to it is TCD with microbubble injection. If PFO is 
found, a TOE should be requested, so that lesion size can be more closely 
defined and the presence of ASA determined. Clinical evidence of DVT 
should be sought and investigated if detected. Ultrasound or venographic 
investigation of patients without symptoms or signs of DVT is likely to be 
unrewarding 84 24°. Positive investigations for thrombophilia may lead to the 
prescription of warfarin in patients known to have a PFO 241, but such
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decisions (without concurrent evidence of DVT) lack any evidence base. It 
would have been interesting to document current practice in this area, but 
thrombophilias are a heterogeneous group of disorders, making such an 
assessment extremely difficult.
The design of therapeutic trials must reflect the management practices 
detailed here. Stratified randomisation techniques, informed by data from this 
analysis and from recent prospective observational studies 90, may permit a 
more inclusive approach that takes patient risk into account before 
randomisation. A consensus for patients with cryptogenic stroke and PFO 
does emerge from analysis of expert opinion, which could be used to inform 
the design of hospital protocols and local guidelines. Initial management 
should consist of antiplatelet therapy, commonly aspirin. There is some 
evidence that dipyridamole is effective in the prophylaxis of thromboembolic 
events 242, and in combination with aspirin was superior to aspirin 
monotherapy in the ESPS-2 trial 32. A case could therefore be made for the 
first-line use of aspirin and dipyridamole in patients with inter-atrial septal 
abnormalities. The recent prospective recurrence data 90, published after 
circulation of this questionnaire, concur with a conservative approach - 
isolated PFO lesions appeared to have no effect on stroke recurrence.
If investigations document large PFO or concomitant ASA, referral for lesion 
correction should be considered, particularly if multiple events have been 
documented. PFO and ASA in conjunction are significantly predictive of 
recurrence in both retrospective 88 and prospective 90 series. The recently 
published prospective study 90 failed to confirm previous reports 234 that the 
degree of shunting was a significant predictor of recurrence. The optimal 
technique for correction is not yet defined. Recent series of patients treated 
with percutaneous closure have showed that persistent shunt is predictive of 
recurrence 86 87. Reported rates of persistent shunt after open heart surgery 
are lower than those after percutaneous closure 86 85, but surgery involves the
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attendant risks of cardiopulmonary bypass.
If clinical events recur the first consideration should be a switch to warfarin: 
the aetiology of recurrence may not be the PFO, an abnormality which is 
found in approximately 25% of the population 81, and warfarin therapy is 
appropriate prophylaxis for all sources of embolism. The presence of DVT 
should also lead to the use of warfarin. Therapy may be deferred if 
haemorrhagic transformation is a concern in the acute phase of stroke. The 
trend to longer periods of anticoagulation for DVT, on the basis of randomised 
data 243, seems even more prudent when there is a risk of recurrent stroke as 
well as venous thromboembolism. Whether and when therapy should stop 
remains unclear, and should be influenced by clinical course. The use of 
corrective techniques in combination with warfarin in a patient known to have 
a DVT was uncommon in respondents to the questionnaire. Such reluctance 
may reflect the fact that the period during which the patient is most at risk of 
stroke recurrence will be covered by warfarin therapy for venous thrombosis, 
making correction less of a priority. Also, although it provides support for a 
paradoxical embolic mechanism, DVT may occur as a consequence of stroke.
Many respondents who returned but did not fully complete the questionnaire 
wrote that they would leave all the decisions which were addressed in the 
questionnaire to a cardiologist, from whom they would seek advice as a 
matter of course. Such a policy means that the secondary prevention of 
stroke is planned by cardiologists, and seems incongruent with other areas of 
neurological practice; we do not leave decisions regarding appropriate use of 
carotid endarterectomy to vascular surgeons. The secondary prevention of 
cerebral infarction should be the realm of neurologists and stroke physicians, 
in consultation with cardiologists and cardiothoracic surgeons. Moreover, 
clinical trials in this area should be initiated, designed and conducted by 
stroke specialists, so that some of the real uncertainty illustrated here may be 
addressed.
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(Y
Y,
 Y
N,
 N
Y 
and
 
NN
). 
Re
sp
on
se
s 
are
 
ca
teg
ori
se
d 
us
ing
 
the
 
key
 
from
 
th
e 
qu
es
tio
nn
air
e 
pro
vid
ed
 
in 
ap
pe
nd
ix 
3. 
Th
us
, 
A 
= 
an
tip
lat
ele
t 
ag
en
t, 
B 
= 
wa
rfa
rin
, 
C 
= 
ins
ert
 v
en
a 
cav
a 
filt
er 
and
 
D 
= 
ref
er 
fo
r 
ca
rd
iol
og
ica
l 
op
ini
on
. 
Re
sp
on
de
nts
 
wh
o 
cir
cle
d 
mo
re 
tha
n 
one
 
ma
na
ge
me
nt 
op
tio
n 
are
 
ch
ar
ac
ter
ise
d 
by 
the
 
‘do
ub
le’
, ‘
tre
ble
’ a
nd
 
‘qu
ad
ru
ple
’ r
es
po
ns
e 
co
lum
ns
. 
Pe
rce
nta
ge
s 
of 
the
 
tot
al 
nu
mb
er
, o
r 
su
bg
rou
p 
nu
mb
er
 fo
r 
the
 
fin
al 
fou
r 
row
s, 
are
 
als
o 
pr
ov
ide
d.
A B C D o  • o o I O •
tre
ble
 
re
sp
on
se
A C D o  ' o  • o  • I o
B C D o o o I o
A B D 1
(0
%
)
1
(2
%
)
O ' I O '
A B C o  • O ' o  • I o
do
ub
le 
re
sp
on
se
B C o o O ' I o
A B o o o I o
0V o  • o o I o
C D 3
(1
%
)
1
(2
%
)
o I 1
(2
%
)
B D 18 (7%
)
6
(1
5
%
)
10 (7
%
) I 2 (4%
)
A D 11 (4%
)
o  ■ 9 (6%
) I 1
(2
%
)
sin
gle
 
re
sp
on
se
Q 11
7
(4
5%
)
18
(4
4%
)
66 (4
6%
)
I 30 (56
%
)
O 3 (1%
)
o 3
(2
%
)
I o
00 26
(1
0
%
)
5
(1
2
%
)
18
(1
2
%
)
I 2 (4%
)
< 26
(1
0
%
)
5
(1
2
%
)
16
(1
1
%
)
I 3 (6%
)
no re
sp
-o
ns
e
56 (21
%) 5
(1
2%
)
23 (16
%) I 15 (28
%)
gr
ou
p
To
ta
l
£  £ (2
)
YN
AN(c) (4
)
NN
Ta
ble
 
4.2
d:
 M
an
ag
em
en
t 
po
lic
y 
(< 
55 
ye
ar
s)
, 
lar
ge
 
(>2
5 
m
ic
ro
bu
bb
les
; 
>4m
m 
on 
TE
E)
 P
FO
. 
Re
sp
on
se
s 
are
 
do
cu
m
en
te
d 
for
 a
ll 
re
sp
on
de
nt
s 
an
d 
the
n 
for
 
ea
ch
 
in
ve
st
ig
at
io
n 
su
bg
ro
up
 
(Y
Y,
 Y
N,
 
NY
 
an
d 
NN
). 
Re
sp
on
se
s 
are
 
ca
te
go
ris
ed
 
us
ing
 
the
 
ke
y 
fro
m 
th
e 
qu
es
tio
nn
ai
re
 
pr
ov
id
ed
 
in 
ap
pe
nd
ix
 
3. 
Th
us
, 
A 
= 
an
tip
la
te
le
t 
ag
en
t, 
B 
= 
w
ar
fa
rin
, 
C 
= 
in
se
rt 
ve
na
 
ca
va
 
fil
te
r 
an
d 
D 
= 
re
fe
r 
fo
r 
ca
rd
io
lo
gi
ca
l 
op
in
io
n.
 
Re
sp
on
de
nt
s 
wh
o 
cir
cle
d 
mo
re 
tha
n 
on
e 
m
an
ag
em
en
t 
op
tio
n 
are
 
ch
ar
ac
te
ris
ed
 
by 
the
 
‘d
ou
bl
e’
, 
‘tr
eb
le
’ a
nd
 
‘q
ua
dr
up
le
’ r
es
po
ns
e 
co
lu
m
ns
. 
Pe
rc
en
ta
ge
s 
of 
the
 
to
ta
l 
nu
m
be
r, 
or 
su
bg
ro
up
 
nu
m
be
r 
for
 t
he 
fin
al
 f
ou
r 
ro
ws
, 
are
 
als
o 
pr
ov
id
ed
.
A B C D o o o I O
tre
bl
e 
re
sp
on
se
A C D o o o  ' I O
B C D o o o  » I O
A B D 1 (0%
)
1 (2%
)
O ' I O
A B C o o  • o I O •
do
ub
le
 
re
sp
on
se
B C o o o I o
A B o o o I o
A C o o o I o  •
C D O ' o o  • I o
B D 18 (7%
)
4
(1
0%
)
10 (7
%
)
I 2 (4
%
)
A D 7 (3%
)
1 (2%
)
5 (3%
)
I 1 (2%
)
si
ng
le
 
re
sp
on
se
D 13
5
(5
2%
)
20 (4
9%
)
80 (5
5%
)
I 32 (59
%
)
O 1 (0
%
)
o 1
(1
%
)
I o
CO 27 (1
0%
)
4
(1
0%
)
19
(1
3%
)
I 2
(4
%
)
< 21 (8
%
)
6
(1
5%
)
12 (8
%
)
I 2
(4
%
)
no re
sp
-o
ns
e
51 (20
%) 5
(12
%) 18 (12
%) I 15 (28
%)
g
ro
up
To
ta
l
(1
)
YY (2
)
YN
AN(e) s  i
Ta
ble
 
4.2
e:
_M
an
ag
em
en
t 
po
lic
y 
(< 
55 
ye
ar
s)
, 
as
so
cia
ted
 
AS
A.
 R
es
po
ns
es
 
are
 
do
cu
me
nte
d 
for
 a
ll 
re
sp
on
de
nts
 
and
 
the
n 
for
 e
ac
h 
inv
es
tig
ati
on
 
su
bg
rou
p 
(Y
Y,
 Y
N,
 N
Y 
and
 
NN
). 
Re
sp
on
se
s 
are
 
ca
teg
ori
se
d 
us
ing
 
the
 
key
 f
rom
 
the
 
qu
es
tio
nn
air
e 
pro
vid
ed
 
in 
ap
pe
nd
ix 
3. 
Th
us
, 
A 
= 
an
tip
lat
ele
t 
ag
en
t, 
B 
= 
wa
rfa
rin
, 
C 
= 
ins
ert
 v
en
a 
cav
a 
filt
er 
and
 
D 
= 
ref
er 
for
 c
ar
dio
log
ica
l o
pin
ion
. 
Re
sp
on
de
nts
 
wh
o 
cir
cle
d 
mo
re 
tha
n 
one
 
m
an
ag
em
en
t 
op
tio
n 
are
 
ch
ar
ac
ter
ise
d 
by 
the
 
‘do
ub
le’
, ‘t
re
bl
e’ 
and
 
‘qu
ad
ru
ple
’ r
es
po
ns
e 
co
lum
ns
. 
Pe
rc
en
ta
ge
s 
of 
the
 
tot
al 
nu
mb
er
, o
r 
su
bg
rou
p 
nu
mb
er
 fo
r 
the
 f
ina
l f
ou
r 
row
s, 
are
 
als
o 
pr
ov
ide
d.
A B C D o  ■ o o I O
tre
ble
 
re
sp
on
se
A C D o o  • o I O
B C D 4 (2%
)
1 (2%
)
3 (2%
)
I O  •
A B D Cp'•»— o'* O, 1 (2%
)
o I O
A B C O  • o  • o I o
do
ub
le 
re
sp
on
se
B C 5 (2%
)
1 (2%
)
1
(1
%
)
I 2
(4
%
)
A B o o o I o
A C 1 (0%
)
o 1
(1
%
)
I o
C D o o  ■ o  ■ I o
B D 24 (9%
)
6
(1
5%
)
15
(1
0%
)
I 2
(4
%
)
A D 1 (0%
)
o  • 1
(1
%
)
I o
sin
gl
e 
re
sp
on
se
Q 32 (1
2%
)
6
(1
5%
)
20 (1
4%
)
I 5
(9
%
)
O 8 (3
%
)
o 3 (2%
)
I 4 (7
%
)
0Q 12
8
(4
9%
)
21 (5
1%
)
77 (5
3%
)
I 26 (4
8%
)
< 9 (3%
)
1
(2
%
)
7
(5
%
)
I 1 (2%
)
no re
sp
-o
ns
e
48 (1
8%
)
4
(1
0%
)
17
(1
2%
)
I 14
(2
6%
)
gr
ou
p
To
ta
l
(1
)
YY (2
)
YN
AN(e)
NN
Ta
ble
 
4.2
f: 
M
an
ag
em
en
t 
po
lic
y 
(< 
55 
ye
ar
s)
, 
do
cu
m
en
te
d 
DV
T 
at 
the
 
tim
e 
of 
str
ok
e.
 R
es
po
ns
es
 
are
 
do
cu
me
nte
d 
for
 
all
 
re
sp
on
de
nts
 
and
 
the
n 
for
 e
ac
h 
inv
es
tig
ati
on
 
su
bg
rou
p 
(Y
Y,
 Y
N,
 N
Y 
and
 
NN
). 
Re
sp
on
se
s 
are
 
ca
teg
or
ise
d 
us
ing
 
the
 
key
 
from
 
th
e 
qu
es
tio
nn
air
e 
pro
vid
ed
 
in 
ap
pe
nd
ix 
3. 
Th
us
, 
A 
= 
an
tip
lat
ele
t 
ag
en
t, 
B 
= 
wa
rfa
rin
, 
C 
= 
ins
ert
 v
en
a 
cav
a 
filt
er 
and
 
D 
= 
ref
er 
fo
r 
ca
rd
iol
og
ica
l 
op
ini
on
. 
Re
sp
on
de
nts
 
wh
o 
cir
cle
d 
mo
re 
tha
n 
one
 
ma
na
ge
me
nt 
op
tio
n 
are
 
ch
ar
ac
ter
ise
d 
by 
the
 
‘do
ub
le’
, ‘
tre
ble
’ a
nd
 
‘qu
ad
ru
ple
’ r
es
po
ns
e 
co
lum
ns
. 
Pe
rce
nta
ge
s 
of 
the
 
tot
al 
nu
mb
er
, o
r 
su
bg
rou
p 
nu
mb
er
 fo
r 
the
 
fin
al 
fou
r 
ro
ws
, a
re 
als
o 
pr
ov
ide
d.
A B C D 1 (0%
)
1 (2%
)
o I O •
tre
ble
 
re
sp
on
se
i
A C D o o o I O
B C D O ' o  • O ' I O '
A B D 2 (1%
)
2
(5
%
)
o  • I O '
A B C o o O ' I o
do
ub
le 
re
sp
on
se
B C o o o  • I O '
A B 3 (1%
)
1 (2%
)
2
(1
%
) I O '
A C o o o I o
C D o o  ■ o I o
B D 7 (3%
)
2
(5
%
)
4 (3
%
) I 2 (4%
)
A D 19 (7%
)
4
(1
0%
)
11 (8%
) I 4 (7%
)
sin
gle
 
re
sp
on
se
Q 17 (7%
)
6
(1
5%
)
8
(6
%
)
I 3
(6
%
)
O o o o I o
cn 22 (8%
)
3
(7
%
)
14
(1
0%
)
I
(%
z)
Z
<
12
3
(4
7%
)
14
(3
4%
)
78 (54
%
)
I 25 (46
%
)
no re
sp
-o
ns
e
67 (26
%
)
10 (2
4%
)
28 (19
%) I 16 (30
%
)
gr
ou
p
To
ta
l
(1
)
YY (2
)
YN
AN(€) (4
)
NN
Ta
bl
e 
4.
3a
: 
M
an
ag
em
en
t 
po
lic
y 
(> 
55 
ye
ar
s)
, 
un
co
m
pl
ic
at
ed
 
pa
tie
nt
 w
ith
 
cr
yp
to
ge
ni
c 
st
ro
ke
 
an
d 
a 
sm
al
l 
PF
O.
 R
es
po
ns
es
 
ar
e 
do
cu
me
nte
d 
for
 a
ll 
re
sp
on
de
nts
 
and
 
the
n 
for
 e
ach
 
inv
es
tig
ati
on
 
su
bg
rou
p 
(Y
Y,
 Y
N,
 N
Y 
and
 
NN
). 
Re
sp
on
se
s 
are
 
ca
teg
or
ise
d 
us
ing
 
the
 
key
 f
rom
 
the
 
qu
es
tio
nn
air
e 
pro
vid
ed
 
in 
ap
pe
nd
ix 
3. 
Th
us
, A 
= 
an
tip
lat
ele
t 
ag
en
t, 
B 
= 
wa
rfa
rin
, 
C 
= 
ins
ert
 v
en
a 
cav
a 
filt
er 
and
 
D 
= 
ref
er 
for
 c
ar
dio
log
ica
l o
pin
ion
. 
Re
sp
on
de
nts
 w
ho 
cir
cle
d 
mo
re 
tha
n 
one
 
ma
na
ge
me
nt 
op
tio
n 
are
 
ch
ar
ac
ter
ise
d 
by 
the
 
‘do
ub
le’
, ‘t
re
ble
’ 
and
 
‘qu
ad
ru
ple
’ re
sp
on
se
 
co
lum
ns
. 
Pe
rce
nta
ge
s 
of 
the
 
tot
al 
nu
mb
er
, o
r 
su
bg
rou
p 
nu
mb
er
 fo
r 
the
 
fin
al 
fou
r 
row
s, 
are
 
als
o 
pr
ov
ide
d.
A B C D o o  • o  • I O
tre
ble
 
re
sp
on
se
A C D o o o I O
B C D 2
(1
%
)
o 2
(1
%
)
I O
A B D Cp■»— o'o. 1 (2%
)
o  ■ I O  •
A B C O  • o o  • I O
do
ub
le 
re
sp
on
se
B C O o o  • I O
A B 1 (0%
)
o  • 1
(1
%
)
I O
A C o o o I O
C D 2
(1
%
)
T— O' o I 1
(2
%
)
B D 15 (6%
)
5
(1
2
%
)
5
(3
%
)
I 4
(7
%
)
A D 6
(2
%
)
1 (2%
)
4
(3
%
)
I 1 (2%
)
sin
gl
e 
re
sp
on
se
Q 46
(1
8
%
)
9
(22
%) 25
(1
7
%
)
I 12 (22
%)
O 5 (2%
)
o 3 (2%
)
I 1 (2%
)
CO 11
2
(4
3
%
)
16
(3
9
%
)
70
(4
8
%
)
I 20
(3
7
%
)
< 11 (4
%
)
1 (2
%
)
8
(6
%
)
I 2
(4
%
)
no re
sp
-o
ns
e
60 (2
3%
)
7
(1
7%
)
27 (19
%
)
I 13 (24
%
)
gr
ou
p
To
ta
l
£  £ (2
)
YN
AN(e)
NN
Ta
ble
 
4.3
b:
 M
an
ag
em
en
t 
po
lic
y 
(> 
55 
ye
ar
s)
, 
re
cu
rre
nt
 e
ve
nts
 
on 
ini
tia
l t
he
ra
py
. 
Re
sp
on
se
s 
are
 
do
cu
m
en
te
d 
for
 a
ll 
re
sp
on
de
nt
s 
an
d 
the
n 
for
 e
ac
h 
in
ve
st
ig
at
io
n 
su
bg
ro
up
 
(Y
Y,
 Y
N,
 N
Y 
an
d 
NN
). 
Re
sp
on
se
s 
are
 
ca
te
go
ris
ed
 
us
ing
 
the
 
ke
y 
fro
m 
the
 
qu
es
tio
nn
ai
re
 
pr
ov
id
ed
 
in 
ap
pe
nd
ix
 
3. 
Th
us
, 
A 
= 
an
tip
la
te
le
t 
ag
en
t, 
B 
= 
w
ar
fa
rin
, 
C 
= 
in
se
rt 
ve
na
 
ca
va
 
filt
er
 a
nd
 
D 
= 
re
fe
r 
for
 c
ar
di
ol
og
ic
al
 o
pi
ni
on
. 
Re
sp
on
de
nt
s 
wh
o 
cir
cle
d 
mo
re
 
tha
n 
on
e 
m
an
ag
em
en
t 
op
tio
n 
are
 
ch
ar
ac
te
ris
ed
 
by 
the
 
‘d
ou
bl
e’
, ‘
tr
eb
le
’ a
nd
 
‘q
ua
dr
up
le
’ r
es
po
ns
e 
co
lu
m
ns
. 
Pe
rc
en
ta
ge
s 
of 
the
 
to
ta
l 
nu
m
be
r, 
or 
su
bg
ro
up
 
nu
m
be
r 
for
 t
he 
fin
al
 f
ou
r 
ro
ws
, 
are
 
als
o 
pr
ov
id
ed
.
A B C D 3 “o . 1 (2%
)
O  ' I O
tre
ble
 
re
sp
on
se
A C D O O  ' o I o
B C
I
D o o o  • I o  •
A B D 3T-  O 'o . 1 (2
%
)
O  ' I o
A B C O  • o  • o I o
do
ub
le 
re
sp
on
se
B C O  ' o  • o I O  '
A B 1 (0%
)
o 1
(1
%
)
I o
A C o o o I o
C D 1 (0%
)
o 1
(1
%
)
I o  ■
B D 6 (2%
)
2
(5
%
)
4
(3
%
)
a o
A D 6 (2%
)
o 3
(2
%
)
i 2
(4
%
)
sin
gle
 
re
sp
on
se
Q 59
(2
3
%
)
13
(3
2
%
)
31
(2
1
%
)
i 15
(2
8
%
)
O 10 (4%
)
2
(5
%
)
5
(3
%
)
i 3
(6
%
)
00 48
(1
8
%
)
8
(2
0
%
)
30
(2
1
%
)
i 6
(1
1
%
)
<
53 (2
0
%
)
6
(1
5
%
)
36
(2
5
%
)
i 10
(1
9
%
)
no re
sp
-o
ns
e
75 (29
%
)
8
(2
0%
)
34 (23
%
)
i 18 (33
%
)
gr
ou
p
To
ta
l
(1
)
YY (2
)
YN
AN(c) s  i
Ta
bl
e 
4.
3c
: 
M
an
ag
em
en
t 
po
lic
y 
(> 
55 
ye
ar
s)
, 
Va
ls
al
va
 
m
an
oe
uv
re
 
or 
co
ug
h 
pr
ec
ed
in
g 
st
ro
ke
. 
Re
sp
on
se
s 
are
 
do
cu
m
en
te
d 
fo
r 
all
 r
es
po
nd
en
ts
 
an
d 
the
n 
for
 e
ac
h 
in
ve
st
ig
at
io
n 
su
bg
ro
up
 
(Y
Y,
 Y
N,
 N
Y 
an
d 
NN
). 
Re
sp
on
se
s 
are
 
ca
te
go
ris
ed
 
us
ing
 
the
 
ke
y 
fro
m 
th
e 
qu
es
tio
nn
ai
re
 
pr
ov
id
ed
 
in 
ap
pe
nd
ix
 
3. 
Th
us
, 
A 
= 
an
tip
la
te
le
t 
ag
en
t, 
B 
= 
w
ar
fa
rin
, 
C 
= 
in
se
rt 
ve
na
 
ca
va
 
filt
er
 
an
d 
D 
= 
re
fe
r 
fo
r 
ca
rd
io
lo
gi
ca
l 
op
in
io
n.
 
Re
sp
on
de
nt
s 
wh
o 
cir
cle
d 
mo
re 
tha
n 
on
e 
m
an
ag
em
en
t 
op
tio
n 
are
 
ch
ar
ac
te
ris
ed
 
by 
the
 
‘d
ou
bl
e’
, 
‘tr
eb
le
’ a
nd
 
‘q
ua
dr
up
le
’ r
es
po
ns
e 
co
lu
m
ns
. 
Pe
rc
en
ta
ge
s 
of 
the
 
to
ta
l 
nu
m
be
r, 
or 
su
bg
ro
up
 
nu
m
be
r 
for
 t
he 
fin
al
 f
ou
r 
ro
ws
, 
are
 
als
o 
pr
ov
id
ed
.
<  CQ O  Q o  • o  ' o I O
tre
bl
e 
re
sp
on
se
A C D o o  • o I O
B C D o o o I O
A B D 1 (0%
)
1
(2
%
)
o I o
A B C o o O ' I o
do
ub
le
 
re
sp
on
se
B C o O  ' o I o
A B C? ■»— 0s O, o  ■ 1 (1%
)
I o  •
A C O ' o o I o
C D 1 (0%
)
1
(2
%
)
o t o
B D 16 (6%
)
7
(1
7%
)
6 (4%
)
I 3 (6%
)
A D 6 (2%
)
o 0sCO I 1 (2%
)
si
ng
le
 
re
sp
on
se
Q 93 (36
%
)
16
(3
9%
)
48 (33
%
)
I 27 (50
%
)
O 2 (1%
)
o 1 (1%
)
I o
OQ 30 (11
%
)
5
(1
2%
)
19 (13
%
)
I 5 (9%
)
<
37 (1
4%
)
4
(1
0%
)
28 (19
%
)
I 3
(6
%
)
no re
sp
-o
ns
e
74 (28
%
)
7
(1
7%
)
38 (26
%
)
I 15 (28
%
)
gr
o
u
p
To
ta
l
(1
)
YY (2
)
YN (3
)
NY £  I
Ta
bl
e 
4.
3d
: 
M
an
ag
em
en
t 
po
lic
y 
(> 
55 
ye
ar
s)
, 
lar
ge
 
(>2
5 
m
ic
ro
bu
bb
le
s;
 >
4m
m 
on 
TE
E)
 
PF
O
. 
Re
sp
on
se
s 
are
 
do
cu
m
en
te
d 
for
 a
ll 
re
sp
on
de
nt
s 
an
d 
the
n 
for
 
ea
ch
 
in
ve
st
ig
at
io
n 
su
bg
ro
up
 
(Y
Y,
 Y
N,
 
NY
 
an
d 
NN
). 
Re
sp
on
se
s 
are
 
ca
te
go
ris
ed
 
us
ing
 
the
 
ke
y 
fro
m 
th
e 
qu
es
tio
nn
ai
re
 
pr
ov
id
ed
 
in 
ap
pe
nd
ix
 
3. 
Th
us
, 
A 
= 
an
tip
la
te
le
t 
ag
en
t, 
B 
= 
w
ar
fa
rin
, 
C 
= 
in
se
rt 
ve
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Chapter 5: The Statins in Acute Stroke (SAS) Trial
161
5.1 Introduction
Inhibitors of the enzyme HMG Co-A reductase, often called ‘statins’, are 
well tolerated and potent drugs used to lower cholesterol. In large scale 
clinical trials, HMG Co-A reductase inhibitors have been shown to reduce 
the long term incidence of myocardial infarction and death, in both primary 
244 and secondary 245 prevention. Published meta-analyses have 
demonstrated a 30% reduction in the incidence of stroke in individuals with 
coronary heart disease (CHD) 246. The secondary prevention of stroke with 
statins is currently being investigated by randomised trials, but subgroup 
analysis of the large (but unpublished) Heart Protection Study 100 has 
suggested benefits in the secondary prevention of stroke similar to those 
demonstrated in CHD.
There appear to be both short and long-term benefits in prescribing statins 
to individuals with coronary artery disease. The effect cannot be solely 
attributed to cholesterol lowering in individuals with hyperlipidaemia, 
because reductions in vascular events seem to occur earlier than could be 
explained by plaque regression, and appear to occur in individuals with both 
low and high initial cholesterol levels 247 104. The effect of statins on 
endothelium, blood rheology and vasomotor tone may explain their efficacy 
in patients at high vascular risk 106.
Various rheological markers (fibrinogen, viscosity, tissue plasminogen 
activator (tPA), plasminogen activator inhibitor (PAI-1) and D-dimer) have 
been shown to be independent predictors of stroke risk 120 127 124 115 (see 
chapter 1). It is thought that treatment to lower such markers may reduce 
the incidence of further stroke and myocardial infarction, and there is limited 
trial evidence that statins may be beneficial in this regard 114. Other putative 
effects of statins have been discussed in chapter 1; effects on blood 
pressure and cerebral blood flow and perfusion have been suggested,
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either directly or indirectly by effects on rheological markers. Anti­
inflammatory effects of statins have generated considerable interest in the 
cardiovascular research community 138t and have also been suggested in 
the cerebrovascular population by observational data 248. The use of statins 
in the acute phase of stroke has not been studied. Knowledge of their 
effects on rheological and inflammatory markers, blood pressure, cerebral 
blood flow and perfusion in the recovery phase of stroke will provide 
important data that should complement the large-scale primary and 
secondary stroke prevention trials due to report in the next few years.
5.2 Methods
Study design and objectives
The study was designed as a randomised, double blind, placebo-controlled 
trial of pravastatin versus placebo. We hypothesised that statin therapy 
would improve cerebral perfusion and cerebral blood flow after ischaemic 
stroke or transient ischaemic attack (TIA). The effect of statin therapy on 
blood pressure and markers of blood rheology was also examined. It was 
hoped that these data would be helpful in generating hypotheses for further 
investigations. Approval was obtained from the West Ethics Committee, and 
patients gave written informed consent to participate.
Patient qualification, enrolment, randomisation and dosing
The following inclusion and exclusion criteria applied to the study 
population:
Inclusion criteria
• Over 40 years of age
• Stroke 36 to 168 hours before randomisation
• Informed consent of patient
• Haemorrhage excluded on CT scanning
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Exclusion criteria
• Treatment with statin or alternative lipid lowering therapy within the 
previous 4 weeks
• History of intolerance to statin therapy
• Concomitant cardiovascular drug therapy maintained or initiated since 
stroke onset, excluding aspirin and digoxin, but including 
antihypertensives, warfarin and heparin.
• Unstable clinical state
• Women in whom possibility of pregnancy cannot be excluded
• Clinically significant liver disease or myositis
After full explanation of the procedures and risks, patients who gave 
informed consent underwent baseline investigations (day 0). These included 
" mTc hexamethyl propylene amine oxide single photon emission computed 
tomography (HMPAO SPECT) brain scanning, common and internal carotid 
artery Doppler examination, fasting blood samples for haemorrheology, total 
cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), 
triglycerides, liver function tests, creatinine kinase (CK), inflammatory 
markers and 24 hour blood pressure monitoring. These techniques, and 
their context in the study, are described further below.
Once baseline investigations were completed, all patients were randomised 
to receive either pravastatin 40mg per day for 56 days or matching placebo, 
in a ratio of 1:1. Randomisation was conducted by an unblinded 
independent research pharmacist who was uninvolved in clinical 
management except for the provision of blinded drug supplies. The day on 
which the first dose of drug was received was labelled day 1. 
Randomisation took place between October 1999 and August 2001.
Study flow (illustrated in figure 5.1)
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Day 3
24 hr blood pressure monitoring and carotid artery Doppler measurements 
were taken during the course of the day. Standard post-stroke management 
was employed, either in the acute stroke unit or in the rehabilitation setting. 
Day 28
Patients returned for repeat measurements of blood rheology, inflammatory 
markers, lipid concentrations, CK, liver function tests, carotid artery Doppler, 
and 24hr blood pressure monitoring.
Day 56
The measurements made on day 28 were repeated, and SPECT scanning 
was repeated at the same time of day as the baseline measurement.
Measurements of liver function and plasma CK were made at baseline and 
on day 28, to exclude the possibility of drug-induced hepatitis or myositis. If 
substantial rises in either of these markers were detected, the patient was 
withdrawn from the study.
Explanation of investigations
HMPAO SPECT scanning
SPECT was undertaken at baseline and on day 56 in the Department of 
Nuclear Medicine of the Western Infirmary using a Picker Prism 2000XP 
large field of view double-headed gamma camera. On each occasion 500 
MBq " mTc HMPAO dissolved in 5 millilitres 0.9% saline was injected as a 
bolus over one second through an 18 gauge intravenous catheter, followed 
by a further bolus of 10 millilitres of saline. An anterior image of 200 x 1s 
frames was then acquired. The patient's head and as much as possible of 
their heart was included in the field of view. SPECT imaging was 
undertaken 15 minutes later using a circular orbit and acquiring 60 angles 
around 360 degrees with 30s per angle. Analysis of the SPECT data was 
undertaken using a combination of Picker supplied software and some 
specialised software written in house. The data were reconstructed using a
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back projection algorithm with a Butterworth filter of order 3.14. Attenuation 
correction was undertaken using the Chang algorithm. A brain perfusion 
index (BPI) was calculated from the first-pass data as described by Matsuda 
et al 249 25°, using the unaffected hemisphere as the reference region. The 
reconstructed data were reorientated to transaxial oblique slices (8mm 
thick) parallel to the orbito-meatal line. Image registration was undertaken, 
registering the two sets of SPECT data for each of the patients (from day 0 
and day 56).
An elliptical region of interest was manually fitted to the outer edge of each 
transaxial oblique slice for each of the sets of data and a set of templates 
constructed 251. Regional cerebral blood flow (rCBF) in ml/100g/min was 
then calculated in each of the segments of the template using the previously 
obtained BPI. Segments were classified according to whether they were 
from right or left hemisphere, or from a cortical or subcortical locality. For 
each analysis (whole brain perfusion, cortical perfusion, symptomatic 
hemisphere perfusion and symptomatic cortex perfusion) the difference 
(day 56 - day 0) in rCBF was calculated for each of the relevant segments, 
and expressed as a percentage of the baseline (day 0) value. The SPECT 
method is analogous to that employed in previous studies of the cerebral 
perfusion effects of antihypertensives reported from our unit41.
Carotid Doppler examination
Doppler measurements (common carotid artery (CCA) and internal carotid 
artery (ICA)) were conducted at 08.45 hours at baseline, and on days 3, 28, 
and 56. Doppler studies were conducted using an Acuson Aspen duplex 
ultrasound machine and a 5MHz probe. The product of peak systolic area 
and mean time averaged velocity gave a measure of total CCA flow 
(millilitres / second). Total ICA blood flow and pulsatility index (a measure of 
peripheral vascular resistance, equalling (systolic velocity - diastolic velocity
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/ mean velocity) 252 253) were calculated from bilateral ICA insonation. 
Arterial flow was calculated (in ml/second) as:
[ n x (peak systolic diameter)2 x mean time averaged velocity] / 4
Details of the Doppler methods have been published previously 254. Each 
Doppler measurement at each time point was conducted in triplicate, and 
averages were calculated. Differences between follow-up measurements 
and the baseline value were expressed as a percentage change from 
baseline (day 0). No significant difference was detected between right and 
left percentage flow changes at each timepoint in the whole group, and so 
for each individual percentage flow change on right and left were averaged 
to provide a summary measure of change in CCA or ICA flow in that 
individual. This value was used for statistical comparisons.
24 hour blood pressure monitoring
Blood pressure monitoring (day 0, day 3, day 28 and day 56) was 
performed using standard ambulatory monitors (Spacelabs Inc, model 
90207). Monitoring commenced at 0900 and was performed for 24 hours. 
Recordings were taken at 30 minute intervals during the day, and hourly 
during the night, and were preceded by a warning bleep. Patients were 
provided with an information sheet detailing how often their blood pressure 
would be recorded, and asking them to keep their arm stationary during 
recordings.
Rheological /  Inflammatory marker assays
Samples were stored at -70 degrees Celsius at the Western Infirmary, and 
transferred at the end of the study to the haemorrheology laboratories at the 
Glasgow Royal Infirmary for analysis. Plasma levels of tPA were measured 
with a commercially available enzyme linked immunosorbent assay (ELISA) 
from Biopool AB, Umea, Sweden. Plasma von Willebrand factor (vWf)
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antigen levels were measured using an in-house ELISA, employing rabbit 
anti-human polyclonal antibodies obtained from DAKO pic, High Wycombe, 
UK. The measurement of plasma fibrin D-dimer, which is present in several 
cross-linked fibrin degradation products, was carried out using the ELISA kit 
from Biopool AB, Umea, Sweden. Clottable fibrinogen was measured by the 
dilute thrombin clotting time on an automated coagulometer (MDA 180, 
Organon Teknika, Cambridge UK), using calibrants and reagents provided by 
the manufacturer. Factor VII was measured by standard clotting assays on 
an automated coagulometer (MDA 180, Organon Teknika, Cambridge UK), 
using calibrants and reagents provided by the manufacturer. C-reactive 
protein (CRP) was measured on a Prospec Nephelometer (Dade Behring, 
Marburg, Germany) using a high sensitivity method with the manufacturer’s 
calibrant and reagent. Plasma viscosity was measured using a semi­
automated capillary viscometer (Beckman Coulter, High Wycombe, UK).
Statistical considerations and justification for sample size
This was based on repeated measurements of extracranial arterial flow 
rates, assessed at the Doppler examinations described. From a previous 
study 255, the average difference between two ICA flow measurements 
within a single patient was 0.07 with a standard deviation of 1.75 ml/sec. An 
analysis based on a simple t-test comparing the mean difference between 
flow measurements at baseline and at day 56 within individual patients was 
calculated to have 77% power to detect a difference between the treated 
and control groups of 1.4 ml/sec (-16% difference) in change over time with 
12 patients per group, at a significance level of 5%. Thus, a sample size of 
24 patients was our recruitment target.
In the SAS trial, each recording was conducted in triplicate by a single 
observer which we estimated would reduce variability by 30% to 1.225 
ml/sec. Using this estimate of sample variability, power levels in excess of 
95% could be obtained with 12 patients per group, and a satisfactory power
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of 90% was achievable with 18 patients (9 per group). SPECT data from 
similar post-stroke studies became available during the course of the trial, 
and indicated that a sample size of 18 would provide sufficient power to 
detect a cerebral perfusion difference between groups of 7ml/100g/min with 
80% power 41. These considerations permitted an alteration in our initial 
assumptions about data variability and sample size, and enabled us to 
absorb dropouts (see below) without compromising the trial.
For all variables measured, changes between the day 56 and baseline 
value within individuals were collated for both the pravastatin and placebo 
groups, using Microsoft Excel 97. For each parameter this difference (day 
56 - day 0), or the percentage difference from baseline calculated using this 
value ((day 56 - day 0) / day 0), was regarded as the primary endpoint. 
More acute effects at day 28 or day 3 ((day 28 - day 0) or (day 3 - day 0)) 
were regarded as secondary for the purposes of statistical analysis. The 
series of differences for each variable was checked for normal (parametric) 
data distribution by visual inspection of histograms, and groups were 
compared by standard t-tests for independent samples. All calculations and 
figures were generated using Statistica for windows (StatSoft Inc., version 
5.1, 1997).
5.3 Results
24 patients were recruited in total, but a number of dropouts occurred during 
the course of the trial. Patient 5 (placebo) was too obese to undergo SPECT 
examination, and so did not continue in the trial. Patient 9 (placebo) was 
discovered by the clinical team to have worsening liver function tests a 
week after randomisation, and was therefore withdrawn. On review, these 
continued to rise after discontinuation of trial medication, suggesting an 
alternative cause. Patient 19 (pravastatin) was also discovered to have an 
increase in alkaline phosphatase to 461 u/l at the day 28 assessment, and
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trial medication was discontinued at that point. Patient 14 (placebo) 
withdrew from the trial after day 3, because the rehabilitation staff caring for 
her felt that further trial visits were too strenuous. Patient 17 (placebo) did 
not attend for final SPECT assessment. Concomitant antihypertensives 
were prescribed to patient 23 (placebo) on the third day after randomisation, 
which may have interfered with our assessment of statin effect on blood 
pressure and cerebral perfusion, and so led to withdrawal. Patient 24 did 
not attend for final follow-up, and so data were only available for the first 3 
visits.
As a result of these numerous dropouts, 18 (10 pravastatin, 8 placebo) 
patients had a full set of Doppler and haemorrheological results, with two 
additional patients (19 and 24) having data for day 0, 3 and 28 
comparisons. Full SPECT data were available for 17 patients (10 
pravastatin, 7 placebo). Problems with compliance and equipment failure 
led to only 13 patients having full blood pressure data. Two further patients 
had day 0 and 3 blood pressure assessments (patient 9 and 14), and three 
had day 0, 3 and 28 assessments (patients 13, 21 and 24). Patients 12, 17 
and 18 had no baseline blood pressure measurement with which to make 
comparisons and patients 19 and 24 had only a baseline measurement.
Clinical details and treatment allocation are shown in table 5.1. Mean 
patient age was 66 years (standard deviation (SD) 14). No significant 
difference in mean age was detected between pravastatin and placebo 
groups (p=0.34). Mean entry NIH score was 2.5 (SD 3.2) for all randomised 
patients, 1.5 for the pravastatin group and 3.5 for the placebo group (p=0.13 
for comparison). At inclusion, 3 patients had suffered posterior circulation 
events, 9 had lacunar events and 12 patients had cortical anterior 
circulation events . No patient had further stroke events during follow up, but 
patient 12 was admitted with DVT (to L external iliac) shortly before his day
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56 visit. He was found during admission to have multiple pulmonary emboli 
and metastatic cancer in his liver.
Table 5.2 details changes in lipid and safety parameters in the pravastatin 
and placebo groups. Mean total cholesterol at baseline was 5.44 mmol/l 
(SD 0.66 mmol/l) in the pravastatin group and 5.49 mmol/l (SD 0.74 mmol/l) 
in the placebo group. Compared with minor increases in the placebo group, 
significant falls were seen in total (p<0.001) and LDL (p<0.001) cholesterol 
in pravastatin treated patients at 56 days. No significant differences 
between pravastatin and placebo were seen when comparing changes in 
triglyceride concentration or HDL level. Although patients 9 and 19 withdrew 
from the trial because of worsening liver function, neither case on review 
could be attributed to statin therapy. Comparisons of change in 
transaminase and CK levels between pravastatin and placebo groups 
revealed no significant difference.
SPECT cerebral perfusion results are illustrated in figure 5.2. Insignificant 
trends towards improvement in cerebral perfusion over the 2 month trial 
time course were seen in both groups, but there was no difference between 
pravastatin and placebo treated patients when comparing whole (p=0.88), 
cortical (p=0.94), symptomatic hemispheric (p=0.78) or symptomatic cortical 
(p=0.99) perfusion.
Figures 5.3 and 5.4 demonstrate the change from baseline in common 
(figure 5.3) and internal (figure 5.4) carotid artery flow over time for both 
the pravastatin and placebo groups. No significant benefit of treatment was 
detected when comparing common carotid (p=0.41) or internal carotid 
(p=0.84) arterial flow changes in the pravastatin and placebo groups 
between day 56 and baseline. Pulsatility index change over the course of 
the trial was not altered by treatment allocation (p=0.58).
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Figure 5.5 illustrates changes from baseline in mean arterial blood pressure 
(MAP) at the 3 follow-up examinations. No significant difference in MAP 
change over time was detected between the pravastatin and placebo 
treated patients (p=0.44 for (day 56 - day 0) comparison). Similarly, no 
significant effects of treatment were apparent when comparing systolic 
(p=0.42) or diastolic (p=0.20) pressures.
Figures 5.6 and 5.7 illustrate the mean difference between the day 56 and 
baseline values of each of the haemorrheological variables for the 
pravastatin and placebo groups. These differences are tabulated, along with 
the differences between day 28 and baseline values, in table 5.3. 
Insignificant trends towards reductions in haematocrit and factor VII were 
detected in the pravastatin group. No effect was seen on plasma fibrinogen, 
or plasma viscosity at 56 days. Plasma CRP appeared to rise in the 
treatment group, attributable to an increase in CRP to 136 mg/l in patient 
12, concurrent with the diagnosis of metastatic cancer.
5.4 Discussion
Cardiovascular research interest into the cholesterol independent 256 and 
acute 257 effects of statins continues to expand, fuelling new approaches to 
their use in the clinical arena. Statin use as a secondary preventative 
measure in cerebrovascular disease is also becoming increasingly 
common. The effects of statins on endothelial function, arterial tone, 
inflammatory processes and haemorrheology are an important and to date 
poorly examined area, both in the cerebrovascular population and in the 
acute phase of stroke itself. Pravastatin was well tolerated and safe in the 
acute phase of cerebrovascular events, and a marked early effect on total 
and LDL cholesterol was observed. Previous studies have shown improved 
blood pressure control with statin therapy in both untreated and treated 
hypertensive patients 258, but no effect on mean arterial blood pressure was
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observed in our cohort, possibly reflecting the small number of patients with 
full data. No effect or trend to effect was seen in common carotid or ICA 
flow, or cerebral perfusion as measured by SPECT.
There are trial design factors that serve as possible explanations for our 
failure to detect an effect of pravastatin on the primary outcome measures 
of SPECT perfusion and ICA flow. The numbers recruited were small, and 
this was compounded by missing data due to dropouts. It was felt that these 
dropouts could be absorbed because of new data on SPECT variability that 
became available during the trial, and improved Doppler accuracy from the 
use of a single observer and triplicate recordings. In fact, variability of 
SPECT differences in whole perfusion was lower in the current study than in 
that which informed our decision 41, probably an effect of the same observer 
examining baseline and follow-up scans, and increased familiarity of nuclear 
medicine staff with the quantitative technique employed 249 25°. Even so, we 
were unable to detect even a trend towards improvement in SPECT 
perfusion and have ruled out differences in whole cerebral perfusion at two 
months between pravastatin and placebo treated ischaemic stroke patients 
of more than 7 ml/100g/min. While it remains possible that small 
improvements in perfusion may be conferred by statin therapy over longer 
periods, these are unlikely to be clinically significant after two months of 
therapy. Similarly sized studies in hyperlipidaemic patients with CHD have 
demonstrated improvements in Positron Emission Tomography (PET) 
coronary flow reserve under dipyridamole stress after 6 months 259 and 
thallium SPECT perfusion after 12 weeks 11°.
The standard deviation of differences in ICA flow recordings between follow- 
up and baseline scans was higher than those obtained during previous 
studies in our unit: 4.2 ml/sec for day 56 - day 0 difference, 4.08 ml/sec for 
day 28 - day 0 difference and 3.99 ml/sec for day 3 - day 0 difference. This 
reduced level of accuracy in the recordings had a major impact on the ability
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of the trial to detect a treatment effect on ICA flow: only differences between 
placebo and pravastatin of approximately 3.2 ml/sec were detectable with 
the numbers recruited. The technique used to assess ICA flow assumes 
that the lumen of the vessel being studied is cylindrical (in other words, the 
cross-sectional area of the vessel can be calculated from its diameter). 
Some of the patients recruited into the trial had haemodynamically 
significant internal carotid disease (patient 6: left carotid occlusion; patient 
13: bilateral moderate stenosis; patient 14 moderate right stenosis; patient 
18: bilateral severe stenosis; patient 19: bilateral occlusion) and if these 
lesions caused a non-concentric reduction in ICA flow, errors may have 
been introduced into its calculation. Such lesions are also likely to increase 
variability in the assessment of flow. However, no significant change over 
time in arterial diameter was seen within groups (mean change 
pravastatin=0.24mm (95% Cl -0.38 to 0.85), mean change 
placebo=0.25mm (-0.31 to 0.80)) or between groups (p=0.98), and so the 
comparison of the change in flow between groups remains valid.
The trial was not powered to detect clinically significant changes in 
haemorrheological variables, but some observations can be made from the 
data presented. Trends towards reduction in factor VII, which plays an 
important role in fibrin generation and thrombus formation, concur with 
previous reports that atorvastatin significantly reduces factor VII levels in 
chronically hyperlipidaemic patients 260 261. Haematocrit (the volume fraction 
of red blood cells) is a major determinant of blood viscosity, and after 56 
days showed a trend towards reduction in the treated group. Higher 
numbers of patients recruited to the trial may have led to significant results. 
Plasma viscosity itself appeared to reduce in the treated group at 28 days 
(p=0.04), but comparison with the placebo group was insignificant at 56 
days. Our failure to demonstrate an effect on fibrinogen and plasma 
viscosity (which have shown significant reductions with pravastatin therapy 
in studies of similar size 114) may be a function either of assessing
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fibrinogen change in the immediate aftermath of acute cerebral ischaemic 
events, or of the short length of therapy. TPA antigen, D-dimer and vWf 
were unaffected by therapy. Whether pharmacological intervention will 
affect these variables, and what significance in terms of vascular event 
prevention this may have, is unclear.
Numerous investigators have reported improvements in CRP level in 
hyperlididaemic and cardiovascular populations with pravastatin therapy 262 
263. A recent retrospective analysis of data from the Air Force/Texas 
Coronary Atherosclerosis Prevention Study has suggested that CRP could 
be used as a means for targeting statin therapy in patients with relatively 
low lipid levels 264. While CRP levels predict poor outcome after stroke 137, 
the effect of statins on CRP in acute ischaemic stroke has not been 
previously studied in a randomised trial. Because of small numbers, the 
results obtained (using a high sensitivity method of CRP detection) were 
strongly influenced by a single individual in the treatment group (patient 12), 
whose CRP rose from 14mg/l at 28 days to 136mg/l at 56 days. The same 
individual similarly affected measurements of differences in other 
haemorrheological parameters that rise as part of the acute phase response 
(fibrinogen, vWF and d dimers). Whether CRP will be useful in assessing 
vascular risk and guiding therapy in ischaemic stroke patients is currently 
unclear. In common with fibrinogen, it may be a practical surrogate marker 
for testing the effectiveness of therapies such as statins and antibiotics in 
targeting the acute phase response element of atherothrombosis 256.
A trend towards improved stroke outcome in patients receiving statins at the 
time of their stroke has been reported in a retrospective case-referent study 
265. While the statistical power and methods of outcome assessment were 
weak, in a logistic regression model the use of statins was a moderately 
strong but statistically non-significant predictor of discharge home (multiple 
adjusted odds ratio 1.42, 95% Cl 0.90 to 2.22). As discussed in chapter 1,
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possible explanations for such an effect include statin-mediated 
preservation of endothelial nitric oxide synthase activity in cerebral 
vasculature, modulation of endothelial function with preservation of blood 
flow to ischaemic regions or the putative anti-inflammatory and antioxidant 
properties of statins 113. The authors 265 indicate that the design of a trial 
examining the acute effects of statins on patient outcome in stroke should 
be based on an estimated 20 to 40% reduction in the risk for poor outcome.
Randomised data from cardiovascular trials have confirmed that statins 
confer a reduced risk of stroke in individuals with CHD across a range of 
cholesterol levels (see chapter 1). Preliminary data from the Heart 
Protection Study 100, which currently remains unpublished, have suggested 
a significant effect on vascular events in individuals with no prior CHD, a 
finding which is being investigated in 'pure' stroke populations by ongoing 
randomised trials. No significant effect on arterial flow, cerebral perfusion or 
haemorrheological markers was demonstrated in this trial, but the early use 
of statin therapy may have wider implications than merely early reduction of 
cholesterol. In common with early ACE inhibitor use after stroke following 
the publication of the PROGRESS trial 39, there may be effects on both 
recovery from the index stroke and vascular risk reduction in the early 
subacute phase, and these must be examined in larger studies with clinical 
endpoints. Such studies must also examine the interaction between statins 
and ACE inhibitors, particularly on blood pressure control, whether different 
statins have different effects, and whether effects are seen only in 
subgroups of the heterogeneous stroke population.
iiif
i
CDOOO
u_
CMo05COo COoCO
•c O c o
9- o c w.2 « Q.
- C  C  <0 CO
p  *(0 Q. >
• c  X  - c  "O
. =  CD •—  COQ.£ Q. Q.
ro ^ w 2
« £ ro :eg c kg-
_ J  TO ®  {g
Ql
Q.Q.Q_Q_Q.
Clc la .CLCLCL CL
in
CD
CD
c  o
O ®
r= w !?# 2 j?
ro  c lo £ o 2 w g
n o r
U  CL Cw o >* c 0) w -C to
CD
</J C
CL
Q.
O
O
O O
O
OO
o
o
oI
_o
05
05
05
05
05
05
05
05
05
05O) oI
05CL>*
05CO
O
CDCO CO
CM COCOCMCMCM OO O
CMCDCOID 05IDCOCO05 CDIDCOCO CO
LL
S3 COCM05COID CDCOCM
VO
t"-
oo
L I-
00 o
.£ ra 0.-0 «  -c ro >»w c
Q . Q_Q_ Q.Q.
Q.CLCL
oooO)3 0)
J=
q . O ( d
-Q *f=r  •-
>*
o
o
o
o
o
oo> oI
0 5
oI
0 5
o oooI-Q 0 5
cn0 5 o
00
0 5
O
00LO
o
0 5 OO ’
m
0 5
LO
incoinLO 0 5f"-05 LO 00
LL
CNCOCMCM00 05LO CO CM
to -o
CO
i  v. 8
1 1 1o iy) w
00 M-00
00o
CD
Ooo o
a o
coO)
CO
m o
CD
O) O 00V <9
'  CD
00 o
CM
o
v4- ^T °>X  CD 00 
00
o 00o 0000CM COoo
CO
CD
o
in CO
o
in ino ^  
d o 
00 oq
00oin■m- oin — 
o 5
o
oh-
PS
COmo> 00in
d
CMoo o>o ooO) ooo CD
oo oo
a o
in
V °° w' o
o>
COm COCD0000(0 tf'o m E S
oo
COoCO
§ £  I ,
oo
co
9 «
S'0
CMo
ino> oo
>» o 
o> E c .E h
Ta
ble
 
5.2
: 
Ch
an
ge
 
in 
lip
id 
and
 
mu
sc
le 
and
 
liv
er 
en
zy
me
 
va
lue
s 
ov
er 
tim
e
o00o
d
oooo0500o CO
do
a  o
COoooh-00
9 cm
:l soo o oCO
d
oooo ^|sj COco q
0505
to 05
V «s CMO00
d
05 P00 05 
d. 00 O O 
IO
00mo> o Z_
00 O COCO W COoo
CO00
cvi
00
CM CO
o
00CO COCO o CM T-I^05 O M-
q  o 00 ~
CO00CO
00h-o ^  o o
05 o CO
oco —- 
°? 8 
X  d
CM
00CM P 
CO 00
CM CM
d   ^id inIOCM05o
in
05 CO 00 oinCMCMo oJZ
lo05CO
d
05N.
CO
d
COo
d
00 M-
d
a o
LOCMCM 00CO '—'■CMO o o O 
o o05o o
COCO
s ^9 s
00 00 °0 05 CO 05 ■ CO
CO ^  CO
COinO)n
COoCO
IO
>»
ooo COCM
LO
o
dCO
IOCO
O o  CO co
^  0 5  CO COm. oh- *-
COinCOr -_« CO O CM
CM
q co
O  CM
in M"CO ^  CO CM — CO 05 CO CM CO
d
CM
CM
d  oo
t  q
’ CO
CM
q©V 00 0005 o
in05 o  cod-O
^  d CO CM COinco °  o  o  
d
oo o
>*
O)
£ o 
O Q.
0 5t--
Ta
ble
 
5.3
: 
Ch
an
ge
 
in 
ha
em
or
rh
eo
lo
gi
ca
l v
ar
iab
les
 
ov
er
tim
e
TR
EA
TM
EN
T 
PE
RI
OD
_j
od d
SP
EC
T o.CO
L.JZir
LU-JQ.Dl
o
LU
COLU—1
> »u.
f i& r f
«•w-CO a o
I I I !=co
COIfl
>
a
dLU Cu—1 COCu L.Cu .cOa CO
ooCJ
>
a
ro
>
a
<co
2Oaz<c*
>-CCa
Y 7
LUz□ _  LU e
■3. g
LU
COz
oo
Fig
ur
e 
5.1
: 
De
sig
n 
of 
the
 
St
ati
ns
 
in 
Ac
ute
 
St
ro
ke
 
Tr
ial
. 
SP
EC
T=
 
Sin
gle
 
ph
oto
n 
em
iss
ion
 
co
mp
ute
d 
to
m
og
ra
ph
y, 
CK
= 
cr
ea
tin
ine
 
kin
as
e, 
LF
T=
 
live
r 
fun
cti
on
 
tes
ts,
 V
isc
= 
pla
sm
a 
vis
co
sit
y, 
Fib
r= 
fib
rin
og
en
, 
Hc
t= 
ha
em
at
oc
rit,
 C
RP
= 
C 
rea
cti
ve
 
pr
ote
in,
 t
PA
= 
tis
su
e 
pla
sm
ino
ge
n 
ac
tiv
ato
r, 
DD
= 
fib
rin
 
d-
dim
er
, 
FV
II=
 
fac
tor
 V
II 
and
 
vW
f= 
vo
n-
W
ille
br
an
d 
fa
cto
r.
pla
ceb
o 
pra
va
sta
tin
O Q
H
O QWw £ 6 
(0  CO
H
uoisrqjad lebipoo u| aBueip % u o i s n p e d  xsijos o u e u i o i d u i A s  u i  sBueup %
0 Q"? w1 i«J a ® a> 3 S
H
So
H
uo|*njj*d 8j»gd*|UJ»q P|)tuJO)duiAs u| aBueqo %uoisnpad lejqajao 0|OL|m u| •Bueip %
Fig
ur
e 
5.2
: 
SP
EC
T 
co
m
pa
ris
on
 
of 
pe
rc
en
tag
e 
ch
an
ge
 
in 
ce
re
br
al 
pe
rfu
sio
n 
(56
 
day
 
sc
an
 
- 
ba
se
lin
e 
sc
an
) 
in 
pr
av
as
ta
tin
 
tre
ate
d 
and
 
pla
ce
bo
 
gr
ou
ps
. 
Co
mp
ar
iso
n 
is 
ma
de
 
be
tw
ee
n 
the
 
two
 
gro
up
s 
usi
ng
 
fou
r 
dif
fer
en
t 
me
as
ure
s 
of 
ce
re
br
al 
pe
rfu
sio
n,
 
na
me
ly 
wh
ole
 
bra
in 
pe
rfu
sio
n, 
wh
ole
 
co
rtic
al 
pe
rfu
sio
n, 
sy
mp
tom
ati
c 
he
mi
sp
he
ric
 
pe
rfu
sio
n 
and
 
sy
mp
tom
ati
c 
co
rte
x 
pe
rfu
sio
n. 
Th
e 
me
an
 
va
lue
 
for
 e
ac
h 
gro
up
 
is 
rep
res
en
ted
 
by 
a 
ba
r, 
and
 
the
 
sta
nd
ard
 
de
via
tio
n 
of 
ea
ch 
me
an
 
va
lue
 
is 
illu
str
ate
d 
by 
br
ac
ke
ts.
da
y 
3 
da
y 
28 
da
y 
56
o U)
(U CtJ O >
JS 2
CL CL
■} t
oo o00 oCD On- oCN o o oCOoCN
Moy. Ajajje pyojeo uoljuluoo 
uj 0 Uj|0SBq 11104 sBueip 06eju0OJ0d ue©|/\|
Fig
ure
 
5.3
: 
Co
mm
on
 
ca
ro
tid
 
art
ery
 
flow
 
in 
pr
av
as
ta
tin
 
and
 
pla
ce
bo
 
gr
ou
ps
. 
Fo
r 
ea
ch
 
fol
low
-up
 
tim
ep
oin
t 
ch
an
ge
 
from
 
th
e 
ba
se
lin
e 
flow
 
va
lue
 
wa
s 
ca
lcu
lat
ed
 
for
 e
ach
 
ind
ivi
du
al 
and
 
ex
pre
ss
ed
 
as 
a 
pe
rce
nta
ge
 
of 
tha
t 
va
lue
. 
Th
e 
me
an
 
pe
rce
nta
ge
 
ch
an
ge
 
for
 th
e 
pla
ce
bo
 
and
 
pra
va
sta
tin
 
gro
up
s 
at 
ea
ch
 
tim
ep
oin
t 
is 
rep
res
en
ted
 
by 
the
 
po
int
 v
alu
e 
sh
ow
n. 
Th
e 
sta
nd
ard
 
err
or 
is 
sh
ow
n 
by 
th
e 
bo
x, 
and
 
the
 
sta
nd
ard
 
de
via
tio
n 
by 
br
ac
ke
ts.
da
y 
3 
da
y 
28 
da
y 
56
O ' 
_ Q  { / )
0  CO O >ro 2
Q. Q.
f1 t
O o o o00ooooCM
mo|j. Aj©^jb pi;ojbo |BUJ9;uj 
uj au!|0SBq luojj. 06uBqo 06Bju0OJ0d UB0|/\|
Fig
ure
 
5.4
: 
In
te
rn
al 
ca
ro
tid
 
art
ery
 
flow
 
in 
pr
av
as
ta
tin
 
and
 
pla
ce
bo
 
gr
ou
ps
. 
Fo
r 
ea
ch
 f
oli
ow
-up
 
tim
ep
oin
t 
ch
an
ge
 f
rom
 
th
e 
ba
se
lin
e 
flow
 
va
lue
 
wa
s 
ca
lcu
lat
ed
 
for
 e
ac
h 
ind
ivi
du
al 
and
 
ex
pre
ss
ed
 
as 
a 
pe
rce
nta
ge
 
of 
tha
t v
alu
e. 
Th
e 
me
an
 
pe
rce
nta
ge
 
ch
an
ge
 
for
 th
e 
pla
ce
bo
 
and
 
pra
va
sta
tin
 
gro
up
s 
at 
ea
ch
 t
im
ep
oin
t 
is 
rep
res
en
ted
 
by 
the
 
po
int
 v
alu
e 
sh
ow
n. 
Th
e 
sta
nd
ard
 
err
or 
is 
sh
ow
n 
by 
th
e 
bo
x, 
and
 
the
 
sta
nd
ard
 
de
via
tio
n 
by 
br
ac
ke
ts.
da
y 
3 
da
y 
28 
da
y 
56
oo
n
_q  ( /)  (D TO O > ro 2 
o. o.
o ooiCD 00 "TCN
(6hujlu) ajnssajd iblibjjb uB0iu uj 0ui|0seq iuojj 06ubip ub0[/\|
Fig
ur
e 
5.5
: 
Me
an
 
ar
te
ria
l 
blo
od
 
pr
es
su
re
 
in 
the
 
pr
av
as
tat
in 
and
 
pla
ce
bo
 
gr
ou
ps
. A 
ch
an
ge
 
fro
m 
th
eir
 b
as
eli
ne
 
re
ad
in
g 
w
as
 
ca
lc
ul
at
ed
 
for
 e
ac
h 
in
di
vi
du
al
 a
t 
ea
ch
 
tim
ep
oi
nt
. 
Th
e 
m
ea
n 
ch
an
ge
 
for
 p
lac
eb
o 
an
d 
pr
av
as
ta
tin
 
tre
at
ed
 
pa
tie
nt
s 
at 
ea
ch
 
tim
ep
oi
nt
 i
s 
re
pr
es
en
te
d 
by 
the
 
po
in
t 
va
lue
 
sh
ow
n.
 T
he
 
st
an
da
rd
 
er
ro
r 
is 
sh
ow
n 
by 
the
 
bo
x,
 a
nd
 
the
 
st
an
da
rd
 
de
vi
at
io
n 
by 
br
ac
ke
ts
.
pl
ac
eb
o 
pr
av
as
ta
tin
 
pl
ac
eb
o 
pr
av
as
ta
tin
© • © ® ©
H □ I
O  q  UJ m 
c £ c £ c
s i  s i  i
H □ f
©CN CO© © CN po o
c
&s©
a .
© oCN o o oCN o oo
(1/6) udOoupqy u| 9 0 ueqo (Ip/nj) HAJopej ui 8 6 ubm o
Q  n  UJ u j
c £ c £ c 
© © © © © s 2  2  s  s
H □ t
O  Q  LU i n
c £ c £ c 
o « • « ©s s  s s  s
H □ #
COo s § COoCN 3
cits©>
eQ.
Ss©
a.
COo CNo g CNoo o
(D9 S e^uj) AjjsoosiA eujseid u; a6ueqo luooiew eeq uj aBueijO
Fig
ure
 
5.6
: 
Ch
an
ge
 
in 
pla
sm
a 
vis
co
sit
y,
 f
ib
rin
og
en
, 
ha
em
at
oc
rit
 a
nd 
fa
cto
r 
VI
I. 
Th
e 
dif
fer
en
ce
 
be
tw
ee
n 
the
 
va
lue
 
at 
day
 
56 
an
d
ba
se
lin
e 
(da
y 
56 
- d
ay 
0) 
wa
s 
ca
lcu
lat
ed
 
for
 e
ac
h 
ran
do
mi
se
d 
ind
ivi
du
al.
 T
he 
me
an
, 
sta
nd
ard
 
err
or 
and
 
sta
nd
ard
 
de
via
tio
n 
for
 t
he
se
 
dif
fer
en
ce
s 
are
 
sh
ow
n 
for
 th
e 
pla
ce
bo
 
and
 
pra
va
sta
tin
 g
ro
up
s. 
A 
line
 j
oin
s 
the
 
me
an
 v
alu
es
 f
or 
the
 
pla
ce
bo
 
and
 
pra
va
sta
tin
 
gr
ou
ps
.
pl
ac
eb
o 
pr
av
as
ta
tin
 
pl
ac
eb
o 
pr
av
as
ta
tin
go gut
H □ t
Si
© • « © •
H □ «
C
COT*
CO>
eQ.
83
o
CD
o o oo
( | iu /6 u )  jo j e A i p e  u a O o u f iu s e id  a n s s n  ui e S u e i jo ( lp /n i )  j o p e ;  p u e jq d i i t M  u o a  u | e O u e q o
O q  LU m
c £ c £ c 
© © © © ©
O Q UJ in 
c £ c £ c
ooa © oCM Oo
c1to©§a
5
S©
a.
ss ss o soo
( l / 0 w )  u p j o j d  8 A j)o e 9 j  Q  u i 8 0 u e i j o ( | iu /0 u )  J8ui;p p  ui 8 0 u e i j o
Fig
ure
 
5.7
: 
Ch
an
ge
 
in 
C-
re
ac
tiv
e 
pr
ot
ein
, 
tis
su
e 
pla
sm
ino
ge
n 
ac
tiv
at
or
, 
d 
dim
er
 a
nd 
vo
n-
W
ille
br
an
d 
fa
ct
or
. 
Th
e 
dif
fe
re
nc
e 
be
tw
ee
n 
the
 
va
lue
 
at 
day
 
56 
and
 
ba
se
lin
e 
(da
y 
56 
- d
ay 
0) 
wa
s 
ca
lcu
lat
ed
 
for
 e
ac
h 
ran
do
mi
se
d 
ind
ivi
du
al.
 T
he 
me
an
, s
tan
da
rd 
er
ro
r 
and
 
sta
nd
ard
 
de
via
tio
n 
for
 t
he
se
 
dif
fer
en
ce
s 
are
 
sh
ow
n 
for
 th
e 
pla
ce
bo
 
and
 
pra
va
sta
tin
 
gr
ou
ps
. A 
line
 
joi
ns
 
the
 
me
an
 
va
lue
s 
for
 t
he
 
pla
ce
bo
 
and
 
pra
va
sta
tin
 
gr
ou
ps
.
187
Chapter 6: The effect of anti-chlamydial antibiotics 
on fibrinogen levels after stroke: the Fibrinogen And 
Chlamydia Experiment (FACET)
188
6.1 Introduction
Numerous observational studies have suggested a link between chronic 
infection and vascular disease. Amongst the putative chronic or acute 
infections that have been studied, chlamydia pneumoniae infection has 
been closely correlated with both coronary heart disease and 
cerebrovascular disease 143 146. Treatment trials with anti-chlamydial 
antibiotics, namely macrolides, have been performed in patients with 
unstable angina and non-Q wave myocardial infarction, and have yielded 
mixed results 152 154 266. No treatment trial in the stroke population has yet 
been published.
Fibrinogen is a well established risk factor for vascular disease in general, 
and more specifically for cerebrovascular disease 117118. It also appears to 
be associated with chlamydial infection in observational studies 149 150 151. 
Reduction in fibrinogen is a pharmacological goal that may be achieved with 
ancrod in the acute phase 121 or fibrates in the longer term, but whether 
fibrinogen can be reduced in a cerebrovascular population by treating 
chlamydial infection is not known. It is also unknown whether treatment of 
stroke patients with macrolide antibiotics will reduce their risk of further 
cardiac and cerebral events or death.
Large scale intervention studies are needed in this area. The study reported 
here represents the pilot phase of a project designed to establish whether 
anti-chlamydial macrolide antibiotics represent a mechanism by which 
fibrinogen can be reduced in the post-stroke phase. A further aim was to 
examine whether this might occur just in those patients seropositive for 
chlamydia or whether macrolides may exert their effects via a more 
generalised anti-inflammatory response, irrespective of chlamydia status.
6.2 Methods
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Study Design and objectives
The study was designed as a randomised, double-blind, placebo-controlled 
trial of azithromycin versus placebo in patients with acute ischaemic stroke, 
and was approved by our local ethics committee. The hypothesis was that the 
difference between baseline acute fibrinogen levels and fibrinogen levels at 1 
and 3 months after stroke would be greater in those treated with macrolide 
antibiotics than in those who received placebo. We wished to assess whether 
such a difference was present only in the group seropositive for chlamydia, 
and whether amongst those patients who received azithromycin larger falls in 
fibrinogen would be seen in seropositive than in seronegative patients, thus 
suggesting a link between chlamydial seropositivity and 
hyperfibrinogenaemia. The effect of azithromycin on other markers of blood 
rheology and inflammation was also examined, to provide exploratory data 
and to generate further hypotheses. Due to a lack of suitable data on the 
variability of differences between fibrinogen levels acutely and at 1 month a 
pilot phase of 30 patients was planned, which is reported in this thesis. 
Sample size calculations using this dataset were conducted in order to plan a 
definitive study. Ethical approval was obtained from the West Ethics 
Committee, and patients gave written informed consent to participate.
Patient qualification, enrolment, randomisation and dosing
The following inclusion and exclusion criteria applied to the study:
Inclusion criteria
• Over 40 years of age
• 4 days to 4 weeks post stroke or TIA
• Written informed consent of patient
• Haemorrhage excluded on CT or MRI scanning
Exclusion criteria
• Chronic Bronchitis
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• Recent (previous month) or current prescription of macrolide antibiotics, or 
prescription of alternative broad spectrum antibiotics during course of trial
• Documented bacterial infection
• Swallowing difficulty, or anticipated high risk of aspiration pneumonia
• QT prolongation on ECG, or concomitant antihistamine preparation
• Prescription of warfarin or heparin before enrolment
• Hepatic impairment
• Pregnancy or breast feeding
Co-prescription of other agents known to interact with macrolides (for 
example digoxin) was monitored, but did not exclude the patient from the 
study.
After explanation of the procedures and gaining of informed consent, 
eligible patients underwent baseline investigations, consisting of fibrinogen 
level, plasma viscosity (PV), von-Willebrand factor (vWF) and C-reactive 
protein (CRP), as well as anti-chlamydial immunoglobulins (IgG and IgA). 
These investigations were carried out in the haemorrheology laboratories of 
Glasgow Royal Infirmary and the West of Scotland Regional Virus 
Laboratory respectively. The qualifying event was classified using 
Oxfordshire Community Stroke Project (OCSP) definitions 171, and stroke 
severity was classified using the National Institutes of Health (NIH) stroke 
scale (see appendix 3).
Once baseline investigations were completed all patients, irrespective of 
chlamydia status which was at that point unknown, were randomised to 
receive either azithromycin capsules 500mg per day for 6 days or matching 
placebo, in a ratio of 1:1. The dosage chosen is double the standard 
azithromycin dose quoted in the British National Formulary, and at the time 
the trial was designed these smaller dosages of 500mg for 3 days had been 
demonstrated to have an effect on event rate in patients with ischaemic
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heart disease 152. Randomisation was conducted by an unblinded 
independent research pharmacist who was uninvolved in clinical 
management except for the provision of blinded drug supplies. 
Randomisation took place between November 1999 and September 2000.
Study flow
The drug course was for 6 days, and fibrinogen levels were measured at the 
end of the course of tablets, along with PV, vWf and CRP. NIH score was 
reassessed. Standard post-stroke management was employed, either in the 
acute stroke unit or the rehabilitation setting. Concurrent antibiotic therapy 
led to withdrawal from the study, and the decision to initiate antibiotic 
therapy outwith the study was that of the clinical team.
Patients returned in 1 month for repeat measurements of chlamydial serology 
and fibrinogen, PV, vWf, and CRP. Fibrinogen, PV, vWf and CRP were 
repeated at 3 months to confirm that any detected effect persisted. NIH score 
was assessed at each visit. An overview of the study design is provided in 
figure 6.1.
Laboratory testing
Anti-chlamydia immunoglobulins were measured using enzyme linked 
immunosorbent assay (ELISA). The use by previous investigators of 
microimmunofluorescence (MIF) and complement fixation (CFT) tests in their 
assessment of 'chlamydia seropositivity' has been criticised, with the 'cut-offs' 
denoting seropositivity and seronegativity varying widely 143. Defining 
boundaries that provide adequate sensitivity and specificity has proven 
problematic 267. After comparing assays using 4 tests (MIF, ELISA IgG, ELISA 
IgA and CFT) on 188 local cases (with proven respiratory infection) and 88 
healthy controls, the West of Scotland Regional Virus Laboratory concluded 
that switching to an ELISA based diagnostic series with higher cut-offs than 
those recommended by the manufacturers provided adequate diagnostic
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accuracy without unacceptable false positive results (personal 
communication, Dr W Carman). Consequently, both IgG and IgA levels were 
measured in the trial. Seropositive patients were defined as having probable 
(IgG index >1) or definite (IgG index >2) previous infection, or evidence of 
infection in the recent past (IgA index > 2.5).
Samples were stored at -70 degrees Celsius at the Western Infirmary, and 
transferred at the end of the study to the haemorrheology laboratories at the 
Glasgow Royal Infirmary for analysis. Clottable fibrinogen was measured by 
the dilute thrombin clotting time on an automated coagulometer (MDA 180, 
Organon Teknika, Cambridge UK), using calibrants and reagents provided by 
the manufacturer. CRP was measured on a Prospec Nephelometer (Dade 
Behring, Marburg, Germany) using a high sensitivity method with the 
manufacturer’s calibrant and reagent. PV was measured using a semi­
automated capillary Viscometer (Beckman Coulter, High Wycombe, UK). 
Plasma vWF antigen levels were measured using an in-house ELISA, 
employing rabbit anti-human polyclonal antibodies obtained from DAKO pic, 
High Wycombe, UK.
Statistical considerations and justification for sample size
The pilot phase (the initial 30 fully evaluable patients) is reported here, with 
the intention being to estimate the variability in fibrinogen in our population 
and likely treatment effect of azithromycin. We expect these data to inform 
both the sizing and the design of a definitive project.
Descriptive statistics and significance calculations were prepared using 
Statistica for Windows (Version 5.1, StatSoft Inc.). Values of Theological 
variables at each timepoint, and calculated differences within individuals 
between values at different timepoints, were normally distributed. After 
calculation of individual differences the data were tested for the effect of 
seropositivity, the effect of treatment, or for an interaction between these
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factors, using two-way factorial analysis of variance (ANOVA). These effects 
were quantified and confidence limits for the effects were generated using 
Minitab for windows (Version 10.1). Sample size calculations were conducted 
with PS sample size calculation software (Version 1.0.13, Dupont and 
Plummer), using variability data detected within the pilot trial sample.
6.3 Results
A total of 34 patients was randomised. Three patients withdrew from the study 
before day 6 (patient numbers 4, 19 and 29). One patient died between day 6 
and day 30 (patient number 14). Thus 30 patients were available for primary 
end point analysis, with 16 randomised to azithromycin and 14 to matching 
placebo. No patient received heparin during the acute stroke phase, nor 
alternative broad spectrum antibiotics during the course of the trial. Two 
patients were started on warfarin during the course of the study (patient 
number 7 and patient number 22, both for deep venous thrombosis). One 
patient was randomised while taking warfarin (patient number 33 who was 
taking warfarin for atrial fibrillation), which represented a protocol violation. 
These three patients were included in the final analysis because the 
prescription of warfarin does not appear to affect fibrinogen levels 268 269.
Table 6.1 shows the characteristics of the 34 randomised patients. Patients 
completing the trial and whose results are reported subsequently are in bold 
type in the table. Mean age was 67 (+/- standard deviation (SD) 14). Mean 
NIH score for all patients at entry was 2.6 (+/- SD 3.09); mean NIH score for 
evaluated patients was 2.0 (+/- SD 2.0). Amongst evaluated patients there 
was no significant difference in NIH score between azithromycin and placebo 
treated groups (p=0.78), or between seropositive and seronegative groups 
(p=0.94). Twelve evaluated patients suffered lacunar events, 3 posterior 
circulation events and 15 cortical anterior circulation events. Three patients 
had further stroke events during follow-up: patients 5 (seronegative-placebo)
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and 33 (seropositive-placebo) had a TIA between day 6 and 30 and patient 9 
(seropositive azithromycin) suffered a repeat cortical stroke between day 30 
and day 90 causing an increase in NIH score to 11 at day 90.
Figure 6.2 shows the mean and spread of values for the total patient group 
for each haemorheological variable at each timepoint. It can be seen from the 
figures that both CRP and fibrinogen tended to rise at day 6 and fall 
subsequently, consistent with an acute phase reaction 270. Table 6.2 and 
table 6.3 detail the mean levels of haemorrheological parameters at each 
timepoint for each subgroup, categorising the patients according to treatment 
(azithromycin or placebo) and chlamydia status.
To eliminate the effect of inter-subject variability, the difference between 
fibrinogen at day 1 and day 90 (day 1-day 90, since it was anticipated that 
fibrinogen would fall after the acute stroke event), and between fibrinogen at 
day 1 and day 30 (day 1 - day 30), was calculated for each patient. This 
represented a summary measure of the change in fibrinogen over time in 
each individual. Comparison was then made between the seropositive and 
seronegative groups and between the azithromycin treated and placebo 
groups. The interaction between these factors was also assessed. Analogous 
calculations were conducted for CRP, PV and vWf. The effects of the 3 
different factors (treatment, seropositivity and the interaction between them) 
were quantified and are presented in table 6.4. Neither azithromycin therapy 
nor chlamydia status had any effect on fibrinogen, CRP, PV or vWf change 
over time. No differential effect of treatment was detected in the seropositive 
group on any of the parameters tested.
Sample size calculations were planned using variability (standard deviation) 
data on the differences within individuals between fibrinogen levels at day 1 
and day 30. With a ratio of experimental to control subjects of 1 (comparing 
azithromycin to control), and a type 1 error probability of 0.05 for a 2 sided
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test, a planned study would have 90% power to detect a difference of 0.2g/l 
between treated and control groups with an experimental sample size of 202 
patients. The spread of values for alternative detectable mean differences, 
and varying levels of power, are depicted in figure 6.3. Two-thirds of the 
patients we included were seropositive; to compare treatment and control 
only in these patients, we would need to screen approximately 300 patients. 
To assess whether falls in fibrinogen are higher in treated seropositives than 
in treated seronegatives, the ratio of control to experimental patients falls to 
0.5, and 304 unselected patients would need to be assigned azithromycin 
treatment to detect a difference of 0.2g/l at 90% power.
6.4 Discussion
The data from this pilot phase have allowed us to size the next stage of the 
project, and have excluded effects of macrolide antibiotics on fibrinogen 
levels in unselected patients after ischaemic stroke of more than 0.36g/l (the 
upper end of the confidence interval for the difference between treated and 
placebo - see table 6.4). Data from epidemiological studies suggest that 
clinically important differences in event rate may be seen between groups 
whose fibrinogen differs by as little as 0.2g/l 117 118, and the adjusted 
difference between seropositive and seronegative patients in the largest 
epidemiological series in which the association between fibrinogen and 
chlamydia status has been described was 0.18g/l (95% C.l.= 0.015 to 0.345) 
15°. For this reason a larger study of the size stated above is required to 
evaluate the primary and secondary hypotheses formulated at the planning 
stage.
Trials in the coronary population have used 'hard' endpoints rather than 
surrogate markers, and treatment trials like these will be needed to assess 
whether antichlamydial antibiotics have any practical role in cerebrovascular 
disease. Longer courses of azithromycin (between 3 and 12 months of
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therapy) have been incorporated into the design of recent trials 271. Alteration 
of the FACET trial protocol to include a longer course of therapy is likely to 
maximise any effect on chronic chlamydial infection and its sequelae. There 
is, as yet, little evidence that lowering fibrinogen reduces rates of vascular 
events. Investigations into treatment effects on surrogate markers such as 
fibrinogen can, however, be useful in confirming hypotheses without the 
considerable expense and planning required for a large scale project. No 
effects on the other haemorrheological parameters tested were detected; 
trends or effects on these parameters may become more evident when larger 
patient numbers are recruited.
As alluded to previously, what constitutes 'seropositivity' is disputed and 
uncertain. Previous studies in the cerebrovascular population have generally 
used MIF techniques, although their 'cut-off levels for seropositive titres have 
varied considerably. When strict or complex criteria involving repeated 
sampling are used, as in the study by Cook et a l146, detected levels of 'acute' 
(13.6%) and 'previous' (32.4%) infection are low. In other published case 
control studies IgA levels > 1:16 have been reported to be present in 46.1% 
272f 46.6% 145 and 45% 148 of ischaemic stroke patients. 'Seropositive' IgG 
levels have been reported in much higher proportions of ischaemic stroke 
patients with the MIF technique (80.9% 272 and 86% 148 > 1:16, 74.1% 145 and 
79% 148 > 1:32). In this study, two-thirds of ischaemic stroke patients were 
classified as seropositive, 43% having IgA index >2.5, and 50% having an 
IgG index >1. Such findings were expected, and reflect the improved 
specificity of the ELISA tests and modified cut-off points employed.
Patients included in this study generally had mild strokes (mean NIH score = 
2.6), a reflection in part of the environment in which the study was conducted. 
The Western Infirmary Acute Stroke Unit is a very active research facility, with 
a number of acute and secondary prevention studies running concurrently. 
Patients with more severe strokes will often have been included in one of the
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acute studies, precluding their involvement in FACET. Patients with 
swallowing difficulties were not included as a result of concerns about 
aspiration risk and likely need for broad spectrum antibiotics. Explaining trial 
plans, and making arrangements to review patients at follow-up visits, 
requires a level of understanding and mobility which renders severely 
affected patients difficult subjects in trials that include repeated assessments. 
This is undoubtedly a difficult issue in stroke research, but trials should be 
conducted in a representative population, to widen the applicability of any 
results, and to broaden the possibilities of subgroup analysis. Attempts will be 
made to recruit a more varied cohort when the definitive project begins.
Elevation of fibrinogen and CRP levels in acute stroke has been amply 
documented, and large prospective studies have demonstrated that each is 
an independent risk factor for both stroke and other vascular events in the 
longer term 120 139. It seems that the 'acute phase response' is superimposed 
upon what appears to be a chronic elevation of fibrinogen and CRP levels in 
patients with cerebrovascular disease. Antibiotic use and recent clinical 
infection preceding ischaemic stroke have correlated strongly with levels of 
CRP but not fibrinogen in observational studies 273 274, and so differential 
effects on CRP and fibrinogen may be useful in separating a 'generalised' 
anti-inflammatory effect from a specific 'anti-chlamydial effect'. The planned 
study randomising 202 patients would be able to detect a difference between 
groups of 7.3mg/l in difference in CRP level between day 1 and day 90 with 
90% power. In a longitudinal analysis of acute phase markers after acute 
ischaemic stroke, Beamer et al found that while CRP, interleukin-6 and 
interleukin-1 receptor antagonist levels returned to those of a 'vascular risk' 
group without a history of recent stroke, fibrinogen levels remained elevated, 
even after a follow-up period of a year (p<0.001) 273. Fibrinogen levels 
predicted new vascular events in this cohort. Other workers have reported 
similar findings 275.
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Multiple stimuli may be responsible for upregulating fibrinogen synthesis: 
smoking, body mass index and serum lipid levels over longer periods, and 
tissue injury and necrosis in the acute phase of vascular events. Chlamydial 
infection may play a role both in the peri-stroke period, contributing to the 
'acute phase response', and in the longer term, as suggested by 
epidemiological data 149. In this trial baseline fibrinogen was assessed at a 
time when the acute phase response may have been an important 
determinant of its level: a mean of 3 days with a maximum of 6 days and a 
minimum of 1 day. If fibrinogen had been measured earlier (<12 hours after 
the acute event) it is less likely that an acute phase reaction, with infarction 
itself being a confounding factor, would interfere with the results. There was, 
however, no significant difference between treatment and placebo groups in 
the time from the stroke event that the baseline samples were taken or in 
stroke severity (as measured by NIH scores), which is an important 
determinant of the level of the acute phase response 276.
Peri-stroke infection (chlamydial or other) may be an important factor in the 
acute rise in fibrinogen levels which occurs, and may be modifiable by 
antibiotic therapy. This in turn may affect the fibrinogen level which is attained 
in the year post-stroke, and which is clearly associated with recurrent 
vascular events 273. The use of day 6 fibrinogen levels (which showed a trend 
upwards from baseline as a result of acute phase response), or of 'area under 
the curve' of fibrinogen levels plotted against time, in outcome summary 
measures would assess such an acute effect more closely, but these are less 
clinically relevant than the outcome measure chosen. The aim was to 
determine whether fibrinogen could be lowered in the recovery phase, with 
the assumption that this would carry a reduced risk of recurrent vascular 
events, not to assess any effect on the acute rise in fibrinogen itself. Acute 
rises in fibrinogen are much more effectively treated with defibrinogenating 
agents such as ancrod 121. It is important that the planned trial continues to 
assess fibrinogen at 90 days, to ensure that any detected effect persists.
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Recent prospective data have raised questions about the association 
between chlamydial infection and CHD. In comparison with retrospective 
studies, prospective studies should reduce selection biases, minimise any 
influence of disease itself on the factor being investigated, and generally 
include better adjustment for potential confounding factors. However, 
adjustment for potential confounding factors, when we know little of the 
mechanism by which such factors may affect the disease under study, may 
lead to 'over-adjustment', thus diluting any true effect. Danesh et al reported a 
large epidemiological survey of 5661 men who provided blood samples 
during 1978-80 271. 40% of the 496 men with CHD were in the top third of C 
pneumoniae titres compared with 33% of the 989 controls. The corresponding 
odds ratio for CHD was 1.66 (95% Cl = 1.25 to 2.21). This remained highly 
significant when adjusted for age, town, smoking and social class, but 
reduced to 1.22 (95% Cl = 0.82 to 1.82) after adjustment for childhood social 
class. There is poor understanding of the mechanism by which childhood 
social class influences adult CHD, but chlamydial infection may play a part, 
therefore possibly rendering such adjustment 'over-adjustment'277.
It was the fully adjusted estimate that was included in Danesh et al's 
accompanying meta-analysis of the 15 published prospective studies of C. 
Pneumoniae and CHD, which yielded a combined odds ratio of 1.15 (95% Cl 
= 0.97 to 1.36). They concluded that the meta-analysis reliably excluded any 
strong association between C pneumoniae IgG titres (or IgA titres) and CHD, 
and that planned randomised trials were unlikely to be large enough to 
confirm or refute the small effect on coronary risk that antibiotics such as 
azithromycin may confer. In a study that minimised the possible detrimental 
effects of over-adjustment, Wald et al 278 reported no association between 
infection with C. pneumoniae and mortality from IHD in a socially 
homogeneous population of middle aged professional men.
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Thus recent data in the cardiovascular population have raised questions 
about whether an association between chlamydia seropositivity and vascular 
disease exists at all, and have strongly suggested that if an association is 
present, it is likely to be only small to moderate. Recent data in the 
cerebrovascular population, however, have continued to find moderate 
associations between chlamydial seropositivity and stroke. Elkind et al 272 
recently reported case-control data from the Northern Manhattan Stroke 
Study that correlates well with previous case control literature 145 146. Elevated 
C. pneumoniae IgA titres were significantly associated with risk of ischaemic 
stroke after adjusting for other stroke risk factors (adjusted OR 4.51, 95% Cl 
1.44 to 14.06). IgG titres were not significantly associated with stroke risk 
(adjusted OR 2.59, 95% Cl 0.87 to 7.75), suggesting that it is persistent 
infection, rather than remote, completed infection which confers risk. Schmidt 
et al 279 demonstrated that seropositivity for C, pneumoniae is associated with 
an increased intima-media thickness (an early sign of atherosclerosis) in the 
common carotid artery in hypertensive men at high risk for cardiovascular 
disease.
Recently it has been stated in the stroke literature that the best means of 
ascertaining a link between C. pneumoniae infection and vascular disease, in 
the context of data suggesting association but not establishing causation, is 
by conducting interventional trials aiming to look at the effect of antibiotics 
that eradicate C. pneumoniae 28°. The study presented here is the first of 
these to report pilot data.
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Difference in Effect of Effect of Effect of treatment
rheological marker seropositivity azithromycin in seropositives
Mean seropositive - (mean treated - (mean treated
mean seronegative mean placebo) seropositive - mean
(p-value for (p-value for other groups)
comparison) comparison) (p-value for 
comparison)
Day 1 fibrinogen - 0.06 (-0.22 to 0.34) -0.02 (-0.30 to 0.27) 0.04 (-0.24 to 0.32)
day 90 fibrinogen
p=0.65 p=0.91 p=0.77(g/i)
Day 1 fibrinogen - 0.05 (-0.20 to 0.30) 0.11 (-0.14 to 0.36) 0.04 (-0.21 to 0.29)
day 30 fibrinogen
(g/i) p=0.67 p-0.37 p-0.74
Day 1 CRP - Day 90 -2.47 (-11.5 to 6.57) 0.01 (-9.03 to 9.05) 3.84 (-5.19 to 12.88)
CRP
(mg/l) p-0.59 p=1.0 p-OAO
Day 1 CRP - day 30 -3.32 (-10.81 to 4.17) 1.49 (-6.00 to 8.98) 1.36 (-6.13 to 8.85)
CRP
(mg/l) p=0.38 p=0.69 p=0.72
Day 1 PV - day 90 -0.0003 (-0.03 to -0.0008 (-0.03 to -0.0092 (-0.04 to
PV 0.03) 0.03) 0.02)
(mPa.sec) p=0.98 p=0.96 p=0.55
Day 1 PV - day 30 -0.01 (-0.03 to 0.02) 0.02 (-0.01 to 0.04) -0.02 (-0.04 to 0.01)
PV
(mPa.sec) p=0.50 p=0.15 p=0.16
Day 1 vWF - Day 90 -11.05 (-22.43 to -3.05 (-14.44 to 8.33) -0.68 (-12.07 to
vWf 0.34) 10.71)
(i.u./dl) p=0.06 p=0.60 p=0.91
Day 1 vWF - day 30 -6.99 (-18.20 to 4.23) 1.06 (-10.16 to 12.27) 0.21 (-11.00 to 11.43)
vWF
(i.u./dl) p-0.22 p=0.85 p=0.97
Table 6.4: The effect of seropositivity and azithromycin treatment on the 
differences between haemorrheological values within individuals between day 
1 and day 90 and between day 1 and day 30. CRP=C reactive protein, vWf=von 
Willebrand factor and PV=plasma viscosity. See text for statistical method. The 
differences that were calculated for each individual are tabulated on the far left. The 
mean difference between seropositive and seronegative patients for each variable 
('the effect of seropositivity') is shown in the first column. The mean difference 
between azithromycin treated and placebo patients for each variable ('the effect of 
treatment') is shown in the second column. The interaction between these factors is 
shown in the third column, which compares azithromycin treated seropositive 
patients to placebo treated and seronegative patients ('the effect of treatment in 
seropositives'). Each value is stated with its confidence limit, and a p-value for the 
comparison is given.
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Conclusions, discussion and future directions
211
The preceding chapters have detailed clinically based investigations 
addressing some of the controversies in ischaemic stroke. The work 
described contributes to a number of areas of expanding research interest. 
The setting, merits and problems with each investigation have been 
discussed in each chapter; further debate and consideration of research 
direction in the future is provided here.
Recent reports from the NASCET trial have improved the accuracy of data 
available to clinicians on the effect of endarterectomy, and the natural history 
of patients with carotid stenosis, but have not fully answered the question 
addressed in chapter 2. In an analysis of stroke patterns in patients with 
asymptomatic internal carotid artery stenosis, Inzitari et a l281 recommend that 
only patients with symptomatic carotid artery stenosis should undergo carotid 
endarterectomy, since 45% of strokes in patients with asymptomatic stenosis 
of 60-99% are attributable to lacunes or cardioembolism, and therefore have 
no relation to their carotid lesion.
This argument, however, seems incongruous with the same authors’ other 
recent publication 54, which was discussed in chapter 2. In those patients 
with lacunar stroke who entered NASCET, a trend to benefit was observed in 
the surgical group, and the authors recommended that such patients be 
considered for endarterectomy. Therefore lacunar stroke denotes a patient 
with sufficient risk of subsequent events to justify surgical correction, yet the 
same authors do not regard lacunar stroke as a relevant endpoint in 
endarterectomy trials. This is despite observations that higher degrees of 
stenosis were associated with a hazard ratio of 3.6 for lacunar stroke 281, and 
that five year risk of ipsilateral lacunar stroke was halved from 5.7% to 2.8% 
by surgery in NASCET 181.
We have shown that an association exists between lacunar stroke and carotid 
disease that confers a poor prognosis. In conjunction with the observations
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from NASCET above and individual patient data from the major randomised 
trials which confirmed the benefit of surgery in lacunar stroke patients with 
higher degrees of stenosis 55, these data suggest that patients with ipsilateral 
lacunar stroke should be considered for endarterectomy. They also indicate 
that it is prescriptive to disregard recurrent lacunar stroke from follow-up 
analysis.
Vascular localisation remains a concern with the analysis presented in 
chapter 2. Distinct subcortical infarct patterns are becoming increasingly 
recognised, and different associations described. A recent report described 
very eloquently the different degrees of stenosis found in the NASCET 
dataset between perforating artery infarction (PAI) and internal border zone 
infarction (IBI) 51. Sixty-three percent of the patients with IBI had severe (70- 
99%) stenosis compared with 42% of patients with PAI; 18% of the IBI 
patients had stenosis of 90% or more compared with 8% of the patients with 
PAI. Similar data support a 'large artery hypothesis' for centrum ovale 
infarction 52 and anterior choroidal territory infarction 179. Such detailed 
vascular localisation, requiring templates for the identification of vascular 
territories, was not conducted on the data presented in chapter 2. Coupled 
with blinded neuroradiological review it would strengthen the analysis 
presented. Furthermore, improved (and updated) record-linkage data, and 
re-analysis of the same database to include patients admitted after 1998, 
would improve the power of the study to detect a significant difference 
between those patients with ipsilateral and contralateral lacunar and carotid 
disease. Both such approaches have been discussed as means of improving 
information about this important clinical issue. It is unlikely that a randomised 
trial will answer directly whether patients with lacunar stroke and ipsilateral 
carotid stenosis should be offered endarterectomy. However, continued 
analysis of individual patient data from the randomised trials already 
conducted is likely to be able to improve our ability to predict whether an
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individual with a particular set of clinical characteristics will benefit from 
endarterectomy,
Chapter 3 summarises data reported over the course of 15 years that has 
examined association between patent foramen ovale (PFO) and atrial septal 
aneurysm (ASA) and stroke. It provides considerable clarity in a confusing 
area by collating and grouping similar studies together. Moreover, careful 
analysis of the data reported in chapter 3 suggests clear directions for future 
work. Firstly, association studies examining the frequency of PFO, ASA or 
both in stroke patients < 55 years are no longer necessary. Association 
between both lesions and ischaemic or cryptogenic stroke is proven and 
indisputable. Association is stronger for ASA than PFO, and is strongest 
when both abnormalities co-exist. Recurrence data have improved since the 
meta-analysis reported in chapter 3 was published 237 - Mas et al have 
reported a large prospective observational study which is discussed in 
chapters 3 and 4. This confirms the importance of the two lesions being 
present in conjunction - only combined lesions were significantly predictive of 
recurrent stroke. Further data on the clinico-radiologic characteristics of the 
patients included in this trial are in press. Useful data on natural history and 
how prognosis may be better defined with echocardiographic information will 
be provided by the full publication of the Patent foramen ovale in Cryptogenic 
Stroke Study (PICSS).
Chapter 3 also confirms that association is not proven in patients older than 
55 years. There are fewer studies that have examined the older age group, 
and they have reached heterogeneous conclusions. In older patients other 
stroke causes are more frequent, and so isolating any effect of PFO is more 
difficult. In the meta-analysis reported heterogeneity within total comparisons 
was eliminated by grouping into age bands, and negative trials were more 
likely to stem from the inclusion of older patients. These findings suggest that 
age exerts an effect on the relationship between interatrial septal
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abnormalities and stroke that is clinically relevant. The presence of PFO 
showed a strong inverse correlation with age in the largest pathological study 
in the literature 81. To address the important issue of whether association 
exists between PFO and stroke in older patients (> 55 years), appendix 1 
describes a planned age matched case control study in patients over 55 
years.
Neither further studies of association, nor improved data on natural history will 
answer the central management questions: 'aspirin or warfarin?1 'warfarin or 
lesion correction?' and 'surgical or percutaneous closure?'. Chapter 4 
examines current practice and opinion in a sample of British neurologists and 
stroke physicians. Generally, recurrent events led to warfarin prescription 
while large lesions or concurrent ASA led to consideration of lesion 
correction. However, considerable uncertainty and disagreement was evident, 
in both investigation and management strategies. Experts who regarded 
investigation for PFO as unnecessary were very clearly influenced both by the 
results of investigations and by clinical course in those with positive 
investigations. While 'consensus' can be reported from analysis of these 
responses (discussed in the conclusion to chapter 4), both the sample of 
respondents and the basis upon which their responses were made are open 
to bias. The analysis, however, does generate useful background data for the 
design of a pragmatic clinical trial.
A randomised trial in PFO-associated stroke is the only way in which the 
uncertainty evident in the survey of specialist opinion can be addressed. The 
current climate of uncertainty is in many ways a perfect backdrop for such an 
investigation. However, the low recurrence rate in patients with cryptogenic 
stroke and PFO presents difficulties in trial design. In neither PICSS nor the 
large prospective series from Mas et a l90 did the presence of isolated PFO 
have any effect on stroke recurrence. This suggests that aspirin alone is 
sufficient for patients with an isolated PFO and a single otherwise
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unexplained stroke. A benign natural history means that large randomised 
trials will be required to investigate any significant benefit of interventional 
techniques, or to study the relative merits of warfarin and aspirin. It militates 
against positive findings in the ongoing randomised investigations of closure 
versus anticoagulants. A trial concentrating on those with combined lesions 
(PFO + ASA) would need a smaller sample size because recurrence risk is 
higher, but these abnormalities are much rarer in clinical practice. Including 
patients with large isolated PFOs in such a 'high risk' trial is supported by 
observational data 213 227 216, but not by the prospective recurrence trial which 
found degree of shunt to be an insignificant factor in predicting recurrence 90. 
Adaptive randomisation techniques may enable both patients with small 
lesions and transient isolated symptoms, and patients with combined lesions 
and recurrent stroke, to be randomised to appropriate comparative therapies. 
Alternatively, use of the uncertainty principle may allow the disparate views of 
randomising physicians to be catered for, while still producing a varied study 
cohort.
Statins are becoming increasingly used in secondary stroke prevention, a 
trend likely to continue after full publication of the Heart Protection Study 
(HPS). The HPS study concurs with data from previous large statin trials in 
the cardiovascular population that have demonstrated benefit in patients with 
a wide range of initial cholesterol levels. The discrepancy between the 
cerebrovascular observational data, which have shown better outcome in 
individuals with high cholesterol 95 and only very weak relations between 
serum cholesterol and stroke risk 91, and the increasing proof of beneficial 
statin effects in intervention trials, is perhaps best explained by the effects of 
statins that are independent of their effect on plasma cholesterol. These 
effects on endothelium, rheology and vasomotor tone may be important both 
in secondary prevention and in the acute phase, and the small trial reported 
in chapter 5 is the first to specifically examine these effects in acute 
ischaemic stroke. The study had sufficient power to exclude a possible effect
216
of statins on subacute whole cerebral perfusion of more than 7ml/100g/min. 
Putative effects on arterial flow, blood pressure, haemorrheological and 
inflammatory markers were not detected, but the sample size was small and 
the analysis cannot exclude clinically significant effects on these markers. A 
number of markers (such as interleukin-6 and plasminogen activator inhibitor- 
1) were not examined. If large statin trials in stroke prevention confirm the 
effects seen in the stroke subgroup of the HPS trial, studies examining acute 
statin effects on clinical endpoints (early recurrence and outcome) will follow. 
In the interim, further investigations properly powered to detect minor to 
moderate effects on surrogate endpoints should be considered, both in acute 
stroke and in the more chronic cerebrovascular population, whose response 
to statins may be at least in part independent of effects on plasma 
cholesterol.
Chapter 6 reports the pilot phase of a project designed to examine macrolide 
antibiotic effects on fibrinogen levels in acute stroke. Variability data have 
allowed us to size the next stage of the project. Fibrinogen remains 
persistently raised after ischaemic stroke 273 and predicts new events 273 12°, 
and so it remains a reasonable surrogate marker to serve as a target for 
macrolides. Whether impact on fibrinogen levels will alter long term risk of 
clinical events is uncertain. A similarly designed trial randomising patients 6 
months or more after stroke would eliminate the 'acute phase response' 
element of fibrinogen elevation. The most recent studies in the CHD 
population are randomising patients to longer courses of antibiotics (up to 18 
months) but have continued to use microimmunofluorescence techniques to 
define seropositivity (generally a titre > 1:16)271. Most, like the study we plan, 
are randomising both seropositive and seronegative patients.
Recent epidemiological data have called into question the association of 
chlamydial infection and vascular disease 271. Observational trials examining 
the association of stroke with chlamydial infection are greatly outnumbered by
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those examining associations with CHD. Given the heterogeneity of stroke, 
and the fact that retrospective observational data pointed to a far stronger 
association in CHD than was eventually evident after meta-analysis of the 
prospective data 271, a properly planned large prospective study and 
systematic review of the evidence linking chlamydia and ischaemic stroke 
should be conducted before large scale intervention trials are planned. Any 
plans for definitive trials in the cerebrovascular population are also likely to be 
informed by the results of trials ongoing in the CHD population (summarised 
in Danesh et al 271), but these are only large enough to detect reductions in 
coronary events with antibiotic therapy of -25%. If effects are smaller than 
this, as seems likely from the strength of the epidemiological association, they 
may be missed by the current group of trials.
This thesis has explored a number of aspects of stroke secondary prevention 
that may become increasingly important in the future. Post-stroke 
management is likely to involve intensified control of traditional risk factors, 
such as hypertension. Research must concentrate on refining the indications 
for more established interventions and on establishing the importance of 
novel causes and risk factors. The work presented here contributes to that 
goal. Randomised trials will be required before therapies designed to combat 
'newer' causes and risk factors are routinely employed.
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Appendix 1: Is patent foramen ovale associated with 
stroke in patients over 55 years?
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The systematic review examining studies that have quantified the relationship 
between patent foramen ovale (PFO) and ischaemic stroke described in 
chapter 3 reported clear evidence of association in patients < 55 years 237. 
Randomised trials must define the best medical therapy for such patients, 
and the relative merits of medical therapy, surgical treatment and 
percutaneous closure techniques.
In patients > 55 years, association is not yet established 237. Other causes 
and stroke risk factors such as atrial fibrillation and hypertension are more 
likely to lead to stroke in older individuals, because they are more common. 
The largest study which compared the prevalence of PFO in stroke patients 
with that in controls contained 194 patients in the 'stroke' group, and 183 
patients in the 'control group' 195. Random effects meta-analysis combining 
this and the two other studies that have examined the same question 197 204 
yielded a combined odds ratio of 1.60 (95% Cl=0.63 to 4.06), thus excluding 
an odds ratio greater than 4.06 or less than 0.63 237. Trend to association was 
more evident in patients > 55 years when comparing cryptogenic stroke to 
known stroke cause. This resulted in an odds ratio of 2.26 (95% Cl=0.96 to 
5.31).
A prospective study in this older population is planned. Eligible patients will 
be aged 55 or greater, and have a history of ischaemic stroke (confirmed by 
CT scanning) or TIA within the preceding 2 months. Stroke type will be 
classified clinically using the Oxfordshire Community Stroke Project (OCSP) 
method 171, but final classification into atherosclerotic stroke, cardioembolic 
stroke, lacunar stroke, stroke of unusual but determined cause or cryptogenic 
stroke will be made using the criteria developed by the National Institute of 
Neurological Disorders and Stroke (NINDS) 282. Stroke classification will be 
made by a neurologist or physician blinded to the presence or absence of 
PFO (see below). Patients with all ischaemic stoke subtypes will be included 
in the study, but pre-defined subgroups will be analysed as stated below.
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After informed consent, PFO will be detected using transcranial Doppler 
(TCD). The main stem of the middle cerebral artery (MCA) will be insonated 
trans-temporally with a 2MHz transducer. Patients in whom MCA insonation 
fails will be withdrawn from the study. Patients will receive a 10ml bolus 
injection of agitated saline into a 16 guage venflon placed in an antecubital 
vein. Agitated saline will be prepared by mixing 8ml of saline with 2 ml of air, 
using 2 syringes mounted on a 3-way stopcock. PFO will be defined as the 
detection of 1 or more spike-like interruptions of the normal pulsatile arterial 
signal detected by the MCA transducer, 4 to 20 seconds after saline injection. 
Examinations will be performed at rest, with coughing and with Valsalva 
manouevre. Valsalva manouvre will be standardised by having the subjects 
blow into a manometer until 50 to 60 mmHg of pressure is reached and 
asking them to maintain this for a period of 5 to 7 seconds immediately prior 
to injection. Patients unable to perform the Valsalva manoeuvre will continue 
in the study.
PFO size will be semi-quantified by dividing patients with right-to-left shunt 
into those with a small (1-5 microbubbles), moderate (6 to 15 microbubbles) 
or large (16 or more microbubbles) degree of shunt detected on middle 
cerebral artery screening. The highest degree of shunt detected during the 3 
phases of the TCD test (rest, Valsalva and cough) will define PFO size. All 
examinations will be video-taped and classified by a second observer, blinded 
to patient details. The classification of this second observer will be used as 
the study data. Control patients will be recruited from the inpatient medical 
population at participating hospitals. They will have no history of 
cerebrovascular disease, nor of valvular heart disease. PFO presence has 
been shown to be highly dependant on age 81, and so cases and controls will 
be matched for age and sex.
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The primary endpoint of the study will be the relative frequency of PFO in 
stroke patients compared to control patients, Since the trial subjects will be 
matched for age and sex, McNemar's version of the chi-squared test with 
Yates's continuity correction will be used to test for association between PFO 
and stroke. Statistical significance will be set at the level of p<0.05. Odds 
ratios will be calculated with the Mantel-Haenstzel test. Other (secondary) 
comparisons will include PFO frequency in cryptogenic stroke patients 
compared to known stroke cause and in cryptogenic stroke patients 
compared to control subjects. To determine whether there is a trend towards 
larger degrees of right-to-left shunt in stroke patients (in comparison to 
controls) and cryptogenic stroke patients (in comparison to patients with 
known stroke cause), a chi-squared test for trend across the PFO size 
categories will be conducted.
The graph shown below details the results of calculations performed to 
determine the correct sample size for the study. The calculations were 
performed using PS power and sample size calculation software (1997).
850
680
1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0
Power = 0.9 
Power = 0.85 
Power = 0.8
Odds ratio
alpha=0.05 phi=0.2 p_0=0.15 m =1, Matched or paired, Case control 
design
Key: alpha: type 1 error probability for a two sided test
phi: correlation co-efficient for PFO presence between matched cases and controls 
p: prevalence of PFO amongst controls
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The table below gives the numbers of patients required in each group (stroke 
and control) to detect different odds ratios, with varying degrees of power, 
derived from the same calcalations that produced the graph above.
Odds
ratio
90%
power
85%
power
80%
power
1.6 821 703 616
1.698 637 546 479
1.81 499 428 375
1.908 415 356 313
2.006 353 303 267
2.51 191 165 146
3 129 112 99
In the absence of age matched case-control data from previous studies, the 
correlation co-efficient (phi) has been estimated at 0.2, as recommended in 
the methodological papers used to design the sample size software that was 
used 283. The prevalence of PFO (p) has been estimated at 15% in control 
subjects over 55 years. Prevalence rates in the studies included in the 
systematic review varied enormously, but for the studies that examined the 
comparison of PFO presence in stroke vs control patients over 55 years 195 
204 197, the control frequencies for PFO were 16%, 15% and 6%. A study 
containing 353 patients in each group would have 90% power to detect an 
odds ratio of 2 or more, should one exist. If such a study were to be included
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in the meta-analysis already reported, and found an odds ratio of 2 (the 
lowest odds ratio that it would be powered to detect), the resulting combined 
odds ratio from 4 studies would be 1.65 (95% C 1=1.22 to 2.23) by fixed 
effects, and 1.67 (0.92 to 3.04) by random effects. If the study were to detect 
a lower odds ratio, a value of 1.47 would still render the combined odds ratio 
of the four studies significant.
Funding is currently being sought for this study, and it is hoped that it will run 
in 3 centres in the Glasgow area, though will be dependant on the provision 
of equipment (for TCD) and staff training in MCA insonation that can be 
provided.
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Appendix 2: Definitions of meta-analytical terms 198199
Heterogeneity The magnitude of statistical diversity that exists between the 
results of different sets of data. The chi-squared test for heterogeneity 
assesses whether the differences between the effect estimated by each data 
set can be assumed to be a consequence of random sampling variation. If 
this test is not significant, outcomes in the individual studies are said to be 
homogeneous, in that they estimate a single underlying effect.
Fixed effects meta-analysis considers that the difference between the effect 
found in each study is exclusively due to random variation. Thus, if all the 
studies were infinitely large they would give identical results.
Random effects meta-analysis assumes a different underlying effect for 
each study and takes this into consideration as an additional source of 
variation.
Funnel plot A plot of effect estimate against sample size which is used to 
assess validity and to detect bias in meta-analyses. These are skewed and 
asymmetrical in the presence of publication and other bias.
Forest plot A figure comprising the estimate and 95% confidence interval 
for each trial, together with an overall estimate and confidence interval.
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Appendix 3: NIH Stroke Scale
Administer stroke scale items in the order listed. Record performance in each category after 
each subscale exam. Do not go back and change scores. Follow directions provided for each 
exam technique. Scores should reflect what the patient does, not what the clinician thinks the 
patient can do. The clinician should record answers while administering the exam and work 
quickly. Except where indicated, the patient should not be coached (i.e., repeated requests to 
patient to make a special effort).
IF ANY ITEM IS LEFT UNTESTED, A DETAILED EXPLANATION MUST BE CLEARLY 
WRITTEN ON THE FORM. ALL UNTESTED ITEMS WILL BE REVIEWED BY THE 
MEDICAL MONITOR, AND DISCUSSED WITH THE EXAMINER BY TELEPHONE.
Instructions Scale Definition Score
1a. Level of Consciousness: The investigator 
must choose a response, even if a full evaluation is 
prevented by such obstacles as an endotracheal 
tube, language barrier, orotracheal 
trauma/bandages. A 3 is scored only if the patient 
makes no movement (other than reflexive 
posturing) in response to noxious stimulation.
0 = Alert: keenly responsive.
1 = Not alert, but arousable by minor
stimulation to obey, answer, or 
respond.
2 = Not alert, requires repeated stimulation
to attend, or is obtunded and requires 
strong or painful stimulation to make 
movements (not stereotyped).
3 = Responds only with reflex motor or
autonomic effects or totally 
unresponsive, flaccid, areflexic.
-
1b. LOC Questions: The patient is asked the 
month and his/her age. The answer must be 
correct - there is no partial credit for being close. 
Aphasic and stuporous patients who do not 
comprehend the questions will score 2. Patients 
unable to speak because of endotracheal 
intubation, orotracheal trauma, severe dysarthria 
from any cause, language barrier or any other 
problem not secondary to aphasia are given a 1. It 
is important that only the initial answer be graded 
and that the examiner not "help" the patient with 
verbal or non-verbal cues.
0 = Answers both questions correctly.
1 = Answers one question correctly.
2 = Answers neither question correctly.
-
1c. LOC Commands: The patient is asked to 
open and close the eyes and then to grip and 
release the non-paretic hand. Substitute another 
one step command if the hands cannot be used. 
Credit is given if an unequivocal attempt is made 
but not completed due to weakness. If the patient 
does not respond to command, the task should be 
demonstrated to them (pantomime) and score the 
result (i.e., follows none, one or two commands). 
Patients with trauma, amputation, or other physical 
impediments should be given suitable one-step 
commands. Only the first attempt is scored.
0 = Performs both tasks correctly
1 = Performs one task correctly
2 = Performs neither task correctly
-
2. Best Gaze: Only horizontal eye movements will 
be tested. Voluntary or reflexive (oculocephalic) 
eye movements will be scored but caloric testing is 
not done. If the patient has a conjugate deviation of 
the eyes that can be overcome by voluntary or 
reflexive activity, the score will be 1. If a patient has 
an isolated peripheral nerve paresis (CN III, IV or 
VI) score a 1. Gaze is testable in all aphasic 
patients. Patients with ocular trauma, bandages, 
pre-existing blindness or other disorder of visual
0=  Normal
1 = Partial gaze palsy. This score is given
when gaze is abnormal in one or 
both eyes, but where forced 
deviation or total gaze paresis are 
not present.
2 = Forced deviation, or total gaze paresis not
overcome by the oculocephalic maneuver.
-
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acuity or fields should be tested with reflexive 
movements and a choice made by the investigator. 
Establishing eye contact and then moving about the 
patient from side to side will occasionally clarify the 
presence of a partial gaze palsy.
3. Visual: Visual fields (upper and lower 
quadrants) are tested by confrontation, using finger 
counting or visual threat as appropriate. Patient 
must be encouraged, but if they look at the side of 
the moving fingers appropriately, this can be scored 
as normal. If there is unilateral blindness or 
enucleation, visual fields in the remaining eye are 
scored. Score 1 only if a clear-cut asymmetry, 
including quadrantanopia is found. If patient is blind 
from any cause score 3. Double simultaneous 
stimulation is performed at this point. If there is 
extinction patient receives a 1 and the results are 
used to answer question 11.
0 = No visual loss
1 = Partial hemianopia
2 = Complete hemianopia
3 = Bilateral hemianopia (blind including
cortical blindness)
-
4. Facial Palsy: Ask, or use pantomime to 
encourage the patient to show teeth or raise 
eyebrows and close eyes. Score symmetry of 
grimace in response to noxious stimuli in the poorly 
responsive or non-comprehending patient. If facial 
trauma/bandages, orotracheal tube, tape or other 
physical barrier obscures the face, these should be 
removed to the extent possible.
0 = Normal symmetrical movement
1 = Minor paralysis (flattened nasolabial
fold, asymmetry on smiling)
2 = Partial paralysis (total or near total
paralysis of lower face)
3 = Complete paralysis of one or both sides
(absence of facial movement in the 
upper and lower face)
-
5 & 6. Motor Arm and Leg: The limb is placed in 
the appropriate position: extend the arms (palms 
down) 90 degrees (if sitting) or 45 degrees (if 
supine) and the leg 30 degrees (always tested 
supine). Drift is scored if the arm falls before 10 
seconds or the leg before 5 seconds. The aphasic 
patient is encouraged using urgency in the voice 
and pantomime but not noxious stimulation. Each 
limb is tested in turn, beginning with the non-paretic 
arm. Only in the case of amputation or joint fusion 
at the shoulder or hip may the score be "9" and the 
examiner must clearly write the explanation for 
scoring as a "9".
0 = No drift, limb holds 90 (or 45) degrees
for full 10 seconds.
1 = Drift, Limb holds 90 (or 45) degrees,
but drifts down before full 10 
seconds; does not hit bed or other 
support.
2 = Some effort against gravity, limb cannot
get to or maintain (if cued) 90 (or 45) 
degrees, drifts down to bed, but has 
some effort against gravity.
3 = No effort against gravity, limb falls.
4 = No movement
9 =  Amputation, joint fusion explain:
-
5a. Left Arm 
5b. Right Arm
0 = No drift, leg holds 30 degrees position
for full 5 seconds.
1 = Drift, leg fells by the end of the 5
second period but does not hit bed.
2 = Some effort against gravity; leg fells to
bed by 5 seconds, but has some 
effort against gravity.
3 = No effort against gravity, leg fells to bed
immediately.
4 = No movement
9 = Amputation, joint fusion 
exDlain:
6a. Left Leg
6b. Right Leg
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7. Limb Ataxia: This item is aimed at finding 
evidence of a unilateral cerebellar lesion. Test with 
eyes open. In case of visual defect, insure testing is 
done in intact visual field. The finger-nose-finger 
and heel-shin tests are performed on both sides, 
and ataxia is scored only if present out of proportion 
to weakness. Ataxia is absent in the patient who 
cannot understand or is paralyzed. Only in the case 
of amputation or joint fusion may the item be scored 
"9", and the examiner must clearly write the 
explanation for not scoring. In case of blindness 
test by touching nose from extended arm position.
0 = Absent
1 = Present in one limb
2 = Present in two limbs
If present, is ataxia in 
Right arm 1 = Yes 2 = No
9 = amputation or joint fusion, explain
-
Left arm 1 = Yes 2 = No
9 = amputation or joint fusion, explain
-
Right leg 1 = Yes 2 = No
9 = amputation or joint fusion, explain
-
Left leg 1 = Yes 2 = No
9 = amputation or joint fusion, explain
-
—
8. Sensory: Sensation or grimace to pin prick 
when tested, or withdrawal from noxious stimulus in 
the obtunded or aphasic patient. Only sensory loss 
attributed to stroke is scored as abnormal and the 
examiner should test as many body areas [arms 
(not hands), legs, trunk, face] as needed to 
accurately check for hemisensory loss. A score of 
2, "severe or total," should only be given when a 
severe or total loss of sensation can be clearly 
demonstrated. Stuporous and aphasic patients will 
therefore probably score 1 or 0. The patient with 
brain stem stroke who has bilateral loss of 
sensation is scored 2. If the patient does not 
respond and is quadriplegic score 2. Patients in 
coma (item 1a=3) are arbitrarily given a 2 on this 
item.
0 = Normal: no sensory loss.
1 = Mild to moderate sensory loss; patient
feels pinprick is less sharp or is dull 
on the affected side; or there is a 
loss of superficial pain with pinprick 
but patient is aware he/she is being 
touched.
2 = Severe to total sensory loss; patient is
not aware of being touched in the 
face, arm, and leg.
-
9. Best Language: A great deal of information 
about comprehension will be obtained during the 
preceding sections of the examination. The patient 
is asked to describe what is happening in the 
attached picture, to name the items on the attached 
naming sheet, and to read from the attached list of 
sentences. Comprehension is judged from 
responses here as well as to all of the commands in 
the preceding general neurological exam. If visual 
loss interferes with the tests, ask the patient to 
identify objects placed in the hand, repeat, and 
produce speech. The intubated patient should be 
asked to write. The patient in coma (question 1a=3) 
will arbitrarily score 3 on this item. The examiner 
must choose a score in the patient with stupor or 
limited cooperation but a score of 3 should be used 
only if the patient is mute and follows no one step 
commands.
0 = No aphasia, normal
1 = Mild to moderate aphasia; some
obvious loss of fluency or facility of 
comprehension, without significant 
limitation on ideas expressed or form 
of expression. Reduction of speech 
and/or comprehension, however, 
makes conversation about provided 
material difficult or impossible. For 
example in conversation about 
provided materials examiner can 
identify picture or naming card from 
patient's response.
2 = Severe aphasia; all communication is through
fragmentary expression; great need for 
inference, questioning, and guessing by the 
listener. Range of information that can be 
exchanged is limited; listener carries burden 
of communication. Examiner cannot identify 
materials provided from patient response.
3 = Mute, global aphasia; no usable
speech or auditory comprehension.
-
10. Dysarthria: If patient is thought to be normal 
an adequate sample of speech must be obtained by 
asking patient to read or repeat words from the 
attached list. If the patient has severe aphasia, the 
clarity of articulation of spontaneous speech can be 
rated. Only if the patient is intubated or has other
0 =  Normal
1 = Mild to moderate; patient slurs at least
some words and, at worst, can be 
understood with some difficulty.
2 = Severe; patient's speech is so slurred
as to be unintelligible in the absence
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physical barrier to producing speech, may the item 
be scored "9", and the examiner must clearly write 
an explanation for not scoring. Do not tell the 
patient why he/she is being tested.
of or out of proportion to any 
dysphasia, or is mute/anarthric. 
9 = Intubated or other physical barrier
11. Extinction and Inattention (formerly 
Neglect): Sufficient information to identify neglect 
may be obtained during the prior testing. If the 
patient has a severe visual loss preventing visual 
double simultaneous stimulation, and the cutaneous 
stimuli are normal, the score is normal. If the 
patient has aphasia but does appear to attend to 
both sides, the score is normal. The presence of 
visual spatial neglect or anosagnosia may also be 
taken as evidence of abnormality. Since the 
abnormality is scored only if present, the item is 
never untestable.
0 = No abnormality.
1 = Visual, tactile, auditory, spatial, or
personal inattention or extinction to 
bilateral simultaneous stimulation in 
one of the sensory modalities.
2 = Profound hemi-inattention or hemi-
inattention to more than one 
modality. Does not recognize own 
hand or orients to only one side of 
space.
-
Additional item, not a part of the NIH Stroke Scale 
score.
A. Distal Motor Function: The patient's hand is 
held up at the forearm by the examiner and patient 
is asked to extend his/her fingers as much as 
possible. If the patient can't or doesn't extend the 
fingers the examiner places the fingers in full 
extension and observes for any flexion movement 
for 5 seconds. The patient's first attempts only are 
graded. Repetition of the instructions or of the 
testing is prohibited.
0 = Normal (No flexion after 5 seconds)
1 = At least some extension after 5 seconds, but
not fully extended. Any movement of the 
fingers which is not command is not scored.
2 = No voluntary extension after 5 seconds.
Movements of the fingers at another time 
are not scored.
a. Left Arm
b. Right Arm
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